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ABSTRACT 
We are living in a post-antibiotic era. The miracle drugs that shaped our modern 
healthcare system are losing effectiveness, and we aren’t developing enough new drugs 
to meet patient needs. Innovative strategies to kill resistant bacteria and protect our 
antibiotic arsenal are urgently needed. Biodegradable polyanhydride nanoparticle-based 
nanomedicines could shape the next generation of antimicrobial therapies by improving 
drug biodistribution and targeting. By controlling drug release and improving antibiotic 
potency, they provide dose sparing and dose frequency reduction capabilities that could 
improve compliance. Unfortunately, traditional screening approaches are impractical for 
nanomedicines due to the massive physicochemical dataspace contributed by drug, 
polymer, and nanoparticle properties. Additionally, the relationships between these 
properties and nanomedicine efficacy are complex and nonlinear, impeding first 
principles modeling. Improved methods of screening and modeling antimicrobial 
nanomedicines are needed to realize their full potential. 
In this dissertation, we report the adaptation of a high-throughput method to 
rapidly screen a novel polyanhydride copolymer chemical space for interesting drug 
delivery properties. These CPTEG:SA copolymers were shown to erode more rapidly 
than traditional polyanhydride copolymers, resulting in rapid, chemistry-dependent drug 
release within three days. This rapid release could be beneficial for fast-growing 
pathogens by providing a quick, suppressive antibiotic dose that is maintained over 
several days. The high-throughput method was adapted to synthesize polymer-drug films 
to screen for thermodynamic mixing interactions that influence release kinetics.  
xiii 
These methods enabled high-throughput synthesis of antibiotic-loaded 
nanoparticle libraries, which were evaluated for their controlled release capabilities and 
antimicrobial efficacy against the opportunistic, resistant pathogen Burkholderia cepacia. 
Multivariate data analytics approaches were used to identify key polymer, drug, and 
nanoparticle properties that determine nanomedicine release kinetics and efficacy. Graph 
theory was used to reduce the dimensionality of the descriptor data while preserving 
nonlinear relationships between formulations, enabling interrogation of nanomedicine 
design pathways. The dimensionally compressed descriptor space was used to develop 
predictive models for nanomedicine release kinetics and efficacy. These models 
successfully predicted the release kinetics and encapsulation efficiency for nanoparticles 
encapsulating two drugs not included in the training data set. In terms of efficacy, the 
model successfully predicted whether untested individual nanomedicines or 
nanomedicine cocktails would provide improved potency over soluble drug.  
From these results, we proposed two informatics-assisted frameworks to rapidly 
screen nanomedicine candidates capable of killing resistant bacteria and controlling drug 
release. Overall, this dissertation has provided the first steps toward a broader framework 
for the rational design of antimicrobial nanomedicines. Lead candidates identified by this 
framework could provide new therapies against resistant pathogens and enable 
repurposing of existing antibiotics limited by resistance. 
 
1 
CHAPTER 1.    INTRODUCTION: THE RESISTANCE THREAT 
We are living in a post-antibiotic era.1 The miracle drugs that laid the foundation of 
the modern healthcare system are no longer broadly effective, and we are at substantial risk 
of losing the effectiveness of the remaining drugs. Without antibiotics, surgeries would be 
much riskier and organ transplants would be nearly impossible.1 Many patients with chronic 
diseases would live shorter, less comfortable lives and septic infections would once again 
become a fatal prospect.1 We urgently need new strategies to kill resistant bacteria and 
protect the potency of our existing antibiotic supply.  
The discovery of penicillin by Alexander Fleming ushered in the modern antibiotic 
era, but in his Nobel lecture he cautioned careful stewardship of antibiotics to ward against 
resistance.2 Indeed, the introduction of each new class of antibiotics into the market has been 
followed by discovery of organisms resistant to them (Figure 1.1).3,4 Recently, antimicrobial 
resistance (AMR) rates in the U.S. and across the globe have been rising due to a 
combination of clinical, agricultural, industrial, and regulatory missteps. Antibiotics are 
overprescribed in the U.S., and studies have shown that antibiotics are inappropriately 
prescribed 30-50% of the time based on drug chosen, therapy duration, and indication.3–5 
Additionally, 20% of patients who take antibiotics experience adverse events,6 which can be 
serious enough to hurt patient compliance.7 Agricultural use of antibiotics has also been 
linked to transferring AMR bacteria from livestock to humans.8 These improper uses of 
antibiotics collectively contribute to AMR by selecting for the most resistant members of a 
bacterial population. This selective pressure, coupled with the high capacity for mutations in 
bacteria and horizontal gene transfer mechanisms, provides a powerful driving force toward 
the cultivation of resistance.  
2 
Compounding these problems, the antibiotic development pipeline has stagnated over 
the past 30 years. The cost of bringing new antibiotics to market is much higher than in the 
past due to new FDA standards for clinical trial design.4 Antibiotics are best used only when 
necessary and for the shortest time possible to prevent risk of AMR, limiting the profitability 
of these drugs to their manufacturers. Antibiotic stewardship guidelines mandate that new 
antibiotics are reserved for use only in last-resort cases, dramatically reducing the patient 
pool. The $2.6 billion cost of bringing a drug to market9 coupled with the idealized low 
utilization of antibiotics makes research and development of new antibiotics an economically 
unfavorable prospect for pharmaceutical companies. Accordingly, most manufacturers have 
left the antibiotic space entirely,10 resulting in an antibiotic clinical development pipeline too 
sparse to meet patient needs and with few new antimicrobial mechanisms.1,11 These factors 
have led to a push for improved antibiotic stewardship and increased public funding for novel 
antimicrobials.1 
Resistant infections have profound socioeconomic impacts. Each year in the U.S, 
AMR microbes cause close to three million infections, resulting in 35,900 deaths.1 Based on 
a case study performed in a Chicago hospital,12 the Alliance for the Prudent Use of 
Antibiotics estimates that in 2000, AMR infections caused greater than $35 billion in 
economic losses to U.S. families due to lost wages, length of hospital stays, and early 
deaths.13 Beyond the U.S. border, AMR infections pose challenges for global healthcare 
systems. AMR infections are associated with higher mortality and increased healthcare costs 
in developing countries.14 Globalized travel carries the risk that local shortcomings, such as 
limitations in AMR surveillance programs and antibiotic stewardship, prevention, and control 
programs,14 become threats to every nation.  
3 
Healthcare experts and scientists have sounded a call to action to combat this dire 
threat. The National Academy of Engineering’s “Engineer Better Medicines” grand 
challenge calls for improved medicines to combat AMR.15 In 2013, the CDC issued a list of 
four core actions it is taking to slow and prevent AMR (Figure 1.2). Since then, the CDC has 
established the AR Lab Network to provide resistance testing services to healthcare facilities, 
launched tools to track antibiotic use and AMR through the National Healthcare Safety 
Network, and identified key organisms that pose AMR threats.1 
This dissertation seeks to respond to these calls to action by developing antimicrobial 
nanomedicine formulations based on polyanhydride nanoparticles and existing antibiotic 
drugs. These nanomedicines have been shown to improve the activity of their antibiotic 
payloads by delivering them past complex biological barriers in a Trojan horse mechanism. 
However, the rules that govern the effectiveness of these nanomedicines are poorly 
understood. Distillation of these nanomedicine design rules would allow more effective 
formulations to be designed de novo and accelerate the rational identification of effective 
nanomedicines. By rationally designing nanomedicines that kill AMR microbes, the research 
described in this thesis could lay the foundation for new therapies to fight resistant organisms 
and enable repurposing of antibiotics currently limited by resistance. 
1.1 References 
(1)  CDC. Antibiotic Resistance Threats in the United States. Atlanta, GA, U.S. Dep. Heal. 
Hum. Serv. CDC 2019. https://doi.org/CS239559-B. 
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(3)  Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United 
States; 2013. https://doi.org/CS239559-B. 
(4)  Ventola, C. L. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. P T  A 
peer-reviewed J. Formul. Manag. 2015, 40 (4), 277–283. https://doi.org/Article. 
4 
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Adverse Events with Antibiotic Use in Hospitalized Patients. JAMA Intern. Med. 2017, 
177 (9), 1308–1315. https://doi.org/10.1001/jamainternmed.2017.1938. 
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Antibiotics. Clin. Infect. Dis. 2013, 56 (10), 1445–1450. 
https://doi.org/10.1093/cid/cit070. 
(9)  DiMasi, J. A.; Grabowski, H. G.; Hansen, R. W. Innovation in the Pharmaceutical 
Industry: New Estimates of R&D Costs. J. Health Econ. 2016, 47, 20–33. 
https://doi.org/10.1016/j.jhealeco.2016.01.012. 
(10)  Young, R. Hunting the Nightmare Bacteria; Frontline, Public Broadcasting Service, 
2013. 
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Figure 1.1 Timeline of antibiotic introduction and resistance.3 Introduction of new antibiotics 
is followed by discovery of organisms resistant to them. 
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Figure 1.2 CDC core action plan for combatting antimicrobial resistance.3 
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CHAPTER 2.    LITERATURE REVIEW  
Adapted with modifications from Mullis, A.; Schlichtmann, B. W.; Narasimhan, B.; 
Cademartiri, R.; Mallapragada, S. K. Ligand-Cascading Nano-Delivery Devices to Enable 
Multiscale Targeting of Anti-Neurodegenerative Therapeutics. Biomed. Mater. 2018, 13 (3).1 
As discussed in the previous chapter, antimicrobial resistance (AMR) is a defining 
challenge for our modern healthcare system. This threat requires innovative solutions to 
preserve our existing antibiotic supply and provide new therapies against resistant pathogens. 
This chapter will begin by introducing major classes of antimicrobial compounds and their 
respective limitations in Section 2.1. Section 2.2 will introduce drug delivery platforms and 
concepts that have been used to improve the activity of antimicrobial drugs. As many AMR 
pathogens inhabit locations where the biodistribution of drugs is poor, Section 2.3 will 
discuss strategies for targeting and crossing complex biological barriers. 
2.1 Antimicrobial Therapies and Antimicrobial Resistance Mechanisms 
The activity of antibiotics against bacteria is dependent on the physiology of the 
bacteria. Gram-positive bacteria have a plasma single membrane and a thick peptidoglycan 
cell wall (Figure 2.1). Gram-negative bacteria have a thinner peptidoglycan layer which is 
sandwiched between two plasma membranes (Figure 2.1). The outer plasma membrane of 
Gram-negative bacteria is an additional barrier to drug diffusion (relative to Gram-positive 
bacteria) and is a major reason many Gram-positive compounds show poor efficacy against 
Gram-negative bacteria.2 
2.1.1 Antibiotic Classification 
Antibiotics can be broadly divided into five major categories based on their targets 
and mechanism of action (Figure 2.2). These targets include the bacterial cell wall, 
8 
metabolism and cofactor synthesis, DNA synthesis, RNA synthesis, and protein synthesis. 
The categories are further broken down into drug classes consisting of a parent compound 
and its derivatives.  
Many successful antibiotics target the bacterial cell wall. b-lactams contribute the 
majority of these compounds, yielding over 100 clinically-relevant antibiotics in the last 75 
years.3 b-lactams target transpeptidases, which are responsible for linking and rearranging 
peptidoglycan in the bacterial cell wall.2 Blocking transpeptidase activity inhibits cell wall 
repair, resulting in weak structural stability and eventual cell lysis.4 Four major classes of b-
lactams exist: penicillin and its derivatives, cephalosporins, carbapenems, and monobactams. 
b-lactams have a broad-spectrum of activity, meaning that they generally have activity 
against both Gram-positive and Gram-negative bacteria.2 Carbapanems have the most 
potency and widest spectrum of all b-lactams, and are the quintessential last-line antibiotics 
that are used when front line drugs are not effective.5 Glycopeptides also target cell wall 
repair by binding to terminal D-alanyl-D-alanine units on peptidoglycan,4 which prevents 
transpeptidase recognition of the peptidoglycan and results in similar outcomes as b-lactams. 
Lipopeptides are a newer class of antibiotics that are often categorized with b-lactams and 
glycopeptides, however they target the cell membrane instead of the cell wall. Although 
some aspects of the mechanism remain unclear, they generally act by insertion of a 
hydrophobic tail into the plasma membrane, which causes pore formation and cell death by 
ion leakage.6 Both glycopeptides and lipopeptides are indicated for Gram-positive 
infections.2 
Sulfonamides and trimethoprim comprise an antibiotic category that inhibits the 
production of bacterial cofactors. Both antibiotics inhibit enzymes along the metabolic 
9 
pathway converting folate to tetrahydrofolate.4,7 Notably, tetrahydrofolate is a cofactor in 
amino acid and nucleic acid metabolism.8 Therefore sulfonamides and trimethoprim interfere 
with the bacterial production of biomolecules essential for life. 
  Some antibiotics target enzymatic machinery that maintains and manipulates DNA. 
Quinolones are a class of broad-spectrum bactericidal and bacteriostatic compounds that 
target DNA gyrase and DNA topoisomerase IV, inhibiting DNA replication and cell growth.9 
Early quinolones generally require protein synthesis and aerobic conditions.4 
Fluoroquinolones are a second-generation set of quinolone derivatives that show improved 
potency and a broader spectrum than the first generation quinolones.2 These have shown 
efficacy against bacteria in hypoxic conditions4 and slow-growing bacteria that can survive 
with DNA gyrase only, such as Mycobacterium tuberculosis.9 
Rifamycins comprise the sole major class of drugs that target RNA synthesis. These 
drugs inhibit transcription by interacting with RNA polymerase, interfering with the initiation 
step but not elongation or termination.4 Rifampicin, a rifamycin derivative, is a front-line 
drug for tuberculosis.10 Rifamycins cover a broad spectrum, but are typically used for Gram-
positive infections.4 
Many antibiotic classes act by interfering with ribosome function, thereby inhibiting 
protein biosynthesis at the translation step. The ribosome is comprised of 30S and 50S 
subunits, both of which are antibiotic targets. The 30S subunit is targeted by tetracyclines and 
aminoglycosides, but are not effective against anaerobic bacteria.4 Tetracyclines bind the 30S 
subunit to block the binding of tRNA to the ribosome-mRNA complex, which inhibits further 
translation.4 Aminoglycosides induce conformational changes in the ribosome that limit 
proofreading, which can result in protein truncation due to aberrant stop codons.4 
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Odilorhabdins, a recently discovered class of antibiotics isolated from Xenorhabdus bacteria, 
operate on a similar mechanism as aminoglycosides.11 Tetracyclines, aminoglycosides and 
odilorhabdins have a wide spectrum of activity, although the latter has only been tested in 
rodent models to date.2,11 
The 50S ribosomal subunit is targeted by macrolides, oxazolidinones, phenicols, and 
lincosamides. Macrolides and phenicols bind domain V of the 23S rRNA of the 50S subunit, 
inhibiting aminoacyl-tRNAs binding the mRNA-ribosome complex.4 Oxazolidinones also 
bind the 23S rRNA of the 50S subunit,4 and are the most recent synthetic antibiotic class to 
be introduced to the clinic.12 Lincosamides also bind the 23S rRNA,13 and are used for Gram-
positive infections.2 Macrolides, oxazolidinones, and amphenicols show a broad spectrum of 
activity.  
2.1.2 Antimicrobial Resistance Mechanisms 
Bacteria have developed multiple mechanisms of resisting antimicrobial therapies. 
These mechanisms, as well as the factors that influence their prevalence in bacterial 
populations, are important to consider when developing therapies against AMR microbes. 
Some bacteria have evolved means of preventing antibiotics from reaching their 
targets. Gram-negative bacteria have a second outer membrane which acts as a permeability 
barrier that hinders the activity of Gram-positive drugs.14,15 Some Gram-negative bacteria 
such as Enterobacteriaceae, Pseudomonads, and Acinetobacter spp. modify the expression or 
type of porins in the outer membrane, which changes the ability of antibiotics to diffuse 
across the membrane.14,16 Additionally, some antibiotics require certain enzymatic machinery 
for activity. For example, anaerobic bacteria are not susceptible to aminoglycosides because 
those compounds require a functional electron transport chain for activity.4 A major 
mechanism of acquired AMR involves bacterial efflux pumps, which actively export toxic 
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compounds outside the bacterium. Of particular interest are the multidrug resistance (MDR) 
efflux pumps, which are capable of transporting a broad range of drugs. ATP-binding 
cassette (ABC) family transporters constitute one subset of MDR efflux pumps that use ATP 
to drive drug efflux.15 A second class of these transporters uses the cell membrane 
electrochemical potential to pump out antibiotics; notable groups of this class include the 
resistance nodulation division (RND), small multidrug resistance (SMR), and multidrug and 
toxic compound extrusion (MATE) families and the major facilitator superfamily (MFS).15 
The RND family contains many clinically important export pumps, like the AcrAB-TolC in 
Escherichia coli and Salmonella enterica, as well as highly homologous systems in P. 
aeruginosa, A. baumannii, and Neisseria gonorrhoeae.14,15 
Other AMR bacteria prevent antibiotic activity by mutating or modifying the drug 
targets. The high mutation rate that many pathogenic bacteria have can result in multiple 
functional genetic copies of an antibiotic target, which can enable bacterial survival when the 
drug has limited affinity for the mutated copy. For example, Pseudomonas aeruginosa 
resistance to the antibacterial agent triclosan has been shown to be due to an alternative 
duplicate of the fabI gene, which encodes the enzymatic target of the drug.17 Additionally, 
bacteria can express enzymes that chemically modify the drug targets, which reduces 
antibiotic binding. Chloramphenicol-florfenicol resistant methyltransferase, which has been 
identified in Staphylococcus aureus and E. coli,  methylates the 23S rRNA of the 50S 
subunit, which causes resistance to drugs that target this site (e.g. phenicols, 
oxazolidonones).14 
Bacteria can also degrade or chemically modify antibiotics to interfere with their 
ability to bind targets. b-lactamases are a classic example of this mechanism, and act by 
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hydrolytically cleaving the b-lactam ring.2 Since the 1970s, a class of antibiotic adjuvants 
called b-lactamase inhibitors have been developed to competitively bind or permanently 
inactivate b-lactamases, allowing b-lactam antibiotics to reach penicillin binding proteins 
and mediate cell killing.18 Carbapenems showed the remarkable capacity to simultaneously 
act as a b-lactamase inhibitor and inhibit penicillin binding proteins, giving them remarkable 
potency and breadth of spectrum.19 Unfortunately, highly active b-lactamases with reduced 
susceptibility to b-lactamase inhibitors, known as carbapenemases, have been recently and 
increasingly identified in multidrug resistant bacteria like Klebsiella pneumoniae.5,20 These 
carbapenem resistant Enterobacteriaceae (CRE) infections are hard to treat and highly lethal, 
and are listed as an urgent threat by the CDC.20,21 By a similar mechanism of chemical 
modulation-mediated inactivation as b-lactams, aminoglycosides are particularly vulnerable 
to transferase-mediated modification with acyl, phosphate, nucleotidyl, and ribotyl moieties 
due to their reactive hydroxyl and amide groups.14 Rifamycin can also be deactivated by a 
rifamycin phosphotransferase that has been recently discovered in Actinomycetes.14 
2.1.3 Acquisition of and Selection for Antimicrobial Resistance 
Mobile genetic elements are a major source of AMR trait acquisition. Bacteria can 
exchange DNA, including resistance genes, that are encoded on plasmids and transposons via 
conjugation.22 Carbapenemases like OXA-48 and K. pneumonia carbapenemase are often 
encoded on plasmids.20,23 Transduction is a mechanism of acquired AMR in which bacterial 
DNA is loaded into bacteriophages and transferred to another bacterium. Additionally, 
bacteria can take up loose DNA, including mobile genetic elements, in their environment in a 
process called transformation.22 Genetic recombination machinery, including integrons, 
allows bacteria to rearrange their genetic material, which can activate AMR genes or allow 
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transfer to other bacteria via plasmids or transposons.22 The free exchange of superbug genes, 
including MDR efflux pumps and carbapenemase, between bacteria enables rapid spread of 
these traits in the clinic, in the environment, and even in the absence of human hosts.23,24 
Bacterial populations are genetically diverse prior to antimicrobial treatment. 
Treatment with antibiotics will kill or inhibit the growth of susceptible strains of the 
population, enriching the percentage of the population that is resistant to the therapy. 
However, these resistant traits come with some evolutionary fitness cost, meaning that 
susceptible strains are typically advantaged in the absence of antibiotics.25 At a certain sub-
therapeutic drug concentration, the selective pressure of the antibiotic balances out the fitness 
detriment of the resistant strains, above which the resistant strains gain a competitive 
advantage.22 These resistance-favoring, sub-therapeutic concentrations can occur at the start 
and end of the therapy due to pharmacokinetics, and in tissues where the drug poorly 
distributes. 
2.2 Countering Antimicrobial Resistance 
To meet the pressing need for effective therapies against AMR bacteria, two 
predominant goals have risen to the fore. Firstly, new bactericidal and bacteriostatic 
compounds and derivatives need to synthesized, developed, tested, and brought into the 
clinic. This strategy is limited due to its potential for further AMR, but is necessary in the 
interim until better means of preventing resistance can be implemented. Secondly, 
approaches for improving the activity of existing antibiotics and blocking key resistance 
pathways need to developed. This allows repurposing of existing antibiotics, which leverages 
the considerable effort and cost of bringing them to market. 
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2.2.1 Synthesis of Novel Bioactive Compounds 
Classical antibiotic screening platforms have been, with a few notable exceptions, 
unable generate successful new antibiotic classes since the golden age of antibiotics. 
Improvements to the screening approach could yield new useful drugs. New approaches have 
enabled in situ growth and screening of “unculturable” bacteria by creating a blended agar-
soil (or water) medium diffusion chamber, which could effectively bypass the cultivability 
limitation of classical screening.26 Additionally, the continual decrease in the cost of 
transcriptomics experiments can aid compound identification in strains that show inhibitory 
activity.26 Prodrugs have been effective in treating challenging intracellular infections, like 
M. tuberculosis, due to their ability to kill persisters.26 Since all of the prodrugs were 
discovered in 1950s, it is likely that the much-larger modern compound libraries could harbor 
promising new candidates.26 The approach of synthesizing new bioactive compounds is also 
severely limited by the current regulatory and economic environment. Due to high risk of 
toxicity compared to other therapeutic compounds, high cost of clinical trials, and limited 
profitability, it remains challenging to bring a brand new antibiotic to market.27,28 
Recently, antimicrobial peptides (AMPs) have been proposed as a supplement to 
conventional antibiotics. Generally, AMPs are a set of eukaryotic peptides that are cationic 
and contain a high proportion of hydrophobic moieties.29 They exhibit a broad spectrum by 
acting on general targets like the cell membrane and DNA,30 which contrasts the molecular 
specificity exhibited by small molecule antibiotics. This could potentially reduce the risk of 
resistance. AMPs are currently limited in their high cost, proteolytic degradability, and 
limited understanding of their molecular mechanism.29 As of 2018, no AMP has reached 
clinical testing.31 
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2.2.2 Improving Activity of Existing Antimicrobials 
2.2.2.1 Antibiotic adjuvants 
Antibiotic adjuvants are a set of compounds that improve the activity of antibiotics. 
They can be divided into Class I, which act on bacteria, and Class II, which act on the host. 
b-lactamase inhibitors comprise a large subset of Class I adjuvants. Clavulanic acid was the 
first antibiotic adjuvant to be clinically approved, and acts by irreversibly inactivating Ser-b-
lactamases.32 Multiple new Ser-b-lactamase inhibitor-antibiotic combinations have 
successfully passed clinical trials in the last five years.32 Metallo-b-lactamases appear to be 
more challenging targets, as there are few adjuvants that show efficacy in animal models.32 
Other Class I antibiotic adjuvants interfere with passive resistance mechanisms. Loperamide, 
for example, interferes with the cell membrane electrochemical potential to drive an 
increased tetracycline permeability.33 Other adjuvants, such as PAbN, can inhibit efflux 
pumps, which improve the activity of multiple classes of antibiotics.32 
Class II adjuvants improve innate host defense mechanisms to assist antibiotic 
activity. LL-37 is an immunomodulatory peptide that stimulates the innate immune system’s 
antimicrobial capabilities.32 Another example is streptazolin, which has been shown to 
stimulate macrophages by NF-kB activation, resulting in improved macrophage phagocytosis 
and subsequent killing of S. mutans.34 Increased induction of the adaptive immune response 
by improving phagocytosis of pathogenic bacteria could provide a complementary 
antimicrobial mechanism to existing antibiotic therapies.  
2.2.2.2 Drug delivery vehicles 
Polymeric nano-delivery devices offer another solution to improving antimicrobial 
activity. These nano-delivery devices can alter the biodistribution of the antibiotic and direct 
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its localization at target tissues within the host, which improves their efficacy and reduces 
their toxicity.35 Increasing dosing frequency is correlated with poorer antibiotic regimen 
compliance.36 The controlled release capabilities of many of these devices can reduce the 
number of administrations needed, and therefore improve compliance. The main classes of 
these (polymeric) devices include dendrimers, micelles, nanoparticles, nanotubes, liposomes, 
and polymersomes.37 These devices typically encapsulate or chemically link a drug payload, 
which is protected from physiological degradation by a biocompatible material.38 
Additionally, the devices offer suitable chemistries for facile linkage of functional groups, or 
targeting ligands to navigate the hurdles associated with brain drug delivery.38,39 The ability 
to link targeting ligands to these devices provides a “plug-and-play” capability in that a 
functionalization used on one device can often be replicated on another to exploit that 
device’s physical properties. 
Dendrimers contain many functional groups that allow for the ability to conjugate 
therapeutics and significantly improve bioavailability, which makes them very versatile.40,41 
Additionally, dendrimers have demonstrated high biocompatibility and enhanced the 
circulation times of conjugated therapeutics.40,42 Liposomes are also biocompatible and can 
be functionalized, but additionally possess lipophilic properties that may be well suited for 
adsorptive-mediated strategies.37 Micelles have a hydrophilic shell and hydrophobic core, 
which gives them amphiphilic properties; this can enable high encapsulation of hydrophobic 
therapeutics.37 
Polymeric nanoparticles, based on biodegradable polymer such as polyesters and 
polyanhydrides, can provide precisely controlled sustained therapeutic release properties and 
easily tailor-able chemistries.43–49 Carbon nanotubes exhibit a high surface area to volume 
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ratio that enables high loading capacity;50 this unique property could be beneficial when 
multiple therapeutics are to be used for the same treatment. Polymersomes, which self-
assemble in water, also feature easily tunable size and chemistry.51  
Metallic nano-delivery devices are also available. While less biocompatible than 
polymeric devices and not biodegradable, they can be made to a smaller size. For example, 
iron oxide nanoparticles can be made with a diameter of less than 50 nm whereas most 
polymeric nanoparticles are limited to sizes of 50 nm or greater.52–57 These small sizes can 
enable more flexibility in organelle targeting by allowing passive NPC transport. 
Additionally, research has demonstrated high levels of internalization of such devices by 
phagocytic immune cells, indicating their promise for cell-mediated delivery.55,58 While an 
extensive review of these core nano-delivery device technologies is outside the scope of this 
paper, Jia et al. and Shadab et al. have written reviews on nano-delivery device 
technologies.59,60 
Polyanhydride nanoparticles represent a promising drug delivery platform. They are 
biodegradable,61 show high biocompatibility,62,63 and are synthesized from the same parent 
materials as an FDA-approved device for treating malignant gliomas, the Gliadel® wafer.64 
Their erosion rate, and therefore their rate of payload release, can be tuned by altering the 
copolymer molar composition.65,66 Typical polyanhydride carriers for drug and vaccine 
delivery are formulated using monomer such as sebacic acid (SA), 1,3-bis-(p-
carboxyphenoxy)propane (CPP),1,6-bis-(p-carboxyphenoxy)hexane (CPH), and 1,8-bis-(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG). Polymer-drug thermodynamic mixing 
interactions are known to influence polyanhydride film and microparticle release kinetics.67,68 
Favorable interactions lead to diffuse drug distribution within the device resulting in erosion-
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controlled release, while unfavorable interactions induce precipitation and localization of the 
drug at the device surface, resulting in a burst release.67,69,70 The tunable release kinetics 
exhibited by polyanhydride particles allows them to be adapted for different therapeutic 
scenarios. Their extended release capabilities could reduce the number of therapeutic 
administrations requires, enhancing patient compliance. 
Polyanhydride nanoparticles have been used to successfully deliver antibiotics past 
complex biological barriers. Phanse et al. showed that nanoparticle chemistries that achieved 
high internalization in phagocytic cells were able kill intracellular Brucella abortus by 
delivering doxycycline.71 Rifampicin-encapsulating polyanhdride nanoparticles showed 
improved elimination of Brucella melitensis infecting macrophages, and protected against B. 
melitensis infection following nanoparticle pretreatment compared to soluble drug in vitro.72 
In vivo, weekly doses of these nanoparticles provided comparable reductions in liver and 
spleen B. melitensis colonization after three weeks as daily soluble drug, a seven fold 
reduction in antibiotic dose.72 Binnebose et al. demonstrated that 20:80 CPTEG:CPH 
nanoparticles could effectively co-deliver ivermectin, a hydrophobic antiparasitic, and 
doxycycline to kill filarial worms in vitro.73 In adult female worms, they observed a 4000x 
dose sparing effect in the nanoparticles compared to soluble drug. These results support the 
hypothesis that the use of such nano-carriers can improve the activity of existing 
antimicrobial drugs.  
2.3 Intracellular Drug Delivery 
In many cases, therapeutic efficacy can be maximized by delivering the therapeutic 
payload to an organelle inside the target cell.74 The scale of impact in organelle delivery is 
significantly smaller than that at the cellular internalization level; host phagocytic cells can 
have a surface area on the order of tens to hundreds of square microns, but the mitochondria 
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and nucleus typically have surface areas of one to tens of square microns. Specifically, 
mitochondria are typically 0.75-3.0 square microns in size, which limits the functional 
surface area for interaction.75 Whereas cell internalization relies on protein-ligand or 
membrane interactions; size, morphology, and charge are the primary determinants of 
intracellular organelle accumulation.  
2.3.1 Surviving the Endocytic Pathway 
The primary concern in designing organelle-specific nano-delivery devices is 
escaping the endocytic pathway. Nano-delivery devices that exploit receptor-mediated 
endocytosis to achieve internalization must be able to protect their payload from acidic 
hydrolysis and escape from endosomes and lysosomes into the cytosol. Several techniques 
for endosomal escape of delivery devices have therefore been developed (Figure 2.3, Table 
2.1). Cationic amphiphilic peptides, like melittin, a major component of bee venom, and 
KALA, a synthetic peptide derived from influenza hemagglutinin, associate strongly with the 
endosomal membrane.76–79 This association disrupts stabilizing tension forces, which causes 
pore formation.80 Alternatively, photoreactive molecules can be released that degrade the 
endosomal membrane via production of reactive oxygen species.80 Another well-studied 
technique is to decorate the device with buffering agents such as quaternary and tertiary 
amines that causes an immense inflow of ions and water and ruptures the endosome 
membrane due to osmotic pressure; this is commonly referred to as the “proton sponge 
effect”.80  
2.4 Conclusions 
Antimicrobial resistance is a rising threat to the modern healthcare system. Due to 
complex economic, social, and regulatory factors, the clinical supply pipeline is too sparsely 
populated to meet current or future patient needs.28 At the same time, the existing supply of 
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antibiotics is being rendered ineffective by resistance. There is an urgent need for new 
antimicrobial therapies and strategies that repurpose existing antibiotics. Polyanhydride 
nanoparticles can improve the activity of encapsulated antibiotics by delivering them to their 
site of action, generating a dose sparing effect. Reducing the dose needed to clear an 
infection can reduce the patient’s risk of toxicity. Gradually releasing drugs over a long 
period of time can reduce the number of administrations, and thereby improve compliance. In 
these ways, antimicrobial-loaded polyanhydride nanoparticles could shape the next 
generation of antimicrobial therapies. These “nanomedicines” have shown the potential to 
contribute new therapies against resistant organisms, and could enable repurposing of 
antibiotics limited by resistance. 
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Table 2.1 Intracellular targeting strategies for CNS anti-neurodegenerative therapeutic 
delivery. Reproduced with permission from Mullis et al.1 
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Figure 2.1 Gram-positive and Gram-negative biological barriers. Reproduced with 
permission from Singh et al.5 
 
Figure 2.2 Antibiotic drug targets. Reproduced with permission from Lewis.21 
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Figure 2.3 Organelle targeting mechanisms for intracellular drug delivery. After 
internalization into the diseased cell, the nanoscale delivery devices must escape the 
endosome to avoid acidic degradation of their payload and enable organelle localization. 
Delivery devices can escape the endosome via (a) partitioning into and disrupting the 
endosomal membrane, (b) device release of reactive oxygen species from photoreactive 
molecules, and (c) rupturing the endosome through osmotic pressure differences (i.e, the 
proton sponge effect). After escaping the endosome, the delivery device can target their 
cargo’s organelles of interest with functionalizations. (d) The mitochondrion can be targeted 
via (i) electrostatic attraction of positively-charged devices, or through (ii) functionalization 
with mitochondria receptor ligands. (e) The nucleus can be targeted through (i) 
functionalization with an NLS ligand, (ii) passive diffusion through the NPC, (iii) shape-
directed localization, or through (iv) mitotic vulnerabilities in the nuclear membrane. 



































































CHAPTER 3.    RESEARCH OBJECTIVES AND THESIS ORGANIZATION 
3.1 Research Objectives 
The overall goal of this dissertation is to develop a new framework for rationally 
designing nanomedicine formulations for antimicrobial therapies and targeted drug delivery. 
While individual antimicrobial nanoparticle formulations have been shown to provide 
sustained drug release and improve antibiotic activity, the factors that influence nanoparticle 
effectiveness are poorly understood. In the past, traditional screening approaches have 
identified lead antibiotic candidates through brute force testing. However, these methods are 
unlikely to show the same level of success for nanoparticles due to the massively larger 
dataspace contributed by polymer and nanoparticle properties, as well as their interactions 
with drug properties. The research described in this dissertation seeks to clarify the 
physicochemical rules governing antimicrobial nanoparticle efficacy. This could streamline 
screening of nanoparticle formulations by identifying candidates with a high likelihood of 
success. 
This dissertation is organized into three specific goals to develop this framework for 
antimicrobial nanoparticle design: 
SG1: Deconvolute complex relationships between polymer chemistry, 
physicochemical properties of payload, encapsulation efficiency, and release kinetics from 
polyanhydride nanoparticles using materials analytics-based approaches. 
SG2: Develop a high-throughput methodology to rapidly synthesize and screen 
libraries of novel nanoparticle formulations encapsulating small molecule payloads. 
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SG3: Use the materials analytics approaches from SG1 to investigate polymer, 
payload, and nanoparticle properties that impact biological efficacy in antimicrobial therapies 
and targeted drug delivery. 
The relationships between carrier chemistry, payload physicochemical properties, 
drug release kinetics, encapsulation efficiency, and biological activity are complex and 
nonlinear. In SG1, we generated release data from multiple polyanhydride nanoparticle-based 
chemistries, payloads, and loading, and employed a materials analytics approach to 
deconvolute these complex relationships. This analysis enabled the design of a predictive 
algorithm for first-pass in silico screening of new antimicrobial nanoparticle formulations. In 
SG2, we utilized a high-throughput synthesis and screening method to characterize new 
rapid-release nanoparticle formulations based on CPTEG:SA copolymers. By pairing in 
silico and in vitro thermodynamic mixing predictions, we demonstrated that copolymer 
chemistry and polymer-drug mixing thermodynamics can be used to explain trends in release 
kinetics data. In SG3, we investigated the ability of individual nanoparticle formulations and 
cocktails of multiple formulations to improve the efficacy of their antibiotic payload against 
Burkholderia cepacia relative to soluble controls. Using a materials analytics approach, we 
identified key attributes of these formulations that govern functional efficacy. This enabled 
predictive modeling of the antimicrobial activity of untested nanoparticle formulations and 
cocktails.  
3.2 Dissertation Organization 
The following three chapters in the dissertation address these specific goals. Chapter 
4 focuses on SG1, discussing the development of structure function relationships for release 
kinetics and a predictive model to program release kinetics. SG2 is addressed in Chapter 5, 
describing the adaptation of a high-throughput method to rapidly synthesize libraries of small 
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molecule-loaded nanoparticles. Chapter 6 outlines SG3, wherein libraries of nanoparticles are 
synthesized via the Chapter 5 method and evaluated for antimicrobial activity. The Chapter 4 
informatics approach is applied to these data, and structure function relationships and a 
predictive model are derived for nanoparticle antimicrobial activity. Chapter 7 summarizes 
the outcomes of this dissertation, and highlight ongoing and future work using polyanhydride 
nanoparticles as carriers for small molecule drugs. 
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4.1 Abstract 
Drug delivery vehicles can improve the functional efficacy of existing antimicrobial 
therapies by improving biodistribution and targeting. A critical property of such 
nanomedicine formulations is their ability to control the release kinetics of their payloads. 
The combination of (and interactions between) polymer, drug, and nanoparticle properties 
gives rise to nonlinear behavioral relationships and a large data space. These factors 
complicate both first-principles modeling and screening of nanomedicine formulations. 
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Predictive analytics may offer a more efficient approach toward rational design of 
nanomedicines by identifying key descriptors and correlating them to nanoparticle release 
behavior. In this work, antibiotic release kinetics data were generated from polyanhydride 
nanoparticle formulations with varying copolymer compositions, encapsulated drug type, and 
drug loading. Four antibiotics, doxycycline, rifampicin, chloramphenicol, and pyrazinamide, 
were used. Linear manifold learning methods were used to relate drug release properties with 
polymer, drug, and nanoparticle properties, and key descriptors were identified that are 
highly correlated with release properties. However, these linear methods could not predict 
release behavior. Non-linear multivariate modeling based on graph theory was then used to 
deconvolute the governing relationships between these properties, and predictive models 
were generated to rapidly screen lead nanomedicine formulations with desirable release 
properties with minimal nanoparticle characterization. Release kinetics predictions of two 
drugs containing atoms not included in the model showed good agreement with experimental 
results, validating the model and indicating its potential to virtually explore new polymer and 
drug pairs not included in training data set. The models were shown to be robust after 
inclusion of these new formulations in that the new inclusions did not significantly change 
model regression. This approach provides the first steps towards development of a 
framework that can be used to rationally design nanomedicine formulations by selecting the 
appropriate carrier for a drug payload to program desirable release kinetics. 
4.2 Introduction 
Intracellular bacterial infections are challenging to treat using traditional 
antimicrobial therapies due to the difficulty in achieving high enough local drug 
concentration for antimicrobial activity without inducing host cell toxicity.1 Elimination of 
soluble drugs through host metabolism and excretion pathways act to reduce bioavailable 
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amounts of antimicrobials requiring repeated dosing to maintain therapeutic concentrations to 
mitigate the development of antibiotic resistant in pathogens.2,3 Drug delivery vehicles can 
improve the efficacy and potency of antimicrobials by altering the drug biodistribution with 
improved intracellular localization and delivery of cargo to the pathogen’s intracellular niche 
within host cells.4,5 Biodegradable polyanhydride nanoparticles show passive targeting and 
payload stabilization properties that make them uniquely suited for antibiotic delivery for 
intracellular infections.4,6 These particles are internalized efficiently by phagocytic cells 
using multiple mechanisms, and have been used to deliver antibiotics to kill intracellular 
Brucella abortus.7 Additionally, polyanhydride nanoparticles mediated efficient killing of 
filarial parasites by co-delivering an antiparasitic with an antibiotic targeting an intracellular 
endosymbiotic bacterium that supports parasite health and reproduction.8  
A key feature of the effectiveness of these nanomedicine formulations is their ability 
to control payload release rate, however rationally designing nanomedicines with 
programmable release remains elusive. Release kinetics are influenced by drug distribution 
within a device and/or a particle, which is in turn influenced by polymer-drug 
thermodynamic interactions.9–11 These interactions give rise to nonlinear release behavior 
which is difficult to predict a priori. Screening nanomedicine formulations is challenging as 
polymer and nanoparticle properties (e.g., polymer chemistry, nanoparticle size, 
polydispersity, release kinetics, and encapsulation efficiency) yield a large number of 
additional variables beyond drug-specific properties. This large dataspace, coupled with the 
multiple length scales at play, poses difficulties for generalizing conclusions to other 
nanoparticle systems and impedes first principles modeling of nanoparticle behavior.12,13 
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Hierarchical modeling may be a more efficient approach for such systems, wherein key 
descriptors are identified and correlated to performance parameters. 
Informatics methods encompass several tools for such hierarchical modeling. Data 
mining techniques can deconvolute complex behavior, unraveling relationships that lie on 
non-Euclidian surfaces,14 which enables pattern recognition and prediction through the 
development of quantitative structure-property relationships (QSPRs).15 To this end, previous 
informatics analyses from our laboratories has enabled identification of polyanhydride 
chemistry and structural factors that influence protein release from films16 and enable 
pathogen-mimicking nanoparticle processing by immune cells.17–20  
The focus of this work was to develop an informatics-based framework that 
determines how polymer, drug, and nanoparticle characteristics influence drug encapsulation 
efficiency and release kinetics. We sought to generate predictive models that can virtually 
test potential new polymer and drug combinations for desirable release kinetics. Our long-
term goal is to develop a predictive analytics framework to enable rational design of 
nanomedicine formulations for different types of therapeutic and prophylactic applications.  
4.3 Experimental Methods 
4.3.1 Materials  
Sebacic acid (SA) was purchased from Sigma Aldrich (St. Louis, MO). Triethylene 
glycol, 4-p-hydroxybenzoic acid, 1- methyl-2-pyrrolidinone, and 1,6-dibromohexane were 
purchased from Sigma Aldrich for 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 
1,6-bis(p-carboxyphenoxy)hexane (CPH) monomer synthesis. Potassium carbonate, dimethyl 
formamide, toluene, acetonitrile, acetic acid, sulfuric acid, N,N-dimethylacetamide, and 
acetic anhydride were purchased from Fisher Scientific (Fairlawn, NJ) for monomer and 
polymer synthesis. 4-p-fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, 
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UK) for use in monomer synthesis. Methylene chloride, pentane, and hexanes were 
purchased from Fisher Scientific for polymer purification and nanoparticle synthesis. 
Doxycycline (DOX), rifampicin (RIF), and pyrazinamide (PZA) were purchased from Sigma 
Aldrich, and chloramphenicol (CAM) was purchased from Fisher Scientific. Meropenem 
(MEM) was purchased from Ark Pharm, Inc. (Arlington Heights, IL) and ceftazidime (CAZ) 
was purchased from Acros Organics (NJ). 1H NMR analysis used deuterated chloroform 
purchased from Cambridge Isotope Laboratories (Andover, MA). Drug quantification used 
UV-transparent microplates from Greiner Bio-One (Kremsmünster, Austria), HPLC grade 
acetonitrile, methanol, and tetrahydrofuran from Fisher Scientific, and phosphoric acid from 
Sigma Aldrich. 
4.3.2 Polymer and Nanoparticle Synthesis 
CPTEG and CPH diacid were synthesized as described previously.10,21,22 
CPTEG:CPH and CPH:SA copolymers were synthesized as described previously.10,21 
Briefly, monomers were weighed in appropriate molar ratios and added to a round bottom 
flask. The monomers were acetylated in excess acetic acid at 125°C for 30 min, and rotary 
evaporation was used to remove excess solvent from the resulting prepolymer. CPTEG:CPH 
was reacted for six hours at 140°C at <0.1 Torr and CPH:SA was reacted for 30 min at 180°C 
at <0.3 Torr. Polymers were purified by precipitation in chilled hexanes. Copolymer 
composition and number average molecular weight (Mn) was confirmed from 1H NMR 
spectra acquired on a Varian MR-400 (Varian, Inc. Palo Alto, CA) and thermal properties of 
the copolymers was characterized by DSC (Q2000, TA Instruments, New Castle, DE).  
Antibiotic-loaded nanoparticles were synthesized as described previously.7,8 Polymer 
and drug were weighed in separate scintillation vials at appropriate %w/w ratios. Enough 
methylene chloride to dissolve the polymer at 20 mg/mL was added to the drug vial to 
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dissolve/disperse the drug, then transferred to the polymer vial. The combined drug and 
polymer solution was poured into a pentane antisolvent bath at room temperature (CPH:SA) 
or -10°C (CPTEG:CPH) at a solvent:anti-solvent ratio of 1:250 and nanoparticles were 
recovered by vacuum filtration. CPTEG:CPH nanoprecipitation was carried out in a cold 
room at 4°C. A total of 68 nanoformulations were tested, spanning drug loadings between 
1% and 20% loading (% w/w). All drugs were tested in 20:80 CPH:SA and 20:80 
CPTEG:CPH nanoparticles, and rifampicin was additionally tested in 10:90, 30:70, and 
50:50 CPTEG:CPH. 1H NMR spectra of empty 20:80 CPTEG:CPH and 20:80 CPH:SA 
nanoparticles indicated undetectable amounts of methylene chloride and trace amounts of 
pentane (data not shown).  
To validate the informatics analysis, nanoparticles encapsulating meropenem or 
ceftazidime were synthesized using a high-throughput method adapted from Goodman et al.23 
Briefly, polymer and drugs were dissolved/dispersed in methylene chloride and dispensed via 
high-throughput robot into 10 mL borosilicate tubes at a final polymer concentration of 20 
mg/mL. The robot sonicated and dispensed the combined polymer and drug solution into 50 
mL conical polypropylene tubes containing 45 mL pentane (1:18 solvent:anti-solvent ratio) 
at the temperatures listed above. Multiple particle batches were pooled and recovered by 
vacuum filtration. Scanning electron microscopy (SEM, FEI Quanta 250, Hillsboro, OR) was 
used to image all nanoparticles, and size distributions were calculated using Fiji image 
analysis software24 and the ParticleSizer plugin script for Fiji. Nanoparticle zeta potential 
was measured using a Zetasizer Nano (Malvern Instruments Ltd., Worcester, UK).    
4.3.3 Drug Release Kinetics 
Nanoparticles (9-11 mg) were dispersed in 0.5 mL PBS, pH 7.4 and suspended by 
sonication (VCX 130 PB, Sonics & Materials, Inc., Newtown, CT). At each time point, the 
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nanoparticles were pelleted by centrifugation and supernatant was collected for drug 
quantification. Fresh PBS was added to maintain perfect sink conditions and the 
nanoparticles were dispersed by sonication. At the end of the release experiment, 40 mM 
sodium hydroxide was added to accelerate polymer degradation and extract the remaining 
encapsulated drug as described previously.25 
The drug mass released at each time point was determined by spectrophotometry 
(SpectraMax M3, Molecular Devices, San Jose, CA) and UV-HPLC (1200 series, Agilent 
Technologies, Santa Clara, CA). Doxycycline, rifampicin, and chloramphenicol were 
quantified by absorbance in UV-transparent 96-well plates at 350, 333, and 293 nm, 
respectively. Pyrazinamide release and base extraction samples were separated using a 
Phenomenex Kinetex 2.6-micron C18 100Å 100x4.6mm column and a 30:5:65 
acetonitrile:methanol:water mobile phase adjusted to pH 5.2 with phosphoric acid.26 The 
flow rate was 0.6 mL/min and pyrazinamide was quantified at 268 nm. Meropenem and 
ceftazidime release and base extraction samples were separated using a Zorbax Eclipse XDB-
C8 5-micron 4.6x150 mm column, monitoring at 299 nm and 246 nm, respectively. 
Meropenem release samples used a mobile phase gradient ramping from 0.1/99.9 (%v/v) 
methanol/water to 50/50 over 15 min. Meropenem base extraction samples used a gradient 
ramping from 0.1/99.9 acetonitrile 0.1% trifluoroacetic acid/ water 0.1% trifluoroacetic acid 
to 50/50 over 15 min. Ceftazidime release samples used a mobile phase protocol with an 
isocratic step at 0.1/99.9 methanol/water for 5 minutes followed by a gradient ramping to 
50/50 over 10 min. Ceftazidime base extraction samples used an isocratic step at 15/85 from 
0.1/99.9 acetonitrile 0.1% trifluoroacetic acid/ water 0.1% trifluoroacetic acid for 1 min 
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followed by a gradient ramping to 40/60 over 5 min. All meropenem and ceftazidime HPLC 
protocols used a flow rate of 1 mL/min. 
The small mass of drug and large volume of antisolvent used in nanoparticle 
synthesis render the non-encapsulated drug concentration below the limit of detection of the 
analytical methods used in this study. Therefore encapsulation efficiency (EE) was calculated 
from the cumulative sum of detected drug mass released in PBS and base extraction samples 
using Eq. 1.25 In a minority of formulations >100% EE was observed, which could arise from 
the presence of drug nanocrystals27 (which was not detected on nanoparticle surfaces by 
SEM), gravimetric inaccuracies due to static charge of the nanoparticles, or residual error in 
the drug concentration quantification assays. Drug release kinetics are presented as fraction 
released, where the cumulative drug mass release is normalized by the total encapsulated 
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4.3.4 Informatics Analysis 
Release behavior parameters, along with polymer, drug, and nanoparticle properties, 
were normalized and mean-centered. Three different informatics approaches were integrated 
and applied to analyze the data in this work. Linear manifold learning approaches, such as 
principal component analysis (PCA),28–30 permit us to identify the right projection of data 
from which meaningful features associated with the input data can be identified. PCA 
performs an eigenvector decomposition and defines a new set of linear combinations of 
descriptors which maximize the amount of unique information in a minimal set of orthogonal 
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axes, termed principal components (PCs). The original data is decomposed into two matrices 
of interest for this work: the scores and loadings. The scores describe the different conditions 
(i.e., nanoparticle and drug chemistry), while the loadings describe the different descriptors 
and properties. The interpretation of these matrices is provided here with the relevant results, 
and an additional term called the variable importance projection (VIP) is calculated from the 
loadings matrix using Eq. 2.  





In this case, x = 5 because 5 PCs captured >90% of the variance in the data. The 
analysis was performed for T = encapsulation efficiency, drug released @2 h, and fraction 
released/day (Figure 4.6). Partial Least Squares (PLS) is a multi-linear regression approach 
which accounts for co-linearity in the data, and therefore limits bias and develops more 
robust quantitative relationships.31–34 PLS performs separate PC analyses on the predictor 
variables (i.e., descriptors) and the predicted variables (i.e., properties). These therefore 
represent linear manifold learning approaches which provide qualitative and quantitative 
design relationships.  
In order to model the drug release properties accurately and robustly, we found that 
non-linearity needed to be accounted for in the modeling. Therefore, we first developed non-
linear parameterization of the data through non-linear manifold learning, based on graph 
theory, using the Isomap algorithm.14,35 This approach generates a graph connecting data 
points on a high dimensional space to their nearest neighbors, mapped out in the high 
dimensional space, and then fit to a low dimensional manifold. The assumption here is that 
the graph Euclidean distance between the points in high dimensions closely approximates the 
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curvilinear distances along the low dimensional manifold. Through dimensionality reduction 
the manifold unravels into two or three dimensions allowing it to be visualized. The result of 
such dimensionality reduction is a weighted graph of the original data points where the edges 
are weighted according to the geodesic distances. Like in PCA, we develop a set of 
parameters for each set of conditions, although in this case the parameters are based on a 
non-linear combination of descriptors. 
4.4 Results 
4.4.1 Building Descriptor Library 
To generate the data set, we focused on nanoparticles composed of CPTEG, CPH, 
and SA copolymers (Figure 4.1a,b). Nanoparticles synthesized from these polyanhydride 
copolymers have been shown to kill intracellular bacteria because of their high 
internalization rates by phagocytic cells,7,36 localization in intracellular compartments that 
harbor these bacteria,17,36 and improved antimicrobial activity of encapsulated drugs.6–8 In 
addition to the structural descriptors defined by Li et al.,16 we included molecular weight and 
compositional data from 1H NMR and thermal characterization from DSC analysis. The 
release kinetics of four antibiotics, doxycycline (Figure 4.1c), rifampicin (Figure 4.1d), 
chloramphenicol (Figure 4.1e), and pyrazinamide (Figure 4.1f), were studied. The choice of 
the drug library was motivated by multiple factors. These drugs were selected due to their 
diversity of molecular weight, chemical structure, and hydrophobicity, among other 
physicochemical differences. All are FDA-approved drugs and belong to separate antibiotic 
classes, target distinct bacterial structures, and have well-characterized 
pharmacokinetics/pharmacodynamics. Experimental and predicted physicochemical 
properties for each of these drugs were gathered from the Drugbank database.37 Predicted 
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drug properties from this database were calculated by ALGOPS and ChemAxon 
methodologies. 
These drugs were encapsulated in polyanhydride nanoparticles by flash 
nanoprecipitation, and zeta potential, size distributions, and polydispersity index were 
obtained. Release profiles and encapsulation efficiencies were obtained from in vitro 
experiments in PBS, pH 7.4 (Figure 4.2). Figure 4.2 shows representative release kinetics 
data for multiple drugs, selected from a total of 68 nanoformulations that were tested. The 
formulations depicted in Figure 4.2 were selected to show the diversity of release behavior in 
the data set. CPH:SA-doxycycline nanoformulations tended to show a higher burst than 
CPTEG:CPH nanoformulations, and the lower loading in the CPH:SA nanoformulations 
tended to have a greater sustained release slope (Figure 4.2a). The chemistry trend was 
reversed in the rifampicin nanoformulations, where the CPTEG:CPH chemistries tended to 
show a higher burst release than the CPH:SA chemistries, and increasing the loading 
increased the burst (Figure 4.2b). For chloramphenicol, both 20:80 CPH:SA and 
CPTEG:CPH nanoformulations tended to generate a large burst release followed by a slow 
rate of drug release (Figure 4.2c). Pyrazinamide formulations generated a large burst from 
the 20:80 CPH:SA nanoparticles followed by a steady rate of drug release (Figure 4.2d). In 
contrast, the 20:80 CPTEG:CPH nanoparticles encapsulating pyrazinamide showed a small 
burst and slow rate of drug release and did not release more than 20% of the payload in one 
week. These results add to the body of literature9–11,38 that indicates that copolymer 
chemistry, drug type, and drug loading influence drug release kinetics from biodegradable 
particles and other devices. 
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4.4.2 Identifying Factors that Influence Drug Release 
The drug release profiles were parameterized using three attributes: (i) fraction 
released at two hours (FR (2h)); (ii) fraction released in one day (FR (24h)), both of which 
characterized the burst effect; and (iii) the slope of the release profile between 2 and 7 days 
to characterize the sustained release (Table 4.1). The normalized and mean-centered data are 
represented in the form of a heat map to provide an overview and to ensure that no outliers 
are biasing the results (Figure 4.3, Supporting Tables 4.1-2). In this step, no data specific to 
particle chemistry was included so as to not bias the analysis. A clustering analysis, based on 
Euclidian distance, was used to visualize broad trends in the data set between descriptors and 
nanoformulations, and is represented in Figure 4.3 by dendrograms which define the 
correlative indices. The clustering along the y-axis of Figure 4.3 can be visualized as plotting 
each nanoformulation in multidimensional space, where each dimension is a different 
descriptor. Encompassing n-dimensional “spheres” are defined at the locations of the 
nanoformulations, and as the radii of the spheres increase additional nanoformulations are 
encompassed. The relative sphere size needed to encompass multiple descriptors is 
comparable to the height of the branch in the dendrogram. Nanoformulations or descriptors 
grouped lower in the dendrograms are likely to show relatively strong, positive correlations. 
Branches higher in the dendrograms are more likely to show weak, positive correlations or 
inverse correlations. 
From Figure 4.3, we find that the primary difference is between CPH:SA and 
CPTEG:CPH, given that the two chemistries branch off at the lowest correlation node. 
Therefore, particle chemistry is the key discriminator for nanoformulation behavior. Within 
each node, the compounds then group based on drug type, and then finally branch off based 
on theoretical drug loading and molar monomer ratios within the copolymer. This defines the 
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order of importance on release properties with CPH:SA versus CPTEG:CPH as the most 
important and the theoretical drug loading having less importance. For CPH:SA 
nanoparticles, rifampicin and pyrazinamide grouped together strongly, whereas doxycycline 
and chloramphenicol grouped together within the CPTEG:CPH chemistries. The 
CPTEG:CPH-chloramphenicol and -pyrazinamide nanoformulations clustered together, and 
diverged from the CPTEG:CPH-rifampicin and -doxycycline nanoformulations. Considering 
correlations to the release properties, the fraction released at two hours and 24 hours are 
strongly correlated with the polymer melting point (Tm) and zeta potential. The fraction 
released/day clustered with nanoparticle diameter and PDI polymer DOP and Mn. The 
relatively low branching of these properties in the dendrogram indicates moderate to strong 
correlation. Encapsulation efficiency (EE) was most strongly correlated with water solubility, 
followed by fraction released/day. This (weak) correlation to water solubility is expected, as 
incompatibility between polymer and drug hydrophobicity/hydrophilicity can result in drug 
partitioning more strongly in the antisolvent than the polymer matrix. The drug release 
properties (burst release, slope of release, and encapsulation efficiency) appeared relatively 
isolated from each other within the dendrogram, suggesting potential for independent control 
of these properties in designing nanoformulations. 
A dimensionality reduction analysis, specifically principal component analysis 
(PCA), was then applied to the data of Figure 4.3, with descriptors specific to the particle and 
drug chemistry added to the data set (Supporting Table 4.3). Plots of formulation mapping 
and descriptor mapping within the dimensionally-reduced space are shown in Figures 4.4 and 
4.5, respectively. In these figures, the principal components (PC) are ordered in terms of 
decreasing variability captured. PC1, the most important PC, captured particle chemistry 
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properties (41.3%); therefore, differences in particle chemistry descriptors explain more 
variance in release behavior than other descriptor sets. The next most important PC, PC2, 
captured differences in drug-specific descriptors (27.9%). The scores plot (Figure 4.4), which 
maps individual nanoparticle formulations onto these PC’s (which, between them, allow us to 
reliably capture correlations in those two dimensions), shows a clear separation between 
CPTEG:CPH and CPH:SA particle chemistries. Within each polymer,  doxycycline, 
chloramphenicol, and pyrazinamide clustered together, whereas rifampicin formulations 
formed a cluster isolated from the other drugs, indicating potentially different types of 
interactions with the particle carriers. 
The loadings plot (Figure 4.5), which maps the descriptor variables onto the PC’s 
shows that the role of the particle and the drug bank descriptors have been isolated (i.e., 
particle data lies along the PC1 axis and drug bank data is along the PC2 axis). Given that 
PC1 is the most important axis, we are capturing that the particle chemistry is the critical 
characteristic for predicting particle release behavior. The drug release properties do not 
adhere exclusively to either PC1 or PC2 axes, indicating that they are influenced by both 
polymer and drug characteristics. The ability to isolate the different controls allows us to 
assess, model, and design by the material characteristics. 
To further quantify the correlation between descriptors and release properties, we 
calculated the VIP. In all, a total of 36 descriptors were used in the VIP analysis (as shown in 
Table 4.2), describing nanoparticle (1-3), polymer (4-13), and drug properties (14-36). The 
encapsulation efficiency was most strongly correlated with zeta potential (-), % Cl (drug) (+), 
% O (drug) (+), Tm,drug (-), predicted water solubility (-), pKa (strongest base) (-), and drug 
rotatable bond count (+). As seen in Figure 4.3, the two-hour burst and slope of release were 
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highly correlated with each other, and showed similar correlations with the descriptors. Both 
the two-hour burst and slope of release were most strongly correlated with % Cl (drug) (+), 
% O (drug) (+), water solubility (-), % N (drug) (-), pKa (strongest acid) (-), and rotatable 
bond count (+). The identification of several highly correlated descriptors allows for 
reduction of the descriptor space to a minimum number and defines the number of 
descriptors necessary for performing high throughput calculations. This minimization is an 
important objective in computational modeling to improve model robustness. The purpose of 
VIP analysis is to assess the descriptors that contribute significant information as well as to 
identify correlated descriptors. While we identify the drug-related descriptors as having the 
highest individual impact, the particle-related descriptors collectively contribute the largest 
amount of information as seen in Figure 4.4. 
4.4.3 Modeling Release Behavior 
Beyond only observing the correlation of data, we wanted to identify similarities and 
design pathways between the various nanoformulations. This connectivity defines samples 
which have the most similar behavior and can provide information on potential replacements 
and design. In order to accomplish this, we performed a graph theory analysis (Figure 4.7). 
For the CPH:SA particle chemistries, there is a high connectivity (illustrated by black lines) 
and tight clustering within individual drugs. For the CPTEG:CPH particle chemistries, 
chloramphenicol,  doxycycline, and pyrazinamide showed a high internal connectivity, but 
rifampicin branched out significantly. Each drug showed some degree of connectivity 
between the CPH:SA and CPTEG:CPH particle chemistries and doxycycline appeared to be 
the most interconnected across particle chemistries.  
The degree of similarity can be defined by the number of connections required to 
connect two points. The distance along the two-dimensional projection also indicates the 
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similarity of formulations. Pyrazinamide and chloramphenicol generated the least similarity 
in release behavior, as they required 4-6 connections, and lie far from each other along the 
projection. Within each particle chemistry, doxycycline showed the most similarity to 
rifampicin and pyrazinamide, and rifampicin showed the most similarity to doxycycline and 
chloramphenicol. The branched region of the CPTEG:CPH-rifampicin nanoformulations 
indicates some dissimilarity from the other rifampicin nanoformulations and some unique 
behavior that will need to be explored more systematically using experiments. Of note, the 
rifampicin formulations with altered molar composition of CPTEG:CPH (from the 20:80 that 
makes up most of the data set) showed high similarity to the 20:80 CPTEG:CPH 
nanoformulations within the cluster. This would suggest that nano-carrier copolymer 
compositions can be interchanged within these rifampicin-loaded formulations without major 
impact.  
This graph theory mapping in Figure 4.7 yielded notably different drug clustering 
within each nano-carrier chemistry compared to PCA (Figure 4.4). Rifampicin and 
chloramphenicol formulations are closely related in this map, while they were distant from 
each other in the PCA scores plot. Strikingly, chloramphenicol and pyrazinamide are most 
distant in the graph theory map, while they were clustered closely in the PCA scores plot. 
These clustering differences are likely due to PCA’s limited ability to capture non-linear 
relationships. Non-linear modeling techniques like graph theory are better equipped to 
capture the non-linear release behavior arising from interactions between polymer and drug 
properties. In summary, the graph theory mapping defined similarity and connectivity 
between different nanoparticle formulations, while capturing non-linearity in relationships 
that can be lost in linear analysis. 
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As PCA projects data onto a linear manifold, it has difficulty explaining non-linear 
relationships. To this end, PCA demonstrated insufficient capability to accurately predict 
release properties in this data set. By contrast, graph theory can be used to project the data 
onto a non-linear manifold. This provides high-throughput modeling that accounts for non-
linearity without requiring so many terms as to reduce the robustness of analysis. Therefore, 
the input into the predictions defines the graph theory values of Figure 4.7, which reflects a 
non-linear combination of descriptors, and a multi-linear regression between these values and 
the drug release properties was developed. It should be noted that the drug release properties 
were not included in the non-linear parameterization used for the prediction input, because 
that would result in predicting a property as a function of itself. The result of the high 
throughput modeling is shown in Figure 4.8. This represents a model with non-linear 
parameters that are a function of nanoparticle chemistry and theoretical drug loading and is 
defined generally so as to be applied to a wide range of chemistries. These models are fairly 
accurate, with R2 values ranging between 70.0% and 75.5%. Cross validation was applied to 
ensure an even trade-off between robustness and accuracy. Since these methods are based on 
descriptors that can be generated for potential new nanoparticle formulations, the models 
provide a method to virtually explore a large search space. This method can guide 
experimentation by predicting target properties for a desired release profile, suggesting 
chemistries that match the targeted properties for testing. 
4.4.3 Model Validation 
To evaluate the robustness and accuracy of the multilinear models, nanoparticles 
encapsulating two new antibiotic drugs (not included in the training data set), meropenem 
and ceftazidime, were synthesized and characterized. Importantly, these drugs contain sulfur 
atoms (Supporting Figure 4.1) which are not present in the four drugs used in the original 
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model training. The models in Figure 4.8 were used to predict the release properties for these 
new formulations (Table 4.3). Based on these predictions, it is expected that all eight 
formulations would show a high (>80%) burst release at 2h and 24h and minimal sustained 
release over d2-d7. With the exception of the 20:80 CPH:SA–meropenem formulation, all 
other nanoformulations are expected to show near-100% encapsulation efficiency.  
Strikingly, these predictions match experimental results closely. These new nano-
formulations displayed similar release profiles characterized by a >90% burst release within 
two hours, followed by small amounts of drug released over the following two weeks 
(Supporting Figure 4.2, Table 4.3). For this data set, the models tended to under-predict the 
burst release and over-predict the sustained release behavior of the nano-formulations. The 
EE model was relatively accurate for 20:80 CPH:SA formulations, within 5%-20% of the 
measured EE’s. The EE model showed more deviation from measured values for 20:80 
CPTEG:CPH formulations, at circa 15-35% differences from the experimental values.  
To test the robustness of the models when adding new, untrained chemistries, eight 
nano-formulations were included in the models (compositional percentages were calculated 
including sulfur atoms, but without a separate descriptor for sulfur) and new regressions were 
calculated. We found R2 values for EE, FR (2h), FR (24h) and d2-d7 slope after these 
inclusions to be 74.3%, 75.5%, 69.9%, and 74.6%, respectively. The small changes in 
regression from the original model data in Figure 4.8 indicates that the analytics 
methodology was able to incorporate new drug chemistries with minor impacts on the 
models. This confirms the robustness of the model and its capability to screen drug and 
polymer chemistries not included in the model development. 
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4.5 Discussion 
Due to the wide diversity of microbial infections, nanomedicines need to be 
customizable. Infections that are responsive to antibiotics may benefit from sustained release-
skewing formulations by leveraging the dose sparing properties, limiting the risk of off-target 
effects, reducing the number of administrations, and enhancing patient compliance.4,8,39 
Polyanhydride nanoparticles represent an attractive and adaptable nanomedicine platform by 
virtue of their tunable degradation and payload release rates,25,40 high biocompatibility,41,42 
and efficient internalization by phagocytic cells.7 
Predictive analytics approaches have the potential to accelerate nanomedicine clinical 
translation, but the application of such informatics and data mining techniques to 
nanomedicine design has been slow to develop.13 To date, the majority of such efforts has 
focused on either linear dimensionality reduction through PCA and regression through PLS,27 
which provides insight into relationships between formulations and variables but has limited 
capacity to capture nonlinear behavior, or else artificial neural network “black box” 
models,43–45 which can capture nonlinear behavior but obscure interpretation of the structure 
of the model and dataspace. As the long-term goal of this research is to facilitate rational 
design of nanomedicine formulations, interpretation of the relationships between 
formulations is important. Accordingly, the dimensionality reduction approach was selected 
for this research, and paired with graph theory mapping to overcome the linearity limitations 
of PCA.  
A hybrid data mining approach was employed to deconvolute the complex polymer 
and drug relationships and develop QSPRs that describe release kinetics and encapsulation 
efficiency. We correlated antibiotic release properties from varying polyanhydride 
chemistries, encapsulated drug types, and drug loading within the nanoparticles. Through 
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PCA analysis, we showed that release properties are dependent on both copolymer chemistry 
properties and drug properties, with polymer properties being more important. VIP analysis 
identified key polymer and drug descriptors that predicted drug release and encapsulation 
properties, but PCA was insufficient to predict release behavior from these formulations.  
Graph theory was used to characterize the multilinear connectedness and similarity of 
formulations, which can guide selection of replacement formulations with similar release 
behavior. For example, it is expected that 20:80 CPH:SA rifampicin-loaded nanoparticles 
(Figure 4.2b) would demonstrate similar release behavior (including burst release, slope of 
release between days 2-7, and encapsulation efficiency) as 20:80 CPH:SA doxycycline-
loaded nanoparticles (Figure 4.2a) based on their close connections and proximal distance on 
the map (Figure 4.7). Similarly, 20:80 CPTEG:CPH pyrazinamide-loaded nanoparticles 
(Figure 4.2d) would be expected to show large differences in release behavior from 20:80 
CPH:SA chloramphenicol-loaded nanoparticles (Figure 4.2c) due to the large number of lines 
needed to connect them and far distance on the map (Figure 4.7). The descriptors identified 
by VIP analysis were paired with the multilinear mapping from graph theory to generate 
predictive models for a priori screening of nanoparticle formulations with desired release 
kinetics and high encapsulation efficiency.  
The physicochemical properties of compounds influence their distribution, either in 
blood plasma or a polymer matrix. To this effect, VIP analysis (Figure 4.6) indicated that the 
descriptors most strongly correlated with release properties were both polymer and drug 
properties. This is expected, as favorable mixing thermodynamics allows distribution of the 
drugs inside the polymer device.10,46 In polyanhydride nanoparticles, such a distribution 
allows an erosion-controlled release profile, which tends toward sustained release.9,11 In 
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contrast, poor mixing between the polymer and drug induces thermodynamic partitioning of 
the drug into polymer microdomains and/or localization at the particle surface, which skews 
the release profile toward a high-burst, diffusion-dominated regime.11 Many of these same 
drug properties were correlated with encapsulation efficiency, supporting the notion that 
polymer-drug mixing influences the carrying capacity of delivery devices. As empty 
polyanhydride nanoparticles have a moderately negative zeta potential,23 the strong negative 
correlation between zeta potential and encapsulation efficiency could reflect a strong surface 
localization of positively charged drugs. If this were the case, however, we would expect a 
strong positive correlation between zeta potential and the two-hour burst release, which was 
not observed. Regardless, the predictive power of this descriptor could support the use of zeta 
potential as a quality control metric to ensure consistent encapsulation efficiencies of lead 
formulations. While it is not surprising that these drug properties affect encapsulation and 
release kinetics, this informatics analysis provides a sense of their relative impact. Reducing 
the data space in this way can help guide rational selection of antibiotic and polymer carrier 
pairs for nanomedicine formulations. These observations underline the complexity of these 
relationships and provide support for the use of data analytics approaches to enable rational 
design of nanomedicines. 
It should be noted that we can only confidently make quantitative predictions in 
chemical spaces represented in our training data. While the additional testing of drugs 
containing sulfur, which was not represented in our training data, resulted in approximately 
no change in accuracy, materials that have unique behavior but with chemistries outside our 
training data may not be quantitatively described by this approach. However, even in these 
cases, our approach has significant impact. While the objective for the systems described by 
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our training data is to predict properties with high accuracy, the objective for systems 
containing groups and elements not in our training data is to identify polymer and drug 
combinations which have the most promising characteristics and identify where additional 
experiments are needed. This leads to an iterative approach where necessary experiments are 
identified, thus feeding back to the analysis. 
From all of these results, we propose a framework for rational design and rapid 
testing of nanomedicine formulations (Figure 4.9). In the first step, selected antibiotic drug 
candidates are encapsulated within nanoparticles of various polymer chemistries (potentially 
using high throughput techniques,23 as demonstrated in section 3.4), and characterization of 
size distribution by SEM and zeta potential is obtained. These nanoparticle characteristics, 
along with polymer properties and drug properties, can then be fed into the multilinear graph 
theory model to predict encapsulation efficiencies and release kinetics. Nanomedicine 
candidates that demonstrate insufficient encapsulation and/or undesirable drug release 
profiles can be discarded. The in vitro performance of the lead nanomedicine candidates that 
emerge from this step can then be validated using drug release kinetics assays. A feedback 
reformulation loop allows gradual optimization of nanomedicine formulations and iterative 
updates to the models when release behavior deviates from predictions. In theory, this 
framework could be expanded to include other performance metrics, including internalization 
by appropriate cells and biological efficacy. As this methodology uses standard polymer and 
nanoparticle characterization techniques used in nano-carrier drug delivery research and 
publicly available drug information, this approach could be expanded to include other types 
of polymeric materials and other classes of small molecule drugs. This data analytics 
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framework constitutes the first steps toward the rational design of nanomedicine formulations 
for antimicrobial therapies. 
4.6 Conclusions 
A multivariate data analytics approach was used to correlate drug release profiles 
from nanomedicine formulations based on different polyanhydride chemistries, encapsulated 
antibiotic drug type, and varying drug loading. We showed that both drug and polymer 
properties influence the drug encapsulation efficiency within the nanoparticles, the 
prevalence of burst in the drug release profile, and the slope of post-burst release. Polymer 
and drug properties that significantly impacted drug encapsulation efficiency and release 
kinetics were identified and defined a minimum descriptor set. The informatics analysis 
captured and preserved non-linear behavior governing relationships between drug type, 
polymer chemistry, and nanoparticle release properties, enabling interrogation of 
nanomedicine design pathways. We developed predictive models for drug release kinetics of 
untested drugs, using data from the Drugbank database and nano-carrier characterization as 
inputs. Release kinetics predictions of two drugs containing atoms not included in the model 
showed good agreement with experimental results, validating the model and indicating its 
potential to virtually explore new polymer and drug pairs not included in training data set. 
The models were shown to be robust after inclusion of these new formulations in that there 
were no significant changes in the model regressions. This multilinear modeling approach 
provides the first steps towards development of a framework that can be used to rationally 
design nanomedicine formulations by selecting the appropriate carrier for a drug payload to 




(1)  Arora, D.; Sharma, N.; Sharma, V.; Abrol, V.; Shankar, R.; Jaglan, S. An Update on 
Polysaccharide-Based Nanomaterials for Antimicrobial Applications. Appl. Microbiol. 
Biotechnol. 2016, 100 (6), 2603–2615. https://doi.org/10.1007/s00253-016-7315-0. 
(2)  Vorachit, M.; Chongtrakool, P.; Arkomsean, S.; Boonsong, S. Antimicrobial Resistance 
in Burkholderia Pseudomallei. Acta Trop 2000, 74 (2–3), 139–144. 
https://doi.org/S0001-706X(99)00063-7 [pii]. 
(3)  Seung, K. J.; Keshavjee, S.; Rich, M. L. Drug-Resistant Tuberculosis. Cold Spring 
Harb Perspect Med 2015, 5, 1–20. 
(4)  Narasimhan, B.; Goodman, J. T.; Vela Ramirez, J. E. Rational Design of Targeted 
Next-Generation Carriers for Drug and Vaccine Delivery. Annu. Rev. Biomed. Eng 
2016, 18 (1), 25–49. https://doi.org/10.1146/annurev-bioeng-082615-030519. 
(5)  Chan, C.-F.; Huang, K.-S.; Lee, M.-Y.; Yang, C.-H.; Wang, C.-Y.; Lin, Y.-S. 
Applications of Nanoparticles for Antimicrobial Activity and Drug Delivery. Curr. 
Org. Chem. 2014, 18 (2), 204–215. https://doi.org/10.2174/13852728113176660144. 
(6)  Lueth, P.; Haughney, S. L.; Binnebose, A. M.; Mullis, A. S.; Peroutka-Bigus, N.; 
Narasimhan, B.; Bellaire, B. H. Nanotherapeutic Provides Dose Sparing and Improved 
Antimicrobial Activity against Brucella Melitensis Infections. J. Control. Release 2019, 
294, 288–297. https://doi.org/10.1016/j.jconrel.2018.12.024. 
(7)  Phanse, Y.; Lueth, P.; Ramer-Tait, A. E.; Carrillo-Conde, B. R.; Wannemuehler, M. J.; 
Narasimhan, B.; Bellaire, B. H. Cellular Internalization Mechanisms of Polyanhydride 
Particles: Implications for Rational Design of Drug Delivery Vehicles. J. Biomed. 
Nanotechnol. 2016, 12 (7), 1544–1552. https://doi.org/10.1166/jbn.2016.2259. 
(8)  Binnebose, A. M.; Haughney, S. L.; Martin, R.; Imerman, P. M.; Narasimhan, B.; 
Bellaire, B. H. Polyanhydride Nanoparticle Delivery Platform Dramatically Enhances 
Killing of Filarial Worms. PLoS Negl. Trop. Dis. 2015, 9 (10), e0004173. 
https://doi.org/10.1371/journal.pntd.0004173. 
(9)  Shen, E.; Kipper, M. J.; Dziadul, B.; Lim, M.-K.; Narasimhan, B. Mechanistic 
Relationships between Polymer Microstructure and Drug Release Kinetics in 
Bioerodible Polyanhydrides. J. Control. Release 2002, 82 (1), 115–125. 
https://doi.org/10.1016/S0168-3659(02)00125-6. 
(10)  Shen, E.; Pizsczek, R.; Dziadul, B.; Narasimhan, B. Microphase Separation in 




(11)  Berkland, C.; Kipper, M. J.; Narasimhan, B.; Kim, K.; Pack, D. W. Microsphere Size, 
Precipitation Kinetics and Drug Distribution Control Drug Release from Biodegradable 
Polyanhydride Microspheres. J. Control. Release 2004, 94 (1), 129–141. 
https://doi.org/10.1016/j.jconrel.2003.09.011. 
(12)  Barnard, A. S. Challenges in Modelling Nanoparticles for Drug Delivery. J. Phys. 
Condens. Matter 2016, 28 (2), 023002. https://doi.org/10.1088/0953-
8984/28/2/023002. 
(13)  Jones, D. E.; Ghandehari, H.; Facelli, J. C. A Review of the Applications of Data 
Mining and Machine Learning for the Prediction of Biomedical Properties of 
Nanoparticles. Comput. Methods Programs Biomed. 2016, 132, 93–103. 
https://doi.org/10.1016/j.cmpb.2016.04.025. 
(14)  Tenenbaum, J.; Silva, V.; Langford, J. A Global Geometric Framewok for Nonlinear 
Dimensionality Reduction. Science (80-. ). 2000, 290 (December), 2319–2323. 
(15)  Broderick, S.; Rajan, K. Informatics Derived Materials Databases for Multifunctional 
Properties. Sci. Technol. Adv. Mater. 2015, 16 (1), 1–8. https://doi.org/10.1088/1468-
6996/16/1/013501. 
(16)  Li, X.; Petersen, L.; Broderick, S.; Narasimhan, B.; Rajan, K. Identifying Factors 
Controlling Protein Release from Combinatorial Biomaterial Libraries via Hybrid Data 
Mining Methods. ACS Comb. Sci. 2011, 13 (1), 50–58. 
https://doi.org/10.1021/co100019d. 
(17)  Ulery, B. D.; Petersen, L. K.; Phanse, Y.; Kong, C. S.; Broderick, S. R.; Kumar, D.; 
Ramer-Tait, A. E.; Carrillo-Conde, B.; Rajan, K.; Wannemuehler, M. J.; et al. Rational 
Design of Pathogen-Mimicking Amphiphilic Materials as Nanoadjuvants. Sci. Rep. 
2011, 1, 1–9. https://doi.org/10.1038/srep00198. 
(18)  Petersen, L. K.; Ramer-Tait, A. E.; Broderick, S. R.; Kong, C. S.; Ulery, B. D.; Rajan, 
K.; Wannemuehler, M. J.; Narasimhan, B. Activation of Innate Immune Responses in a 
Pathogen-Mimicking Manner by Amphiphilic Polyanhydride Nanoparticle Adjuvants. 
Biomaterials 2011, 32 (28), 6815–6822. 
https://doi.org/10.1016/j.biomaterials.2011.05.063. 
(19)  Phanse, Y.; Carrillo-Conde, B. R.; Ramer-Tait, A. E.; Roychoudhury, R.; Pohl, N. L. 
B.; Narasimhan, B.; Wannemuehler, M. J.; Bellaire, B. H. Functionalization of 
Polyanhydride Microparticles with Di-Mannose Influences Uptake by and Intracellular 
Fate within Dendritic Cells. Acta Biomater. 2013, 9 (11), 8902–8909. 
https://doi.org/10.1016/j.actbio.2013.06.024. 
(20)  Phanse, Y.; Carrillo-Conde, B. R.; Ramer-Tait, A. E.; Roychoudhury, R.; Broderick, S.; 
Pohl, N.; Rajan, K.; Narasimhan, B.; Wannemuehler, M. J.; Bellaire, B. H. 
Functionalization Promotes Pathogen-Mimicking Characteristics of Polyanhydride 
Nanoparticle Adjuvants. J. Biomed. Mater. Res. - Part A 2017, 105 (10), 2762–2771. 
https://doi.org/10.1002/jbm.a.36128. 
 63 
(21)  Torres, M. P.; Vogel, B. M.; Narasimhan, B.; Mallapragada, S. K. Synthesis and 
Characterization of Novel Polyanhydrides with Tailored Erosion Mechanisms. J. 
Biomed. Mater. Res. - Part A 2006, 76 (1), 102–110. 
https://doi.org/10.1002/jbm.a.30510. 
(22)  Conix, A. Poly[1,3-Bis(p-Carboxyphenoxy)-Propane Anhydride]. Macromol. Synth. 
1966, 2, 95–98. 
(23)  Goodman, J. T.; Mullis, A. S.; Dunshee, L.; Mitra, A.; Narasimhan, B. Automated 
High-Throughput Synthesis of Protein-Loaded Polyanhydride Nanoparticle Libraries. 
ACS Comb. Sci. 2018, 20 (5), 298–307. https://doi.org/10.1021/acscombsci.8b00008. 
(24)  Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; 
Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An Open-Source 
Platform for Biological-Image Analysis. Nat. Methods 2012, 9 (7), 676–682. 
https://doi.org/10.1038/nmeth.2019. 
(25)  Carrillo-Conde, B. R.; Darling, R. J.; Seiler, S. J.; Ramer-Tait, A. E.; Wannemuehler, 
M. J.; Narasimhan, B. Sustained Release and Stabilization of Therapeutic Antibodies 
Using Amphiphilic Polyanhydride Nanoparticles. Chem. Eng. Sci. 2015, 125, 98–107. 
https://doi.org/10.1016/j.ces.2014.08.015. 
(26)  Prasanthi, B.; Ratna, J. V.; Phani, R. S. C. Development and Validation of RP-HPLC 
Method for Simultaneous Estimation of Rifampicin, Isoniazid and Pyrazinamide in 
Human Plasma. J. Anal. Chem. 2015, 70 (8), 1015–1022. 
https://doi.org/10.1134/S1061934815080146. 
(27)  Silva, J.; Mendes, M.; Cova, T.; Sousa, J.; Pais, A.; Vitorino, C. Unstructured 
Formulation Data Analysis for the Optimization of Lipid Nanoparticle Drug Delivery 
Vehicles. AAPS PharmSciTech 2018, 19 (5), 1–12. https://doi.org/10.1208/s12249-018-
1078-0. 
(28)  Broderick, S. R.; Suh, C.; Provine, J.; Roper, C. S.; Maboudian, R.; Howe, R. T.; 
Rajan, K. Application of Principal Component Analysis to a Full Profile Correlative 
Analysis of FTIR Spectra. Surf. Interface Anal. 2012, 44 (3), 365–371. 
https://doi.org/10.1002/sia.3813. 
(29)  Ashton, M.; Hennig, R. G.; Broderick, S. R.; Rajan, K.; Sinnott, S. B. Computational 
Discovery of Stable M2AX Phases. Phys. Rev. B 2016, 94 (5), 054116. 
https://doi.org/10.1103/PhysRevB.94.054116. 
(30)  Ericksson, L.; Byrne, T.; Johansson, E.; Trygg, J.; Vikstrom, C. Multi- and 
Megavariate Data Analysis : Basic Principles and Applications; Umetrics Ab,: Umea, 
2001. 
(31)  Wold, S.; Sjöström, M.; Eriksson, L. PLS-Regression: A Basic Tool of Chemometrics. 
Chemom. Intell. Lab. Syst. 2001, 58 (2), 109–130. https://doi.org/10.1016/S0169-
7439(01)00155-1. 
 64 
(32)  Nguyen, D. V.; Rocke, D. M. Tumor Classification by Partial Least Squares Using 
Microarray Gene Expression Data. Bioinformatics 2002, 18 (1), 39–50. 
https://doi.org/10.1093/bioinformatics/18.1.39. 
(33)  Balachandran, P. V.; Broderick, S. R.; Rajan, K. Identifying the “inorganic Gene” for 
High-Temperature Piezoelectric Perovskites through Statistical Learning. Proc. R. Soc. 
A Math. Phys. Eng. Sci. 2011, 467 (2132), 2271–2290. 
https://doi.org/10.1098/rspa.2010.0543. 
(34)  Wodo, O.; Broderick, S.; Rajan, K. Microstructural Informatics for Accelerating the 
Discovery of Processing-Microstructure-Property Relationships. MRS Bull. 2016, 41 
(8), 603–609. https://doi.org/10.1557/mrs.2016.161. 
(35)  Srinivasan, S.; Broderick, S. R.; Zhang, R.; Mishra, A.; Sinnott, S. B.; Saxena, S. K.; 
LeBeau, J. M.; Rajan, K. Mapping Chemical Selection Pathways for Designing 
Multicomponent Alloys: An Informatics Framework for Materials Design. Sci. Rep. 
2015, 5, 1–8. https://doi.org/10.1038/srep17960. 
(36)  Ulery, B. D.; Phanse, Y.; Sinha,  a.; Wannemuehler, M. J.; Narasimhan, B.; Bellaire, B. 
H. Polymer Chemistry Influences Monocytic Uptake of Polyanhydride Nanospheres. 
Pharm. Res. 2009, 26 (3), 683–690. https://doi.org/10.1007/s11095-008-9760-7. 
(37)  Wishart, D. S.; Feunang, Y. D.; Guo, A. C.; Lo, E. J.; Marcu, A.; Grant, J. R.; Sajed, 
T.; Johnson, D.; Li, C.; Sayeeda, Z.; et al. DrugBank 5.0: A Major Update to the 
DrugBank Database for 2018. Nucleic Acids Res. 2018, 46 (D1), D1074–D1082. 
https://doi.org/10.1093/nar/gkx1037. 
(38)  Kipper, M. J.; Shen, E.; Determan, A.; Narasimhan, B. Design of an Injectable System 
Based on Bioerodible Polyanhydride Microspheres for Sustained Drug Delivery. 
Biomaterials 2002, 23 (22), 4405–4412. https://doi.org/10.1016/S0142-9612(02)00181-
3. 
(39)  Thomas, S. N.; Schudel, A. Overcoming Transport Barriers for Interstitial-, Lymphatic-
, and Lymph Node-Targeted Drug Delivery. Curr. Opin. Chem. Eng. 2015, 7, 65–74. 
https://doi.org/10.1016/j.coche.2014.11.003. 
(40)  Petersen, L. K.; Sackett, C. K.; Narasimhan, B. Novel, High Throughput Method to 
Study in Vitro Protein Release from Polymer Nanospheres. J. Comb. Chem. 2010, 12 
(1), 51–56. https://doi.org/10.1021/cc900116c. 
(41)  Huntimer, L.; Ramer-Tait, A. E.; Petersen, L. K.; Ross, K. a.; Walz, K. a.; Wang, C.; 
Hostetter, J.; Narasimhan, B.; Wannemuehler, M. J. Evaluation of Biocompatibility and 
Administration Site Reactogenicity of Polyanhydride-Particle-Based Platform for 




(42)  Adler, A. F.; Petersen, L. K.; Wilson, J. H.; Torres, M. P.; Thorstenson, J. B.; Gardner, 
S. W.; Mallapragada, S. K.; Wannemuehler, M. J.; Narasimhan, B. High Throughput 
Cell-Based Screening of Biodegradable Polyanhydride Libraries. Comb. Chem. High 
Throughput Screen. 2009, 12 (7), 634–645. 
https://doi.org/10.2174/138620709788923764. 
(43)  Metwally, A. A.; Hathout, R. M. Computer-Assisted Drug Formulation Design: Novel 
Approach in Drug Delivery. Mol. Pharm. 2015, 12 (8), 2800–2810. 
https://doi.org/10.1021/mp500740d. 
(44)  Shalaby, K. S.; Soliman, M. E.; Casettari, L.; Bonacucina, G.; Cespi, M.; Palmieri, G. 
F.; Sammour, O. A.; El Shamy, A. A. Determination of Factors Controlling the Particle 
Size and Entrapment Efficiency of Noscapine in PEG/PLA Nanoparticles Using 
Artificial Neural Networks. Int. J. Nanomedicine 2014, 9 (1), 4953–4964. 
https://doi.org/10.2147/IJN.S68737. 
(45)  Husseini, G. A.; Mjalli, F. S.; Pitt, W. G.; Abdel-Jabbar, N. M. Using Artificial Neural 
Networks and Model Predictive Control to Optimize Acoustically Assisted 
Doxorubicin Release from Polymeric Micelles. Technol. Cancer Res. Treat. 2009, 8 
(6), 479–488. https://doi.org/10.1177/153303460900800609. 
(46)  Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Theoretical and Practical Approaches for 





Table 4.1 Representative antibiotic release properties 
 
FR (2h) fraction released in two-hour burst, FR (24h) fraction released in 24-hour burst. Data 
are presented as mean ± SD. 
Table 4.2 List of descriptors used in VIP analysis 
 
Table 4.3 Parameterized release properties of nanoparticles encapsulating two drugs 
(meropenem and ceftazidime) not included in training data set 
 





Figure 4.1 Polymer and antibiotic chemical structures. (a,b) Structures of CPH:SA (a) and 
CPTEG:CPH (b) copolymers, where m and n are the number of repeats for each unit. (c-f) 
Structure of doxycycline (DOX, a), rifampicin (RIF, b), chloramphenicol (CAM, c), and 
pyrazinamide (PZA, d). 
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Figure 4.2 Representative antibiotic release kinetics from nanoparticles encapsulating 
doxycycline (DOX, a), rifampicin (RIF, b), chloramphenicol (CAM, c), and pyrazinamide 
(PZA, d). The depicted nanoformulations represent a subset of the 68 formulations tested and 
were selected to display the diversity of release behavior in the data set. Data are presented as 
mean ± SD. Error bars are not depicted in cases where the error bar height is smaller than the 
symbol. Release profiles were parameterized into two-hour burst, one day burst, and 2-7 day 
sustained release slope. 
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Figure 4.3 Representation of correlations in data using Euclidian distance-based clustering, 
with the dendrograms defining the degree of correlation (i.e., branches at the bottom of the 
dendrogram have high correlation and correlation decreases as moving along the branches). 
From the dendrograms, the key discriminators among nanoformulations (vertical axis) in the 
order of importance are carrier chemistry (CPTEG:CPH versus CPH:SA), drug type, and 
theoretical drug loading. Concerning correlations between drug release properties and 
descriptors (horizontal axis), nanoparticle burst release (FR (2hr) and FR (24 hr)) was most 
strongly correlated with zeta potential and drug melting point. The release slope was most 
strongly correlated with the nanoparticle and polymer size properties. Encapsulation 
efficiency was most strongly correlated with the water solubility of the drug. That these data 
fall within comparable ranges demonstrates the robustness of the method and data set, 
enabling interrogation of nanoformulation behavior. Drug abbreviations: doxycycline 
(DOX), rifampicin (RIF), chloramphenicol (CAM), and pyrazinamide (PZA). Raw and 
processed input data are included in Supporting Tables 4.1-2.  
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Figure 4.4 PCA scores plot. PC1 captures differences due to particle chemistry (10:90 
CPTEG:CPH in blue, 20:80 CPTEG:CPH in black, and >30:<70 CPTEG:CPH in green) and 
PC2 captures the differences due to drug. There is a clear separation of formulations due to 
different chemistries, with a demonstrated capability to isolate the effects of particle 
chemistry from drug properties. PC1 and PC2 captured 43.1% and 27.9% of variability, 
respectively. Drug abbreviations: doxycycline (DOX), rifampicin (RIF), chloramphenicol 
(CAM), and pyrazinamide (PZA). Raw input data are provided in Supporting Table 4.3. 
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Figure 4.5 PCA loadings plot. Particle descriptors lie along the PC1 axis and drug descriptors 
lie along the PC2 axis. Drug release properties lie along both axes, indicating some 
dependence on both particle and drug descriptors. PC1 and PC2 captured 43.1% and 27.9% 
of variability, respectively. Raw input data are provided in Supporting Table 4.3. 
72 
 
Figure 4.6 Variable importance projection of descriptors with respect to drug release 
properties. Descriptors are listed in Table 4.2. Positive VIP values correspond to positive 
correlation, and negative values to inverse correlation. 
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Figure 4.7 Graph theory map of formulation connectivity of release properties. Similarity 
between points is defined as the number of connections (solid lines) required to connect 
points. CPH:SA chemistries are represented by orange squares, while CPTEG:CPH 
chemistries are represented by circles (10:90 CPTEG:CPH in blue, 20:80 CPTEG:CPH in 
black, and >30:<70 CPTEG:CPH in green) This represents an approach for building a set of 
non-linearly derived parameters for performing high-throughput predictions. This approach 
was applied to a reduced descriptor set in order to develop a parameterization of the data, 
which ensures robustness by minimizing the number of input parameters, while incorporating 
non-linear relationships and maximizing variance in the data. Drug abbreviations: 
doxycycline (DOX), rifampicin (RIF), chloramphenicol (CAM), and pyrazinamide (PZA). 
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Figure 4.8 Graph theory high-throughput modeling of drug release properties. The horizontal 
axis is the experimental measurements. The vertical axis is the predicted encapsulation 
efficiency (a), 2-hour burst release (b), 24-hour burst release (c), and the d2-d7 release profile 
slope values from our model based on the reduced descriptor set. These calculations are 
based on a new hybrid informatics approach where non-linear manifold projections serve as 
the input, thereby accounting for greater complexity in descriptor-property relationships 
while also increasing the robustness of the models. The models are reasonably accurate for 
all tested release properties. 
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Figure 4.9 Data analytics framework for rapid nanomedicine design and screening 
 
Figure 4.10 Table of contents graphic 
  
76 
4.10 Supporting Information 
Supporting Table 4.1 Dendrogram raw input data 
 
Encapsulation efficiencies (EE) are formatted as fractions. 
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Supporting Table 4.2 Dendrogram processed input data 
 




Supporting Table 4.3 Principal component analysis raw input data 
 




Supporting Figure 4.1 Chemical structures of antibiotics in model validation data set. 
Meropenem (MEM, a) and ceftazidime (CAZ, b) both contain sulfur atoms, which were not 
included in training data set. 
 
 
Supporting Figure 4.2 Release kinetics from nanoparticles encapsulating drugs not included 
in training data set. All formulations showed an extensive burst. Release property 
parameterization is shown in Table 4.3. Drug abbreviations: meropenem (MEM); ceftazidime 
(CAZ). 
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5.1 Abstract 
Combinatorial techniques can accelerate the discovery and development of polymeric 
nanodelivery devices by pairing high-throughput synthesis with rapid materials 
characterization. Biodegradable polyanhydrides demonstrate tunable release, high cellular 
internalization, and dose sparing properties when used as nanodelivery devices. This 
nanoparticle platform shows promising potential for small molecule drug delivery, but the 
pace of understanding and rational design of these nanomedicines is limited by the low 
throughput of conventional characterization. This study reports the use of a high-throughput 
method to synthesize libraries of a newly synthesized, rapidly-eroding polyanhydride 
copolymer based on 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and sebacic acid 
(SA) monomers. The high-throughput method enabled efficient screening of copolymer 
microstructure, revealing weak block-type and alternating architectures. The high-throughput 
method was adapted to synthesize nanoparticle libraries encapsulating hydrophobic model 
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drugs. Drug release from these nanoparticles was rapid, with a majority of the payload 
released within three days. Drug release was dramatically slowed at acidic pH, which could 
be useful for oral drug delivery. Rhodamine B (RhoB) release kinetics generally followed 
patterns of polymer erosion kinetics, while Coomassie brilliant blue (CBB) released the 
fastest from the slowest degrading polymer chemistry and vice versa. These differences in 
trends between copolymer chemistry and release kinetics were hypothesized to arise from 
differences in mixing thermodynamics. A high-throughput method was developed to 
synthesize polymer-drug film libraries and characterize mixing thermodynamics by melting 
point depression. Rhodamine B had a negative χ for all copolymers tested, indicating a 
tendency toward miscibility. By contrast, Coomassie brilliant blue c increased, eventually 
becoming positive, with increasing CPTEG content. This indicates an increasing tendency 
toward phase separation in CPTEG-rich copolymers. These in vitro results screening 
polymer-drug interactions showed good agreement with in silico predictions from Hansen 
solubility parameter estimation and were able to explain the observed differences in model 
drug release trends. 
5.2 Introduction 
Combinatorial and high-throughput screening of polymeric biomaterials is a 
burgeoning field. While early combinatorial approaches were successfully applied to drug 
discovery in the pharmaceutical industry, biomaterials pose several challenges for such 
approaches. Complex, interconnected relationships between molecular and bulk properties of 
materials and payloads and biological outcomes give rise to nonlinear behavior that is 
challenging to predict from first-principles.1 As a result, recent years have seen an increased 
use of high-throughput experimentation to screen many polymer formulations in parallel.2,3 
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By pairing simultaneous synthesis of polymer libraries with material characterization 
techniques, combinatorial science has the potential to advance understanding and 
development of biomaterials much more rapidly than conventional methods. Key challenges 
to these “omics” approaches include the relatively small throughput of polymer screening 
(hundreds, at most, in parallel) relative to traditional drug screening experiments (millions of 
compounds), as well as the adaptation of computational and informatics tools to reveal 
underlying structure-property relations.1  
 While many combinatorial techniques have been applied to macro- and micro-scale 
polymeric devices, nanoparticle-based drug delivery devices have received less attention. 
Previous work from our and collaborators’ laboratories has focused on combinatorial 
investigation of protein release,4,5 protein stability,6 biocompatibility,7 and immune 
activation8 of polyanhydride nanoparticles composed of sebacic acid (SA), 1,6-bis(p-
carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
monomers. An automated, high-throughput methodology was recently developed in our 
laboratory for synthesizing copolymer libraries, protein-encapsulating nanoparticle libraries, 
and surface-functionalized nanoparticle libraries, as well as validating through comparisons 
with conventionally synthesized polymers and nanoparticles.9 Small molecule drug release 
from CPH:SA and CPTEG:CPH copolymer films and microparticles have been investigated 
conventionally.10–12 Polyanhydride nanoparticles have also shown promising capabilities for 
delivery of small molecule drugs,13–15 but the pace of understanding and rational design of 
these nanomedicines is limited by the low throughput of conventional methods. Additionally, 
newly synthesized polyanhydride copolymers, such as CPTEG:SA,16 have limited supporting 
literature to guide understanding of their nano-scale drug delivery properties. These 
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CPTEG:SA copolymers are hypothesized to combine the favorable thermal properties of SA-
rich polymers, such as high melting point (Tm), that enables room temperature nanoparticle 
synthesis and discrete nanoparticle morphology,9 with the amphiphilicity, payload-
stabilizing,6 and high cellular internalization15 properties of CPTEG-rich polymers. 
Furthermore, the relatively low hydrophobicity of these monomers is predicted to provide 
rapid polymer erosion, corresponding with faster release kinetics of encapsulated payloads 
from nanoparticles. 
In this work, the high-throughput method developed in our laboratory was used to 
characterize the morphology of CPTEG:SA copolymer libraries. With this high-throughput 
method, CPTEG:SA nanoparticle libraries were synthesized to investigate the effect of 
varying copolymer composition on the release kinetics of model hydrophobic drugs. As 
release kinetics are known to be influenced by drug distribution in such particles,10 a high-
throughput film synthesis method was developed to test polymer-drug thermodynamic 
mixing interactions and illustrate the connectivity between copolymer chemistry, 
thermodynamic interactions, and drug release kinetics.  
5.3 Experimental Methods 
5.3.1 Materials  
Sebacic acid was purchased from Sigma Aldrich (St. Louis, MO). Triethylene glycol 
was purchased from Sigma Aldrich for CPTEG monomer synthesis. Potassium carbonate, 
dimethyl formamide, toluene, acetonitrile, acetic acid, sulfuric acid, N,N-dimethylacetamide, 
and acetic anhydride was purchased from Fisher Scientific (Fairlawn, NJ) for monomer and 
polymer synthesis. 4-p-fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, 
UK) for use in monomer synthesis. Nanoparticle synthesis utilized methylene chloride, 
chloroform, pentane, and hexanes from Fisher Scientific. Rhodamine B (RhoB) and 
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Coomassie brilliant blue G 250 (CBB) from Sigma Aldrich were used as model small 
molecule drugs. Deuterated chloroform was purchased from Cambridge Isotope Laboratories 
(Andover, MA) for 1H NMR analysis. A custom-built Nanoprep 24 automated high-
throughput robot (OMNI International, Kennesaw, GA) was used for polymer and 
nanoparticle library synthesis. 
5.3.2 Polymer Library Synthesis  
CPTEG monomer was synthesized as described previously (Supporting Figure 5.1).17 
Conventional CPTEG:SA copolymer was synthesized by acetylating CPTEG and SA 
monomers in excess acetic anhydride at 125°C for 30 min (Supporting Figure 5.2). Acetic 
anhydride was removed by rotary evaporation, and polymerization was carried out for one 
hour at 140°C and 0.2 torr. The polymer was dissolved in methylene chloride and 
precipitated in hexanes.16 High-throughput synthesis of CPTEG:SA copolymer libraries was 
carried out with a protocol modified from that reported by Goodman et al. (Supporting 
Figure 5.2).9 This method can produce up to 24 different polymers in parallel. Briefly, 15 
mg/mL stocks of CPTEG and SA monomers in acetic anhydride were created, and monomers 
were acetylated at 125°C for 30 min. These acetylated monomer solutions were dispensed by 
the automated high-throughput robot into 10 mL glass test tubes (VWR International, 
Radnor, PA) at 100 mg per tube. The test tubes were transferred to a 180°C vacuum oven for 
copolymerization of the acetylated monomers. Polymer libraries were allowed to react 
between 5 and 10 h, starting after evaporation of acetic anhydride. Polymer libraries not 
intended for nanoparticle synthesis were dissolved in methylene chloride (7 mL per tube) and 
precipitated in hexanes in 50 mL conical tubes. The tubes were centrifuged, solvent was 
decanted, and the purified polymers were dried by vacuum overnight to remove residual 
solvent. Throughout this work, libraries of 8 different copolymer compositions in triplicate or 
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6 different compositions in quadruplicate were prepared. Copolymer composition, molecular 
weight, and purity were confirmed using 1H NMR spectra gathered from a Varian MR-400 
(Varian, Inc. Palo Alto, CA). 1H NMR spectra were used to calculate number-average 
sequence lengths following the methods described in Shen et al. and Ron et al.12,18 
Differential scanning calorimetry (DSC) was used for thermal characterization (Q2000, TA 
Instruments, New Castle, DE). 
5.3.3 Tablet Erosion 
Fourteen mm diameter, 1 mm thick tablets of approximately 200 mg were prepared 
from conventionally synthesized CPTEG:SA copolymers. Tablets were pressed for 10 min at 
5000 lb pressure at a temperature above polymer melting point. Tablets were incubated in 
duplicate in glass vials with 20 mL phosphate buffer saline (PBS), pH 7.4 at 37°C with 
agitation at 100 rpm. Fifteen mL PBS was replaced with fresh PBS daily. At regular time 
intervals, buffer was removed and tablets were dried by vacuum. Mass loss of the tablets was 
monitored by gravimetry. 
5.3.4 Nanoparticle Library Synthesis  
Conventional nanoparticle synthesis from high-throughput polymer libraries was 
carried out to determine the optimal parameter space of copolymer composition and 
molecular weight. Nanoparticles were synthesized by flash nanoprecipitation as described 
previously.16 Briefly, CPTEG:SA polymers were weighed and dissolved in methylene 
chloride at 25 mg/mL. The polymer solutions were quickly poured into a pentane bath at -
10°C at a solvent:antisolvent ratio of 1:250 to precipitate nanoparticles. Nanoparticles were 
harvested via vacuum filtration.  
High-throughput synthesis of CPTEG:SA nanoparticle libraries was carried out using 
a modified protocol from that reported by Goodman et al.9 Methylene chloride solutions 
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containing appropriate concentrations of the model drugs, RhoB or CBB, were dispensed by 
the robot into polymer library test tubes to dissolve polymer at 20 mg/mL. Fifty mL 
centrifuge tubes were filled with 45 mL of hexanes chilled to -10°C and placed in the robot’s 
stainless-steel rack, which had been chilled in a -80°C freezer and filled with dry ice. The 
robot sonicated each test tube at 30% amplitude for 30 s and transferred the contents to its 
corresponding 45 mL centrifuge tube with its stainless-steel pipet nozzle to precipitate 
nanoparticles. A solvent:anti-solvent ratio of 1:9 was found to be adequate for 
nanoprecipitation of sub-micron particles, while maintaining the 100 mg scale desired for 
characterization of small molecule drug-encapsulating nanoparticle libraries. The tubes were 
centrifuged, hexanes were decanted, and the nanoparticle-containing pellets were dried 
overnight in a vacuum oven. Scanning electron microscopy (SEM, FEI Quanta 250, 
Hillsboro, OR) was used to characterize nanoparticle dry powders. Average size distributions 
were calculated from SEM micrographs using Fiji image analysis software19 and the 
ParticleSizer plugin script for Fiji,20 using 200 nanoparticles per image. Zeta potentials of 
particle suspensions (0.25 mg/mL) were characterized on a ZetaSizer Nano (Malvern 
Panalytical, Malvern, UK). 
5.3.5 Drug release kinetics  
Nine to eleven mg RhoB- and CBB-loaded nanoparticles were placed in 1.5 mL 
microcentrifuge tubes, 0.5 mL PBS (pH 7.4) was added to each tube, and the nanoparticles 
were dispersed by sonication. The tubes were incubated at 37°C with agitation at 100 rpm. At 
regular time points, the nanoparticles were pelleted by centrifugation, supernatants were 
extracted, and fresh PBS was added to maintain sink conditions. At the conclusion of the 
release experiment, 40 mM sodium hydroxide was used to extract remaining encapsulated 
drug and this information was used to calculate the drug encapsulation efficiency, as 
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previously described.21 RhoB and CBB release in acidic conditions were similarly assayed by 
incubating particles in 0.1 M acetate buffer, pH 4.3 for one week, followed by base 
extraction. Mass drug released was quantified via fluorescence (RhoB, lex 553 nm, lem 627 
nm) and absorbance (CBB, PBS and acetate buffer labs 580 nm, NaOH labs 590 nm) 
spectrophotometry (SpectraMax M3, Molecular Devices, San Jose, CA) in 96-well plates. 
Drug release kinetics are presented as a cumulative mass fraction, in which mass released is 
normalized by total mass encapsulated. 
5.3.6 Polymer-drug interaction screening  
The Fedors method22,23 was used to estimate molar volume (V), cohesive energy 
density, and the solubility parameter (d) for representative CPTEG:SA copolymers and 
model drugs. The Fedors method-derived molar volume and the Hoftyzer-Van Krevelen 
method22 were used to estimate solubility parameter components resulting from dispersion 
forces, polar forces, and hydrogen bonding. Polymer-drug compatibility was then estimated 
from the difference between the solubility parameter components for two species:22 
∆" = $%"!,# − "!,$'
$ + %"%,# − "%,$'
$ + %"&,# − "&,$'
$)
#/$
  (1) 
In Eq. 1, d represents the dispersion forces, p the polar forces, and h the hydrogen 
bonding forces. Good solubility is predicted to occur at small Dd, generally below 5 
(J/cm3)1/2. A Flory-Huggins interaction parameter, cFH, can then be estimated using: 
    c() =
*!"#(Dd)$
-.   (2) 
In Eq. 2, Vseg is the volume of a mole of lattice sites, defined here as the molar 
volume of the SA monomer. R is the ideal gas constant and T is the temperature. The cFH 
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represents the enthalpic contribution to polymer-drug interactions and complete solubility 
occurs at cFH < 0.5.22  
Polymer-drug interaction was investigated using melting point depression studies of 
polymer-drug films. In these experiments, the model drugs were dissolved in methylene 
chloride and dispensed with the robot into polymer library test tubes. Solvent was evaporated 
under nitrogen, and the films were dried by vacuum and stored under desiccation prior to 
DSC analysis. The melting point depression that arises from polymer-drug mixing 








(+ − ,+$)  (3) 
In Eq. 3, f is the volume fraction of the diluting drug, R is the ideal gas constant, Vu 
is the molar volume of the polymer repeat unit, and V1 is the molar volume of the diluting 
drug. By plotting 1/Tm - 1/Tm0 against f and performing a quadratic least squares regression 
with a y-intercept of zero, a c value was extracted from the second-degree term. 
5.4 Results 
5.4.1 Polymer Library Synthesis and Characterization  
CPTEG:SA copolymers were synthesized with the high-throughput method and 
characterized by 1H NMR spectroscopy and DSC (Figures 5.1, Supporting Table 5.3, Table 
5.1). This method afforded tight control over copolymer composition and produced 
copolymers of high purity (Figure 5.1a, Table 5.1). Copolymers of greater than 40 mol% 
CPTEG were sticky and either had near-zero °C Tg or were thermally unstable (Supporting 
Figure 5.4). The Tm and crystallinity of the copolymer decreased as the CPTEG content 
increased (Figure 5.1b, Table 5.1). All copolymers included in the analysis had Tm’s above 
37°C. Copolymers with less than 25 mol% CPTEG did not display distinct Tg’s. The more 
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amorphous 30:70 and 35:75 CPTEG:SA copolymers showed Tg’s near 20-25°C. The molar 
composition, molecular weight, and thermal properties of the combinatorially-synthesized 
CPTEG:SA copolymers were consistent with those observed in conventionally synthesized 
polymers (Table 5.1). 
Number-average sequence lengths of the CPTEG:SA copolymer library ranging in 
composition from 100% poly(CPTEG) to 100% poly(SA) were calculated using 1H NMR 
spectra (Figure 5.2). For near-equimolar compositions of CPTEG and SA, copolymers 
displayed moderate sequence lengths for both CPTEG and SA (Figure 5.2a). This is 
indicative of an alternating copolymer sequence.12 For compositions richer in either 
monomer, the majority component sequence length greatly increased while the minority 
component remained moderate. Such divergence in number-average sequence length 
indicates a weak block-like microstructure.25 Following the same methodology, reactivity 
ratios were calculated for this library (Figure 5.2b). At compositions between 20:80 and 
80:20 CPTEG:SA, the reactivity ratios for both components were near unity. This indicates a 
nearly equal tendency of a chain ending in SA to add another SA monomer versus a CPTEG 
monomer, and conversely so for a chain ending in CPTEG. For copolymer compositions rich 
in one component, the minority component reactivity ratio was elevated while the majority 
component remained near unity, suggesting an increased affinity for minority components to 
self-assemble into blocks. All copolymers in the library displayed a degree of randomness 
near two, indicating a nearly alternating copolymer structure.18  
The high-throughput polymer synthesis methodology facilitated rapid screening of 
CPTEG:SA copolymers, as up to 24 polymers can be synthesized in parallel. In conventional 
polymer synthesis CPTEG and SA monomer must be weighed, acetylated, evaporated, and 
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reacted separately. By contrast, the high-throughput method requires a single stock solution 
of each acetylated diacid for the entire polymer library and enables simultaneous evaporation 
and reaction. The robot can be programmed to autonomously precipitate the resulting 
polymer in hexanes, and the purified polymer can be recovered by centrifugation for 
characterization. Additionally, polymer libraries were synthesized at much smaller mass 
scales (100 mg per formulation) relative to conventional polymer synthesis (>1-2 g per 
formulation). This reduced the material costs of screening individual polymer compositions, 
particularly for CPTEG monomer which is synthesized in-house. Additionally, 100 mg is the 
same mass scale used in conventional synthesis of nanoparticles encapsulating small 
molecule drugs,26 whereas the previously published high-throughput polymer and 
nanoparticle synthesis protocol9 used a 14 mg scale which is insufficient for small molecule 
efficacy assays (e.g. minimum inhibitory concentration for antibiotics). Synthesizing polymer 
libraries at the same scale as conventional nanoparticle synthesis could facilitate translation 
and scaleup of lead formulations. Finally, reacting the polymer in a heated vacuum oven 
improved the safety of polymer synthesis by mitigating the fire risks associated with oil 
baths.  
5.4.2 Screening CPTEG:SA material properties.  
Previous experiments suggested that CPTEG:SA copolymer films rich in SA degrade 
more rapidly than CPTEG-rich copolymers in unbuffered water.16 To validate these results, 
CPTEG:SA tablet erosion was investigated in buffered conditions at physiological pH using 
conventionally synthesized polymers (Figure 5.3). Only semicrystalline copolymers (<30 
mol% CPTEG) were pressed into tablets. CPTEG:SA copolymers eroded rapidly, losing 
approximately 50% of their mass within four days and >75% of their mass within 11 days. 
CPTEG:SA tablets showed similar erosion rates across chemistries, with 30:70 CPTEG:SA 
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showing slightly lower mass lost after 11 days. All CPTEG:SA copolymers eroded more 
rapidly than 20:80 CPH:SA. While statistically significant differences between CPTEG:SA 
chemistries were not observed, SA-rich chemistries tended to show higher percent erosion 
than CPTEG-rich chemistries after 11 days. Regardless, these results support the hypothesis 
that the semicrystalline CPTEG:SA copolymers degrade more rapidly than the more well-
described and more hydrophobic CPH:SA copolymers.  
To aid screening of nanomedicine formulations based on CPTEG:SA copolymers, the 
effect of polymer molecular weight on nanoparticle size and morphology was studied. 
Polymer libraries between 10:90 and 50:50 CPTEG:SA were synthesized with the high-
throughput method, and the reaction time was varied. As described in Supporting Table 5.1, 
reaction times of 4, 5, 6, and 10 hours yielded mean (across compositions) number-average 
molecular weights of approximately 12, 13.5, 15, and 23 kDa. These polymer libraries were 
precipitated following the conventional nanoparticle synthesis method, and SEM was used to 
determine size distributions of the resulting particles (Supporting Table 5.1, Supporting 
Figure 5.5). For given reaction times, increasing CPTEG content generally corresponded 
with an increase in particle size. There was not a strong trend between reaction time and 
nanoparticle size within chemistries, however increasing reaction time corresponded with 
increasing aggregation of nanoparticles. 50:50 CPTEG:SA polymers did not result in 
nanoparticles at any reaction time tested, likely due to the tackiness of this chemistry. 
Polymer reacted for both 4 and 5 hours yielded nanoparticles for compositions between 
10:90 and 30:70 CPTEG:SA. For these reaction times, SA-rich chemistries produced more 
discrete particles at 5 h than at 4 h reaction time. At the 6 h reaction time, only CPTEG:SA 
compositions between 10:90 and 20:80 CPTEG:SA formulations resulted in nanoparticles, 
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while 40:60 CPTEG:SA particles were highly aggregated. At the 10 h reaction time, only 
10:90 and 20:80 CPTEG:SA compositions yielded recoverable particles, both of which were 
nanoparticles.   
These results allowed a reduction of the screening space for the various CPTEG:SA 
compositions with respect to particle formation. The 5 h reaction time was chosen for 
ongoing experiments as it yielded the most-discrete, sub-micron particles at high yield for 
copolymer compositions up to 30:70 CPTEG:SA. Additionally, copolymer compositions 
below 40:60 CPTEG:SA were selected, because they consistently returned high yields and 
sub-micron particles. 
5.4.3 Synthesis and characterization of model drug-encapsulating nanoparticle libraries 
Previous work from our laboratories described the development of a high-throughput 
method to synthesize nanoparticle libraries with comparable properties to conventionally 
synthesized particles.9 We adapted this method for CPTEG:SA copolymers, increasing the 
mass scale to improve yields and to enable a wider battery of tests to be performed on 
individual nanoparticle lots. Methylene chloride and chloroform were tested as polymer 
solvents, and pentane and hexanes at 4°C, -10°C, and -20°C were tested as anti-solvents 
(Supporting Figure 5.6). For all experiments, the polymer concentration in the solvent was 
kept constant at 20 mg/mL and the solvent:anti-solvent volume ratio was kept constant at 1:9. 
Optimal nanoparticle synthesis conditions were found using methylene chloride as the 
solvent and hexanes at -10°C as the antisolvent, precipitating the nanoparticles with the 
lowest melting point first.  
SEM was used to image the nanoparticles and size distributions were calculated from 
the resulting micrographs (Figure 5.4, Table 5.2). The nanoparticles gradually increased in 
size with increasing CPTEG copolymer content, from count mean diameters of 272.3 nm for 
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5:95 CPTEG:SA to 482.3 nm for 30:70 CPTEG:SA. Smaller nanoparticles could likely be 
achieved by reducing the mass scale and increasing the solvent:anti-solvent ratio. These 
unloaded nanoparticles had negative zeta potentials between -37 and -46 mV, which is 
attributed to terminal carboxylic acid groups that form when polyanhydrides are exposed to 
water.  
Two hydrophobic dyes, rhodamine B (RhoB) and Coomassie brilliant blue (CBB), 
were selected as model small molecular weight drugs to probe release kinetics from 
CPTEG:SA nanoparticles. RhoB has an ALGOPS-predicted logP of 2.37 and logS of -6.02, 
and CBB has a logP of 4.34 and logS of-7.42.27 As these dyes have varying degrees of 
hydrophobicity, they were used to simultaneously probe the effects of polymer composition 
and drug chemistry on release kinetics. Polyanhydrides exhibit surface erosion, and drug 
distribution within a particle is known to influence release kinetics.10 Given the 
hydrophobicity of polyanhydrides, it was hypothesized that the more hydrophobic drug 
(CBB) would achieve a more homogeneous distribution within nanoparticles than the less 
hydrophobic drug (RhoB). Both drugs were expected to exhibit erosion-controlled release, 
wherein faster eroding polymer compositions (lower CPTEG) provided faster release kinetics 
than slower eroding compositions. The hypothesized more homogeneous distribution of CBB 
within the particles was expected to yield a lower burst and slower release kinetics than 
RhoB. 
Nanoparticle libraries encapsulating these compounds at 5% (w/w) were synthesized 
and analyzed via SEM to calculate size distributions (Table 5.2). As observed with the 
unloaded particle library, mean size of nanoparticles increased as CPTEG content increased. 
Encapsulating payloads also increased the size of the nanoparticles. Significant differences 
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(P<0.05) in count mean diameter between the model drug-encapsulating particle libraries and 
their unloaded counterparts were observed for CBB in 10:90 CPTEG:SA, as well as for 
RhoB and CBB for 20:80 – 30:70 CPTEG:SA. RhoB nanoparticles had near-neutral zeta 
potentials, which deviated from the unloaded library (Table 5.2). CBB nanoparticles had zeta 
potentials close to those measured in the unloaded library. 
The effect of polymer composition on in vitro drug release kinetics from these model 
drug-encapsulating nanoparticle libraries was investigated (Figure 5.5). All RhoB 
formulations yielded measured encapsulation efficiencies greater than 100% (Table 5.2) and 
between 73-82% mass yield. This apparent “over-encapsulation” is attributed to non-uniform 
losses of polymer and RhoB payload during nanoparticle synthesis. Polymer is typically lost 
during nanoprecipitation and filtration, whereas the RhoB may be preferentially localizing in 
the nanoparticles collecting in the filter cake. This would therefore result in an enrichment of 
RhoB in the collected nanoparticles, violating the assumption of uniform losses of polymer 
and payload typically employed in encapsulation efficiency calculations. To compensate for 
the shortcoming of this assumption, these encapsulation efficiency values are interpreted as 
100%. SA-rich chemistries showed the highest burst and the quickest timescale of release 
(Figure 5.5a). Increasing CPTEG content reduced the burst and slowed the rate of RhoB 
release. All formulations released the majority of their payloads in three days, although 
detectable amounts of RhoB were observed throughout two weeks of sampling for all 
chemistries. RhoB release was consistent with previous polymer film erosion kinetics 
results.16 This erosion-controlled release and high encapsulation efficiency likely indicates 
favorable mixing thermodynamic interactions between RhoB and the CPTEG:SA polymers 
tested. 
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In contrast, CBB formulations displayed lower encapsulation efficiencies, ranging 
from 35-60% (Table 5.2). The only pair that showed statistically significant differences (P < 
0.05) in encapsulation efficiency were 5:95 and 25:75 CPTEG:SA, using Tukey’s multiple 
comparisons test. Increasing CPTEG content had a moderate positive correlation with 
encapsulation efficiency. CBB formulations showed chemistry-dependent release, but with 
an opposite trend to that seen in rhodamine B (Figure 5.5b). SA-rich chemistries displayed 
the lowest burst and the longest timescale of release. Increasing CPTEG content tended to 
increase the burst and shorten the timescale of release. These observations contradicted our 
earlier hypothesis that CBB would show slower release and a lower burst than RhoB. Based 
on the lower encapsulation efficiency and inverse correlation between the CBB release and 
the polymer erosion data, we hypothesized that unfavorable polymer-CBB interactions may 
have impacted drug distribution within the nanoparticles. 
Given the fast release rate provided by CPTEG:SA copolymers and the base-
catalyzed degradation of polyanhydrides,28 CPTEG:SA nanoparticles could have promise for 
oral drug delivery applications. To probe the release kinetics in acidic environments that 
approximately model gastrointestinal tract conditions, the RhoB and CBB nanoparticle 
libraries were incubated in acetate buffer pH 4.3 for three days (Figure 5.5c-d). All RhoB 
formulations showed a small burst (less than 20% of encapsulated drug) in the acetate buffer 
for three hours (Figure 5.5c). RhoB formulations gradually released their payloads over three 
days in acetate buffer, with SA-rich chemistries releasing more of their payload at faster rates 
than CPTEG-rich chemistries. CBB nanoparticles showed bursts between <1% and 40% of 
encapsulated drug in acidic conditions, with burst prevalence generally increasing with 
increasing CPTEG (Figure 5.5d). The only exception to this trend was the higher burst 
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observed in 25:75 CPTEG:SA than 30:70 CPTEG:SA. These particles released none to very 
little CBB after the initial burst. No formulation released its entire payload within three days 
in the acetate buffer.  
The release profiles of both drugs showed similar trends with changing copolymer 
composition in acidic conditions compared to neutral pH. CBB had more variability in burst 
than RhoB, while RhoB had more variability in day 1-3 release than CBB. Release kinetics 
from all formulations were slowed at reduced pH, as expected from the base-catalyzed 
hydrolysis of polyanhydrides. 
5.4.4 Screening polymer-model drug interactions  
Group contribution methods were used to estimate solubility parameters of 
CPTEG:SA copolymers and model drugs for initial in silico screening of polymer and drug 
interactions (Table 5.3) and to test their relationships with copolymer chemistry and drug 
release kinetics. The Fedors method yielded d values that increased as CPTEG content 
increased. The d values for both model drugs and poly(CPTEG) were similar. Given the 
similarity in d values for compounds tested, the Fedors method was not sufficient to explain 
differences in polymer-drug compatibility in this system. This necessitated the use of an 
alternative method, namely the Hoftyzer-Van Krevelen method. 
The Hoftyzer-Van Krevelen method yielded a greater difference in drug d values. 
Copolymers had greater δd than the model drugs, and δd increased with CPTEG content. 
RhoB had a greater δp than CBB, and δp stayed relatively constant across copolymer 
composition. The largest difference in drug δ components occurred in δh, where RhoB had a 
much greater δh than CBB. CPTEG:SA copolymers had δh values similar to RhoB, and δh 
increased as CPTEG content increased. Overall δ values were calculated from these 
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solubility parameter components. RhoB had a similar d to all copolymer compositions tested, 
whereas CBB showed a greater similarity to poly(SA) than poly(CPTEG). Dd values were 
calculated for polymer-drug pairs from Eq.1. Dd analysis predicted solubility for both model 
drugs in all copolymers tested in the nanoparticle library, because all Dd values were less 
than 5 (J/cm3)1/2. Solubility for both RhoB and CBB is predicted to decrease as CPTEG 
content increases. These Dd values were used to predict χFH values using Eq. 2. These χFH 
parameters predicted complete RhoB solubility only in 5:95 CPTEG:SA and poly(SA). No 
polymer in the analysis was predicted to provide complete CBB solubility. 
Melting point depression experiments were used to probe the thermodynamics of 
polymer-model drug mixing and to validate the results from group contribution methods 
(Figure 5.6). Polymer-model drug film libraries were synthesized and analyzed for Tm using 
DSC. RhoB produced a melting point depression effect for all CPTEG:SA copolymers tested 
(Figure 5.6a), wherein increasing volume fractions of the drug produced a larger magnitude 
of difference between the polymer-drug film (Tm) and the polymer control (Tm0). CBB 
produced a mild melting point depression effect for CPTEG:SA copolymers, with less than 
7°C of suppression for all films (Figure 5.6b). The 15:85 CPTEG:SA-CBB films did not 
show a melting point depression effect.  
The Flory-Huggins c parameter values were extracted from these melting point 
depression data using Eq. 3 (Figure 5.6c-d, Table 5.4). RhoB had negative c values for all 
copolymers except 30:70 CPTEG:SA, which is indicative of exothermic mixing 
interactions.29 The positive c values between 30:70 CPTEG:SA and RhoB is indicative of 
endothermic mixing. Copolymers with ≤10 mol% CPTEG, when mixed with CBB, had 
negative c values. Copolymers with ≥20 mol% CPTEG, when mixed with CBB, had positive 
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c values. The absence of a melting point depression effect in 15:85 CPTEG:SA-CBB films is 
indicative of a lack of mixing interactions or unfavorable mixing thermodynamics, which 
occurs at some sufficiently positive c value.29  
The high-throughput method was effectively integrated with the melting point 
depression analysis. Twenty-four different films could be autonomously dispensed from a 
combinatorially-synthesized copolymer library, a stock solution of drug in methylene 
chloride, and a diluting stream of methylene chloride. A multiplexed nitrogen evaporator 
allowed simultaneous drying of the films. Using this method, a library of polymer-drug films 
could be synthesized, dried, and prepared for DSC analysis within one day. 
5.5 Discussion 
Herein, we describe the value of a previously described automated high-throughput 
method to rapidly screen a newly discovered rapidly degrading polyanhydride copolymer 
system for its ability to serve as a carrier for drug delivery. The high-throughput method 
enabled rapid, simultaneous synthesis of multiple CPTEG:SA copolymers, which was 
validated by comparison with conventionally synthesized copolymers, as shown by the NMR 
and DSC data in Figure 5.1. This validation enables facile scaleup when lead formulations 
are identified. The high-throughput method yielded precise control over copolymer 
composition and molecular weight could be modified by altering reaction time (Table 5.1 & 
Supporting Table 5.1). Favorable thermal properties (e.g., Tm values that are higher than 
body temperature) with respect to processability and particle synthesis were identified for a 
subset of copolymers between 5:95 and 25:75 CPTEG:SA.   
The copolymer microstructure is of interest for drug delivery because microphase 
separation can affect encapsulated drug distribution and drug release profiles.12,30 Copolymer 
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sequence length analysis (Figure 5.2) indicated a weakly segregated block-like 
microstructure for CPTEG:SA copolymers, especially for copolymer compositions that are 
rich in one monomer. As the copolymer composition approached 50:50, the microstructure 
shifted toward an alternating architecture. These gradual changes in microstructure may be 
attributed to the differences in hydrophobicity between the amphiphilic CPTEG monomer 
and the weakly hydrophobic SA monomer.12 The high throughput, tight control over 
composition, and small mass scale offered by the combinatorial method proved especially 
advantageous to analyze this microphase separation. A high-resolution library spanning a 
wide range of compositions was synthesized with comparable material and time demands to 
a single batch of conventionally-synthesized copolymer. 
Understanding the degradation rate of biodegradable polymers is important for 
tailoring device drug release kinetics. Erosion of degradable polymers can be affected by 
composition, crystallinity, and local pH changes due to monomer dissolution.17,31 To this end, 
only semicrystalline CPTEG:SA copolymers were investigated to avoid confounding 
variables arising from compounded versus melt-pressed tablets, and a 14:1 aspect ratio was 
used to ensure nearly one-dimensional erosion. CPTEG:SA copolymers tablets exhibited 
rapid erosion, losing approximately 50% mass in four days (Figure 5.3). This CPTEG:SA 
mass loss rate was much faster than the 20:80 CPH:SA tablets in the same geometry (Figure 
5.3). Previous experiments in 10 mm diameter 20:80 CPH:SA tablets showed a 50% mass 
loss in less than two days,12 which is attributed to the much smaller tablet aspect ratio than 
the tablets used herein. CPTEG:SA erosion was faster than CPTEG:CPH copolymers as well, 
which show half-lives on the order of six days to >one month in the 10 mm tablet 
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geometry.17 CPTEG:SA polymer films have been shown to degrade faster in nanopure water 
than CPH:SA or CPTEG:CPH polymers,16 supporting these results. 
Polymer molecular weight influences viscosity and dissolution in solvents, and 
therefore can impact nanoparticle synthesis by nanoprecipitation. A 5 h reaction time for 
CPTEG:SA libraries, corresponding to Mn’s between 12-15 kDa, was found to be optimal for 
conventional nanoparticle synthesis (Supporting Figure 5.5). The high-throughput 
methodology allowed rapid screening of copolymer properties, which aided the reduction in 
design space to copolymers containing <40 mol% CPTEG.  
Drug delivery vehicles can improve the activity of hydrophobic drugs by increasing 
their bioavailability.32 Poly(lactic-co-glycolic acid) nanoparticles have been used to improve 
the bioavailability and efficacy of the hydrophobic drug ivermectin, an antiparasitic used to 
treat lymphatic filariasis, which suffers from poor bioavailability in deep tissues.33 Similarly, 
20:80 CPTEG:CPH nanoparticles co-delivering ivermectin and the hydrophilic drug 
doxycycline achieved macrofilaricidal effects with 4000-fold less drug than soluble 
controls.13 RhoB and CBB were used as two hydrophobic model drugs to test the CPTEG:SA 
copolymers’ potential for controlled release. The high-throughput method was used to 
synthesize drug-encapsulating, sub-micron particle libraries at high encapsulation efficiency. 
The nanoparticle libraries demonstrated chemistry-dependent, controlled release capabilities 
over three days as shown in Figure 5.5. Drug release kinetics were slower in acidic 
environments, while maintaining chemistry dependence, consistent with the base-catalyzed 
degradation of polyanhydrides.5,34  
The rapid release from CPTEG:SA nanoparticles adds a new tool in designing 
polyanhydride-based drug delivery devices, because conventional CPH:SA and CPTEG:CPH 
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nanoparticles release their payloads on the order of several weeks to several months.5,35,36 
Some biomedical applications, such as delivery of antimicrobial therapeutics to counter acute 
infections, may require release over shorter timescales, such as 3-5 days. Additionally, these 
CPTEG:SA nanoparticles could have competitive advantages for oral drug delivery. The 
gastric emptying half-life is approximately 1.2 hours,37 so the small burst release at low pH 
could protect labile drugs like insulin38 or protect the stomach from toxic drugs like cancer 
chemotherapeutics.39 The mean small bowel residence time is approximately four hours37 and 
the downstream colonic environment can be challenging for drug transport.39 Rapid release at 
more neutral pH, such as that displayed by CPTEG:SA nanoparticles, could exploit the 
favorable conditions for bloodstream partitioning in the intestine (i.e., high surface area of 
absorptive tissue and microvasculature).39 The high-throughput method aided rapid 
identification of nanoparticle properties by simultaneously synthesizing a two-dimensional 
nanoparticle library with varying copolymer chemistry and model drugs for encapsulation. 
The relationship between copolymer chemistry and drug release is driven by 
thermodynamic interactions between the copolymer and model drug. In microphase-
separated copolymers, drugs tend to partition into compatible microdomains until a saturation 
threshold is reached, after which they are forced to disperse into less favorable regions.12 
Differences in hydrophilicity of polyanhydride monomers result in different rates of erosion, 
so partitioning of the drug directly influences the rate of drug release. Unfavorable 
interactions between the drug and polymer can cause the drug to migrate to the surface, 
resulting in a more pronounced burst effect.40 Based on the erosion-mediated release of 
RhoB, we predicted favorable mixing thermodynamics for RhoB and CPTEG:SA 
copolymers. In contrast, the counter-intuitive release trends for CBB suggested unfavorable 
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interactions between the CBB and CPTEG monomer, because increasing CPTEG content 
increased the rate of release and the prevalence of the burst. 
Solubility parameter estimation by group contribution methods was used as a rapid 
screening tool to predict polymer-drug interactions and to test the hypotheses about mixing 
thermodynamics. Hildebrand solubility parameter predictions from the Fedors method are 
frequently used in the polymer literature, but rely on assumptions of no specific forces within 
the system.22 Given the semicrystallinity of the CPTEG:SA copolymers, the presence of 
polar groups in the model drugs, and the possibility of hydrogen bonding between the model 
drugs and the copolymers, it is unsurprising that this method failed to explain the differences 
in drug release in the system.23,41 In contrast, Hansen solubility parameter predictions from 
the Hoftyzer-Van Krevelen method take into account dispersion forces, polar forces, and 
hydrogen bonding.22 This method captured more of the hypothesized differences in polymer-
drug interactions between RhoB and CBB. Based on Δδ and χFH predictions, RhoB was 
expected to be more soluble in CPTEG:SA copolymers than CBB. This result matched 
observations in release kinetics, where RhoB exhibited erosion controlled release while CBB 
showed precipitation-mediated release (Figure 5.5). For both drugs, increasing CPTEG was 
expected to correlate with poorer drug solubility. This prediction agrees with the increasing 
burst with increasing CPTEG for CBB-encapsulating particles, but no such trend was 
observed for RhoB. It is possible that the difference between RhoB-CPTEG:SA and CBB-
CPTEG:SA Dd and χFH values are large enough to discriminate solubility and insolubility 
between the drugs in CPTEG-rich polymers, but the heuristics for solubility in the Hoftyzer-
Van Krevelen method did not have predictive power for explaining release kinetics trends. 
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However, the Hoftyzer-Van Krevelen method could provide useful information for 
polyanhydride nanomedicine design by more clearly depicting contributions of dispersion 
forces, polar forces, and hydrogen bonding to polymer-drug compatibility. For example, 
CPTEG-rich chemistries may be more appropriate for payloads with high hydrogen bonding, 
whereas SA-rich chemistries may be more appropriate for those with more moderate 
hydrogen bonding. Neither homopolymer was predicted to have high polarity (as expected, 
based on their hydrophobicity), so stabilizers/excipients or alternate chemistries may be 
needed for highly polar payloads.  
Melting point depression results (Figure 5.6)  showed better agreement with release 
kinetics trends than group contribution analysis. RhoB showed a strong diluent effect within 
CPTEG:SA copolymers, corresponding with a negative χ and exothermic mixing for 
copolymers with compositions between 5:95-25:75 CPTEG:SA (Table 5.4). Negative χ 
values indicate strong adhesive interactions and a tendency toward miscibility.29 CBB 
showed a milder diluent effect, producing χ values that were higher than those of RhoB for 
the given copolymer chemistries. Copolymers with ≥15 mol% CPTEG had positive χ values, 
which corresponds with endothermic mixing. Positive χ values indicate strong cohesive 
interactions and a tendency towards phase separation.29 Mixing interactions between the 
copolymer and model drugs are driven by interactions between the drugs and individual 
monomers, as well as by the polymer architecture. The melting point depression-derived c 
values for the model drugs went from negative to positive for copolymer compositions 
around 15:85-25:85 CPTEG:SA (Table 5.4). This region is predicted to represent a shift from 
weakly segregated block-like microstructure to an alternating copolymer system (Figure 5.2). 
Both drugs were predicted to be more soluble in SA-rich polymers than in CPTEG-rich 
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polymers by group contribution methods (Table 5.3). As the copolymer becomes more 
alternating in sequence, there are likely fewer and smaller SA-rich domains in the copolymer 
for the drugs to distribute into.42 Therefore, there is likely a critical composition threshold 
wherein CPTEG-model drug interactions begin to drive drug precipitation out of the 
copolymer. As RhoB has less unfavorable interactions with CPTEG than CBB by Δδ 
analysis, it is predicted that RhoB would have a higher precipitation threshold than CBB. 
Indeed, this transition appears to occur between 25:75 and 30:70 CPTEG:SA for RhoB and 
between 10:90 and 15:85 CPTEG:SA for CBB. However, such a threshold would be 
expected to correspond with an increased burst, which was not observed for 30:70 
CPTEG:SA RhoB particles. 
These results have identified shortcomings in the current framework of using 
thermodynamic mixing relationships to explain release kinetics behavior from polyanhydride 
nanoparticles. It is possible that polymer-drug mixing kinetics during nanoparticle synthesis 
are different than those in thermal analysis experiments for polymer drug films. Additionally, 
microphase distribution within CPTEG:SA nanoparticles may be sufficiently different from 
polymer films to significantly alter drug localization, thereby affecting release kinetics. 
Given these shortcomings, the current framework still needs further development.  
Overall, the high-throughput method was capable of rapidly synthesizing libraries of 
polymer-drug films, which facilitated screening for favorable interactions. Pairing in silico 
thermodynamic predictions with in vitro validation efficiently estimated polymer-drug 
mixing interactions, although their predictive power for release kinetics was limited. 
Altogether, the proposed framework can be useful in the rational design of nanomedicine 
formulations for drug delivery. 
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5.6 Conclusions 
CPTEG:SA copolymers exhibit rapid, tunable erosion and interesting nanoparticle 
properties for drug delivery. The high-throughput methodology described in this work 
enabled efficient screening of bulk polymer properties with good agreement with 
conventionally synthesized polymers. This high-throughput method was used to synthesize 
and characterize the controlled small molecule drug release from CPTEG:SA nanoparticles, 
revealing chemistry-dependent effects. This recently discovered copolymer system 
demonstrates tunable release of hydrophobic model drugs at short timescales, which is 
slower in acidic conditions. The high-throughput method was adapted to synthesize polymer-
drug films to screen for thermodynamic mixing interactions by melting point depression, 
which showed mixed agreement with predictions from group contribution methods. An 
important trend that these methods identified is that CBB is predicted to become increasingly 
insoluble in the copolymer as CPTEG content increases. This supports our hypothesis that 
the trends in release kinetics for CBB-loaded particles is driven by partitioning of CBB to the 
particle surface with increasing CPTEG. These methods were less capable of explaining 
RhoB release, as some methods predicted partial solubility while others predicted full 
solubility for a model drug that showed erosion-controlled release. These polymer-drug 
interaction screening data were able to explain trends in drug release from nanoparticle 
libraries. 
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Table 5.1 Characterization of CPTEG:SA copolymers synthesized using the high-throughput 
method. Values in parentheses indicate averages for conventionally-synthesized 
copolymers.16 
Copolymer Actual Molar Ratio Mn (Da) Tm (°C) 
Reaction 
Time (h) 
05:95 CPTEG:SA 04:96 (04:96) 30,100 (24,700) 76.8 (74.6) 7 
10:90 CPTEG:SA 11:89 (09:91) 27,100 (29,800) 71.8 (70.0) 7 
15:85 CPTEG:SA 16:84 (14:86) 23,900 (25,900) 65.9 (64.5) 7 
20:80 CPTEG:SA 21:79 (20:80) 19,500 (21,100) 65.2 (58.9) 7 
25:75 CPTEG:SA 25:75 (23:77) 20,900 (36,300) 60.2 (52.3) 7 
30:70 CPTEG:SA 30:70 18,300 54.6 7 
35:65 CPTEG:SA 35:65 16,700 48.9 7 
40:60 CPTEG:SA 42:58 14,400 TD 6 





Table 5.2 Characterization of non-encapsulating and model drug-encapsulating nanoparticle libraries. Count mean size distributions 
were calculated from SEM micrographs. Rhodamine B formulations showed >100% measured encapsulation efficiency (values in 
parentheses), which are interpreted as 100%. Data are presented as mean ± standard deviation. 
 
 Unloaded 5% Rhodamine B 5% Coomassie brilliant blue 



















CPTEG:SA 272 ± 90 -37.7 ± 3.4 299 ± 101 -6.4 ± 0.4 100% (128%) 291 ± 95 -34.3 ± 0.6 35.7% 
10:90 
CPTEG:SA 319 ± 107 -46.0 ± 1.0 295 ± 105 7.2 ± 1.2 100% (131%) 356 ± 141 -41.7 ± 0.9 42.1% 
15:85 
CPTEG:SA 342 ± 129 -38.0 ± 1.1 328 ± 121 -6.7 ± 1.4 100% (129%) 366 ± 145 -49.2 ± 0.7 46.7% 
20:80 
CPTEG:SA 363 ± 126 -42.9 ± 0.3 425 ± 165 12.0 ± 0.8 100% (146%) 442 ± 194 -50.0 ± 2.0 44.3% 
25:75 
CPTEG:SA 418 ± 156 -41.7 ± 1.9 552 ± 231 17.7 ± 1.5 100% (119%) 535 ± 240 -46.6 ± 1.3 58.0% 
30:70 




Table 5.3 Group contribution method estimation of polymer and model drug solubility parameters. Units are as follows: V (cm3/mol), 
δ’s (J/cm3)1/2. Dd and cFH values at 298 K were predicted using Eq. 1 and 2, respectively. 
 Fedors Hoftyzer-Van Krevelen 
Polymer or Compound V (cm3/mol) δ (J/cm3)1/2 δd δp δh δ Δδ RhoB Δδ CBB χFH RhoB χFH CBB 
0:100 CPTEG:SA 17247 21.0 17.9 0.6 7.5 19.4 2.5 3.4 0.44 0.84 
5:95 CPTEG:SA 17722 21.2 18.1 0.5 7.7 19.7 2.6 3.6 0.47 0.94 
10:90 CPTEG:SA 18196 21.4 18.4 0.5 7.8 20.0 2.7 3.8 0.51 1.03 
15:85 CPTEG:SA 18670 21.6 18.6 0.5 7.9 20.2 2.8 4.0 0.56 1.14 
20:80 CPTEG:SA 19144 21.8 18.8 0.5 8.0 20.5 2.9 4.1 0.62 1.24 
25:75 CPTEG:SA 19618 21.9 19.0 0.5 8.2 20.7 3.1 4.3 0.68 1.35 
30:70 CPTEG:SA 20092 22.1 19.2 0.5 8.3 20.9 3.2 4.5 0.75 1.46 
100:0 CPTEG:SA 26730 23.6 21.2 0.5 9.2 23.2 5.0 6.4 1.82 2.96 
Rhodamine B 339 23.0 17.3 2.9 7.3 19.0 





Table 5.4 Interaction parameters calculated from melting point depression of polymer-model 
drug films. c values were predicted from Figure 5.8 data using Eq (3). No melting point 
depression effect was observed for 15:85 CPTEG:SA-CBB films. 
Copolymer χ RhoB χ CBB 
05:95 CPTEG:SA -18.3 -2.6 
10:90 CPTEG:SA -9.9 -2.6 
15:85 CPTEG:SA -8.7 N/A 
20:80 CPTEG:SA -0.2 0.6 
25:75 CPTEG:SA -4.9 1.4 




Figure 5.1 Representative 1H NMR spectra and DSC thermograms of CPTEG:SA copolymer 




Figure 5.2 CPTEG:SA copolymer microphase composition analysis. (a) CPTEG:SA number 
average sequence length, determined from 1H NMR. (b) CPTEG:SA reactivity ratio, 
determined from 1H NMR.  
115 
 
Figure 5.3 Percent mass lost from tablets of CPTEG:SA copolymersin PBS, pH7.4. Data are 
presented as mean ± standard deviation. 
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Figure 5.5 Model drug release from nanoparticle libraries. (a,b) RhoB (a) or CBB (b) release 
from 5% loaded (w/w) CPTEG:SA nanoparticles in PBS, pH 7.4. (c,d) RhoB (c) or CBB (d) 
release from 5% loaded CPTEG:SA nanoparticles in acetate buffer, pH 4.3. In both buffers, 
RhoB release profiles follow erosion trends from polymer tablets, while CBB release profiles 
are inverted from these trends. Data are presented as mean ± standard deviation. 
 
Figure 5.6 Melting point depression of polymer-model drug films. (a) DSC thermograms of 
05:95 CPTEG:SA-RhoB films at 0%, 9%, 17%, 23%, and 29% (w/w) RhoB, from bottom to 
top. The melting point is gradually decreased with increasing  (b) DSC thermograms of 05:95 
CPTEG:SA-CBB films at 0%, 17%, 23%, and 29% (w/w) CBB, from bottom to top. (c,d) 
Determination of the polymer-model drug interaction parameters from melting point 
depression data for RhoB (c) and CBB (d). Quadratic curves were fitted and c values were 
extracted using Eq. (3).  
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5.10 Supporting Information 
Supporting Table 5.1 Effect of reaction time on copolymer molecular weight and 
nanoparticle size distribution. Molecular weight was determined by 1H NMR, and 
nanoparticle diameter was determined by SEM. Cells left blank indicate no nanoparticles 
were recovered. Size distributions are presented as mean ± standard deviation. 
 Reaction time: 4 hours 5 hours 6 hours 10 hours 
10:90 CPTEG:SA 
Mn (Da) 14,000 14,800 15,300 27,900 
Diameter (nm) 297 ± 125 291 ± 107 370 nm ± 165 286 ± 98 
20:80 CPTEG:SA 
Mn (Da) 12,000 13,600 14,000 24,300 
Diameter (nm) 445 ± 114 657 ± 257 492 ± 155 355 ± 126 
30:70 CPTEG:SA 
Mn (Da) 11,800 12,200 14,600 24,800 
Diameter (nm) 796 ± 189 868 ± 313 1,054 ± 350 N/A 
40:60 CPTEG:SA 
Mn (Da) 10,600 14,000 14,400 18,400 
Diameter (nm) 295 ± 123 1,505 ± 204 N/A N/A 
50:50 CPTEG:SA Mn (Da) 11,200 12,700 16,500 20,800 
 
 
Supporting Figure 5.1  1H NMR spectrum of CPTEG diacid. 
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Supporting Figure 5.2 CPTEG:SA copolymerization scheme. CPTEG (1) and SA (2) 
dicarboxylic acid monomers are acetylated in acetic anhydride, yielding CPTEG (3) and SA 
(4) prepolymers. Acetic anhydride is removed by rotary evaporation and the remaining 
prepolymers are reacted under vacuum to yield CPTEG:SA copolymers (5). Polymerization 
used a melt polycondensation mechanism, where acetic anhydride is produced and 










Hydrogen Shift # of H Splitting 
a 8.0 4 d 
b 7.0 4 d 
c 4.2 4 t 
d 3.9 4 m 
e 3.75 4 m 
f 2.6 2 t 
f' 2.45 2 t 
g 1.65 4 m 
h 1.32 8 m 


























































































































































































































































































































































Supporting Figure 5.3 CPTEG:SA 1H NMR peak assignment and labeled spectra of high-
throughput polymer library. 
 
Supporting Figure 5.4 DSC thermograms of CPTEG-rich copolymers. 40:60 CPTEG:SA was 





























































































Supporting Figure 5.5 Screening high-throughput CPTEG:SA copolymers for conventional 
nanoparticles. Size distributions are provided in Supporting Table 5.1. Empty spaces indicate 
that no particles were able to be recovered due to polymer tackiness. The 5 hour reaction 
time was selected for ongoing experiments as it produced the most discrete, sub-micron 







Supporting Figure 5.6 Optimization of high-throughput nanoparticle synthesis conditions. Methylene chloride (DCM) and chloroform 
were tested as solvents, and pentane and hexanes were tested as anti-solvents at 4, –10, and –20°C. For all, polymer concentration in 
methylene chloride was kept constant at 20 mg//mL and solvent to anti-solvent ratio was kept constant at 1:9. Scale bars represent 1 
µm (black), unless noted otherwise (white, 10µm). Star represents the optimal conditions for synthesizing spherical, sub-micron 
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Nanoparticle carriers can improve antibiotic functional efficacy by altering drug 
biodistribution. However, the dataspace is massive, limiting the feasibility of traditional 
screening approaches. Informatics-assisted screening could streamline screening, but 
nanoparticle efficacy is governed by nonlinear relationships with descriptors that are 
challenging to model. A hybrid informatics approach was used to identify polymer, drug, and 
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nanoparticle properties that determine the antimicrobial activity of nanomedicines against the 
opportunistic, intrinsically resistant pathogen Burkholderia cepacia, and to develop a model 
for predicting nanomedicine performance. Polymer Tg, polymer backbone Ngroup, drug 
LogP3, nanoparticle diameter and zeta potential, the fractional drug released at two hours, 
and the mass of drug released at 24 hours were identified as key descriptors associated with 
particle antimicrobial performance. Graph analysis provided dimensionality reduction of the 
descriptor space while preserving nonlinear descriptor-property relationships, enabling 
accurate modeling of nanomedicine performance. Out-of-library validation confirmed the 
model’s accuracy, supporting its use in prioritizing candidate formulations and cocktails for 
in vitro testing based on predicted performance. This approach provides an important step 
toward the development of a framework to rationally design nanomedicines with improved 
potency to counter antimicrobial resistant infections. 
6.2 Introduction 
Burkholderia cepacia complex (BCC) bacteria are a group of hard-to-treat 
opportunistic pathogens primarily affecting immunocompromised and cystic fibrosis (CF) 
patients [1]. BCC bacteria are only present in a minority of CF infections, approximately 2–
4% of CF patients [2,3]. BCC infections can be highly virulent, in some cases causing 
necrotizing pneumonia and septicemia, and are “correlate[d] with poorer prognosis, longer 
hospital stays[,] and an increased risk of death” for CF patients [1]. All species of BCC 
bacteria exhibit intrinsic resistance to multiple antibiotic classes due to efflux pumps, β-
lactamases, trimethoprim-resistant dihydrofolate reductase, and lipopolysaccharide moieties 
that have been implicated in resistance [1]. Additionally, a B. cepacia clinical isolate has 
shown the ability to enter and survive within cultured human macrophages and epithelial 
cells [4]. This intracellular lifestyle establishes the host cell membrane as an additional 
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diffusional barrier to antibiotics, further contributing to the resistance of BCC pathogens. 
Due to these factors, BCC infections can be extremely challenging to treat, to the extent that 
94% and 50% of B. cenocepacia and B. multivorans infections become chronic despite 
antimicrobial therapy, respectively [2]. There exists an unmet need for effective 
antimicrobial therapies against BCC pathogens, as a recent review identified a complete lack 
of high-quality studies investigating either therapies to eradicate BCC infections or to prevent 
or delay chronic BCC infections [2].  
Nanoscale delivery vehicles constitute a modern approach to the challenge of 
antibiotic delivery for intracellular infections. Such technologies can improve the 
intracellular localization of antibiotics by guiding the drugs past complex biological barriers 
such as the host cell membrane [5,6]. Polyanhydride nanoparticles, synthesized from 
biodegradable copolymers with high biocompatibility [7–9], are internalized by the 
phagocytic cells targeted by BCC pathogens and distribute into intracellular niches wherein 
such pathogens reside [5]. By this mechanism, antibiotic-loaded polyanhydride nanoparticles 
have been shown to improve the in vitro activity of doxycycline of against intracellular 
Brucella abortus [5], and to improve the in vitro and in vivo performance of rifampicin 
against Brucella melitensis [10]. These nanoparticles have also been shown to achieve faster 
killing rates and lower effective concentrations against parasitic filarial worms than soluble 
drugs by co-delivering an antiparasitic drug and doxycycline, which targets an endosymbiotic 
bacterium of the worms [11]. Additionally, the antibiotic release kinetics from these 
nanoparticles can be tuned based on drug and polymer chemistry as well as nanoparticle size 
[12]. This controlled release, coupled with their passive targeting of intracellular niches, can 
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alter the absorption, distribution, metabolism, and excretion properties of the drug to 
maintain consistent selective pressure against pathogens. 
While polyanhydride nanoparticles have demonstrated the potential to contribute 
improved therapies against bacteria, to date the identification of such formulations has relied 
on a traditional screening approach. This poses an immense feasibility challenge as the data 
space expands significantly from individual microbial susceptibility factors and drug 
physicochemical properties to now include polymer chemical and material properties as well 
as nanoparticle gross material properties. Hierarchical modeling offers a pragmatic solution 
to this problem, wherein key descriptors are identified and correlated to antimicrobial 
performance. Our group has previously used such an approach to develop a graph-theory 
based framework to predict release kinetics based on key polymer, drug, and nanoparticle 
physicochemical properties [12].  
The focus of this work was to expand upon the existing framework by identifying 
polymer, drug, and nanoparticle properties that strongly influence the in vitro antimicrobial 
potency of individual nanoformulations. The major goal was the development of a predictive 
model to suggest untested nanoformulations or combinations of nanoformulations with high 
antimicrobial activity to improve screening efficiency. This would constitute an important 
step toward our long-term goal of developing predictive analytics frameworks to enable 
rational design of nanomedicines for therapeutic applications. 
6.3 Materials & Methods 
6.3.1 Materials 
Monomer and polymer synthesis used sebacic acid (SA), triethylene glycol, 4-p-
hydroxybenzoic acid, 1-methyl-2pyrrolidinone, and 1,6-dibromohexane purchased from 
MilliporeSigma (Burlington, MA), potassium carbonate, dimethyl formamide, toluene, 
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acetonitrile, acetic acid, sulfuric acid, N,N-demethylacetamide, and acetic anhydride from 
Thermo Fisher Scientific (Waltham, MA), and 4-p-fluorobenzonitrile from Apollo Scientific 
(Cheshire, U.K.). Methylene chloride, pentane, and hexane from Fisher Scientific were used 
in polymer purification and nanoparticle synthesis. 1H NMR analysis was performed in 
deuterated chloroform from from Cambridge Isotope Laboratories (Andover, MA). 
Antibiotic payloads doxycycline (DOX), rifampicin (RIF), and gentamicin (GEN) were 
obtained from MilliporeSigma, meropenem (MEM) from Ark Pharm (Arlington Heights, IL) 
and ceftazidime (CAZ) from Acros Organics (Thermo Fisher Scientific). Drug quantification 
used UV-transparent microplates from Greiner Bio-One (Kremsmünster, Austria), HPLC-
grade acetonitrile, methanol, and trifluoroacetic acid from Thermo Fisher Scientific, and 
phosphoric acid and o-phthaldialdehyde from Sigma-Aldrich. Burkholderia cepacia strain 
UCB 717 was obtained from BEI Resources, NIAID, NIH (Bethesda, MD). 
6.3.2 Polymer and Particle Synthesis and Characterization 
CPTEG and CPH diacids were synthesized as described previously[8,13,14]. 20:80 
CPTEG:CPH [8], 20:80 CPH:SA [12], and 10:90 CPTEG:SA [15] copolymers were 
synthesized by melt condensation as described previously. Briefly, appropriate masses of 
monomers were added to a round bottom flask and acetylated in excess acetic anhydride at 
125°C for 30 min. Excess acetic anhydride was removed from these prepolymers by rotary 
evaporation. CPTEG:CPH was polymerized for 6-8 h at <0.1 Torr to a number average 
molecular weight (Mn) of 5-10 kDa, while CPH:SA and CPTEG:SA polymers were 
polymerized for 80 min at 0.25 – 0.3 Torr to a Mn of 15-20 kDa. Polymers were purified by 
precipitation in chilled hexanes. Polymer composition and Mn were characterized by 1H 
NMR spectra acquired on a Varian MR-400 (Varian, Inc., Palo Alto, CA) and thermal 
properties were characterized by DSC (Q2000, TA Instruments, New Castle, DE).  
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Antibiotic-loaded particles were synthesized using a previously described high-
throughput flash nanoprecipitation method [12]. Briefly, polymer and drugs were 
dissolved/dispersed in methylene chloride and dispensed using a high-throughput, automated 
robot into 10 mL borosilicate tubes at a final polymer concentration of 20 mg/mL. The robot 
sonicated the mixed solutions and dispensed into 50 mL conical polypropylene tubes 
containing 45 mL hexanes (-10°C for CPTEG:CPH, room temperature for CPH:SA and 
CPTEG:SA) to precipitate the particles. Gentamicin-loaded particles were synthesized by 
conventional flash nanoprecipitation [12] as the antibiotic was too insoluble in methylene 
chloride to be dispensed with the robot. Multiple particle batches for each formulation were 
pooled and recovered by vacuum filtration. Scanning electron microscopy (SEM, FEI Quanta 
250, Hillsboro, OR) was used to image all nano- particles, and size distributions were 
calculated using Fiji image analysis software [16] and the ParticleSizer plugin script for Fiji 
[17]. Particle ζ-potential was measured using a Zetasizer Nano (Malvern Instruments Ltd., 
Worcester, U.K.).  
Particle release kinetics were characterized as described previously [12]. Briefly, 9-11 
mg particles were dispersed in 0.5 mL phosphate buffered saline (PBS), and supernatants 
containing released drug were extracted at regular time points. After one week of release in 
PBS, 40 mM sodium hydroxide was added to rapidly degrade the polymer, freeing any 
remaining entrapped drug. Meropenem and ceftazidime in release and base extraction 
samples were quantified by RP-HPLC-UV (1200 series, Agilent Technologies, Santa Clara, 
CA). For brevity, HPLC protocol details are provided in Supplemental Table 6.1. 
Doxycycline and rifampicin were quantified by UV spectrophotometry in UV-transparent 96-
well plates using absorbance at 350 and 333 nm, respectively (SpectraMax M3, Molecular 
 135 
Devices, San Jose, CA). Gentamicin samples were derivatized with o-phthaldialdehyde [18] 
prior to quantification using absorbance at 340 nm. Encapsulation efficiency (EE) was 
calculated from the cumulative sum of drug mass released in PBS and base extraction 
samples [12]. In some samples >100% EE was observed, likely due to greater masses of 
polymer than payload being lost during particle synthesis [12]. For these situations, EE is 
interpreted as a “normalized EE” of 100%. Drug release kinetics are presented as fraction 
released, where the cumulative drug mass release is normalized by the total encapsulated 
drug mass. Release kinetics were parameterized for the informatics analysis by calculating 
the fraction released at 2 h and 24 h (burst release) and the slope of the release profile at 2 h 
and 24 h using the nearest neighbors in the time domain.  
6.3.3 Antimicrobial Susceptibility Assays 
Growth inhibition assays followed CLSI guidelines for broth microdilution 
antimicrobial susceptibility testing. Cultures of B. cepacia UCB 717 in Mueller Hinton 
Media were diluted to an OD600 value of 0.5. Fifty µL aliquots of a 1:100 dilution of this 
solution were added to well plates, and 50 µL of the treatment was added to yield a final 
volume of 100 µL. Resazurin reduction was used to quantify changes in bacterial viability. 
From these viability curves, half maximal inhibitory concentrations (IC50) were extracted for 
soluble drug controls and nanoparticle treatments. Nanoparticle IC50 values were normalized 
by EE to reflect the maximal potential dose from nanoparticles regardless of release kinetics. 
As we are interested in identifying nanoparticle candidates that improve antibiotic activity, 
the Log2 ratio of the nanoparticle to soluble IC50 was defined as the objective function for 
antimicrobial performance.  
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6.3.4 Informatics Analysis 
Log2 ratios for individual nanoparticle formulations and cocktails, along with 
polymer, drug, and nanoparticle properties, were normalized and mean centered. Three 
different informatics approaches were integrated in a hybrid approach to identify interesting 
features in the data, develop structure-function relationships, and model nanoparticle 
antimicrobial performance. Principal component analysis (PCA), a linear manifold learning 
approach, was used to reduce the dimensionality of the data to analyze the impact of 
individual descriptors on nanoparticle performance [19–21]. Through eigenvector 
decomposition, PCA defines composite orthogonal axes that are constructed from linear 
combinations of descriptors, maximizing the variance captured within a minimal set of these 
axes (termed principal components or PCs). The original data are decomposed into two 
matrices: the loadings and scores. Loadings describe the contributions of input descriptors to 
each PC, while scores describe the objective function (i.e. Log2) of each formulation or 
cocktail in the PC space. From the loadings matrix, the variable importance projection (VIP) 
was calculated for each descriptor using Eq. 1. In this case, T = Log2 ratio, and x = 2 because 
two PCs captured  >80% of the variance. VIP analysis provides an estimation of the 
correlation of individual descriptors to the objective function. 




PC regression modeling of Log2 values was found to be insufficient (data not shown), 
likely due to nonlinearity which is lost in the Euclidean decomposition of PCA. Graph 
analysis, using the Isomap algorithm, was used for nonlinearity-preserving dimensional 
reduction to parameterize the descriptor space [22,23]. This nonlinear manifold learning 
approach functions on the principal that for data lying on a non-linear manifold in high-
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dimensional space, points that are far apart by geodesic distances might appear closely 
related by Euclidean distance [22]. Graph theory generates a graph connecting closely related 
data points along the high-dimensional manifold via geodesic distances, and then projects 
onto a low-dimensional manifold. The manifold unravels in two or three dimensions, 
allowing visualization of the curvilinear relationships between formulations in high-
dimensional space as connecting lines in the low-dimensional projection. Therefore, graph 
analysis yields composite dimensions or parameters (in this case, five) based on nonlinear 
combinations of descriptors. Finally, a multilinear regression using these parameters was 
derived for modeling Log2 values of nanoparticles and cocktails. 
6.4 Results 
6.4.1 Particle Library Synthesis and Characterization 
For this analysis, we focused on nano- and microparticles synthesized from CPTEG, 
CPH, and SA copolymers (Figure 6.1a-c). Such nanoparticles demonstrate high 
internalization in phagocytic cells that are infected by Burkholderia spp [5,15,24], localize in 
intracellular compartments where these bacteria reside [24,25], and have been shown to 
improve the antimicrobial activity of encapsulated small molecule drugs [5,10,11]. Five 
antibiotics with orthogonal antimicrobial mechanisms and a range of physicochemical 
properties were used in these studies, namely rifampicin (transcription inhibition), 
doxycycline and gentamicin (translation inhibition), and meropenem and ceftazidime (cell 
wall synthesis inhibition) (Figure 6.1d-h). These antibiotics are all FDA-approved and have 
well-characterized pharmacokinetic, pharmacodynamic, and structural data available on the 
DrugBank database [26]. Meropenem and ceftazidime are commonly administered in the 
acute phase of Burkholderia pseudomallei treatment, while doxycycline was included in a 
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cocktail along with chloramphenicol and co-trimoxazole that served as the primary acute 
phase treatment until 1985 [27].  
These antibiotics were encapsulated within polyanhydride nano- and microparticles 
using high-throughput flash nanoprecipitation method at 5% and 10% loadings (w/w%) 
[28,29]. Gentamicin was too insoluble in methylene chloride for this high-throughput 
method, and was synthesized by conventional flash nanoprecipitation. This particle library 
was analyzed for size distributions, ζ-potential, release kinetics, and EE (Supplementary 
Figure 6.1, Table 6.1). Particle size was primarily influenced by polymer chemistry, with 
CPTEG:CPH and CPH:SA forming nanoparticles with mean diameters of approximately 150 
nm and 500 nm. CPTEG:SA formed microparticles with mean diameters of approximately 
1.3 µm. A moderately negative zeta potential was observed for nearly all particle 
formulations. Gentamicin formulations tended to have near-zero zeta potentials.  
Release kinetics from the particle library are shown in Supplementary Figure 6.2. All 
antibiotics except rifampicin showed burst-dominated release kinetics. CPTEG:CPH–
rifampicin formulations showed a high burst followed by a trickling sustained release 
through two weeks. CPTEG:SA–rifampicin formulations showed a similarly high burst 
followed by a steady sustained release through one week. CPH:SA–rifampicin formulations 
showed the most sustained-release of all chemistries tested, characterized by a moderate 
(<40%) burst followed by near zero-order release through two weeks. 
6.4.2 Antimicrobial Screening 
Broth microdilution antimicrobial susceptibility assays with Burkholderia cepacia 
strain UCB 717 were used to characterize nanoparticle efficacy. Resazurin reduction was 
used to calculate the IC50 for nanoparticles and soluble drug controls. Nanoparticles show 
lower effective concentrations, and improved antimicrobial activity relative to soluble 
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controls at negative log2 ratios. These formulations are referred to as “hits”. Conversely, a 
positive Log2 ratio corresponds with poorer nanoparticle activity compared to soluble drug. 
For example, if the soluble drug IC50 is 10 µg/mL and the nanoparticle IC50 is 5 µg/mL, the 
Log2 ratio would be –1. 
Single formulation antimicrobial activity is presented in Table 6.2. Strong hits 
(defined as Log2 < –0.5) tended to occur in ceftazidime and meropenem-based 
nanomedicines. For ceftazidime, this may be related to the relatively higher soluble IC50 
compared to the other drugs. Doxycycline-based nanomedicines produced a mix of weaker (–
0.5 < Log2 < 0) hits and non-hits (Log2 > 1), and showed the greatest inter-replicate 
variability of the four drugs tested. Rifampicin nanoparticles performed the worst, as no 
formulation showed improved activity over soluble drug. This is likely due to the delayed 
release kinetics in rifampicin nanoparticles (Supplementary Figure 6.2a) rather than 
increased resistance to the drug, as the soluble IC50 values for rifampicin are similar to 
doxycycline and meropenem. With respect to particle chemistry, CPH:SA–meropenem 
formulations showed a stronger tendency toward improved activity compared to 
CPTEG:CPH–meropenem formulations. By contrast, all other drugs showed comparable 
Log2 values across particle chemistries. Based on these results, ceftazidime-, meropenem-, 
and doxycycline-based nanomedicines show the potential to improve antimicrobial activity 
compared to soluble drug. 
Treating resistant infections with antibiotics using orthogonal antimicrobial 
mechanisms could provide improved killing and reduce the risk of persistence. Dual drug 
nanomedicine cocktails at differing drug mass ratios were tested and compared to soluble 
drug mixes (Table 6.3). Hits were exclusively composed of cocktails of ceftazidime-, 
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meropenem-, and doxycycline-based nanomedicines at 1:1 drug ratios. Altering the mass 
ratio of these antibiotics from 1:1 tended to reduce the antimicrobial performance, producing 
non-hits. However, some of these altered drug ratios reduced the soluble IC50 value. No 
nanomedicine cocktail including rifampicin produced a hit.  
Paired doxycycline and rifampicin were highly represented in the ten lowest soluble 
cocktail IC50 values. This supports the above hypothesis that orthogonal antibiotic 
mechanisms can improve antimicrobial activity, as rifampicin and doxycycline inhibit 
bacterial transcription and translation, respectively. By contrast, pairs of doxycycline, 
meropenem, and ceftazidime were highly represented in the ten highest soluble cocktail IC50 
values. For meropenem and ceftazidime, this result may be due to similar mechanisms of 
action, namely inhibition of cell wall biosynthesis. In accordance with these soluble drug 
cocktail results, the ten nanomedicine cocktails with the lowest IC50 values tended to include 
20:80 CPTEG:CPH–DOX and 20:80 CPTEG:CPH–RIF nanoparticles. Drug pairs of 
rifampicin with either meropenem or ceftazidime was strongly represented in the ten highest 
nanomedicine cocktail IC50 values. No strong particle chemistry effect was observed in these 
ten nanomedicine cocktails with high IC50 values. 
From these results in single formulations and nanomedicine cocktails, we conclude 
that both drug and particle chemistry influence antimicrobial activity in B. cepacia UCB 717. 
However, beyond gross generalizations about certain high- or low-performing drugs or 
particle chemistries, it is difficult to draw conclusions regarding the underlying reasons these 
formulation inputs are performing well. This means expanding our particle library outside the 
drug and particle chemistry dataspace represented in Table 6.2 and 6.3 requires repetition of 
the physical screening of these new formulations. This would require a massive endeavor 
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particularly for the nanomedicine cocktails, as the dataspace significantly expands with each 
new formulation. Accordingly, we sought to use these antimicrobial activity data to define 
QSPRs (expand) and enable virtual exploration of potential new nanomedicine-based single 
formulations and cocktails. 
6.4.3 Identifying Factors Influencing Antimicrobial Performance 
A hierarchical modeling approach was used to define these QSPRs, wherein key 
descriptors are identified based on correlations to nanomedicine performance and used as 
inputs to model antimicrobial activity. A descriptor set was defined from polymer material 
characteristics, polymer chemical structure (based on molecular descriptors describing molar 
average monomers previously used by Li et al.) [30], drug physicochemical properties 
(acquired from the Drugbank database) [26], nanoparticle material characteristics, and 
parameterized release kinetics and encapsulation efficiency (Table 6.4). 
To characterize the relative influence of these descriptors on antimicrobial activity in 
B. cepacia, we performed a PCA. This analysis compressed the 58 descriptor dimensions into 
composite axes (or PCs). In this case, two PCs captured 80.51% of the variability. PCs are 
ordered by decreasing variability captured, with PC1 capturing 59.97% and PC2 capturing 
20.56%. The contributions of each descriptor (Table 6.4) to each PC are plotted in a loadings 
plot (Figure 6.2), where each point is a different descriptor. Polymer material characteristics 
and polymer chemical structure adhered primarily along PC1. Nanoparticle material 
descriptors fell primarily along PC1, with a minor contribution to PC2. Drug 
physicochemical properties and nanoparticle release kinetics descriptors scattered across both 
PC1 and PC2. As the previous descriptor groups lied along PC1, PC2 was primarily 
composed of these drug physicochemical and release kinetics descriptors. All input 
descriptor groups contributed to PC1. The objective function, the Log2 ratio of nanoparticle 
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IC50 to Soluble IC50, did not adhere to either PC axis, indicating antimicrobial activity is 
influenced by all groups of polymer, drug, and nanoparticle physicochemical properties. 
While unsurprising, this result matches our conclusion from section 6.4.2. 
The Log2 values of individual particle formulations and cocktails are plotted in the 
compressed dimensional space in a scores plot (Figure 6.3). As the Log2 ratio was located in 
the bottom left quadrant in the loadings plot (Figure 6.2), more negative Log2 values (and 
corresponding improved antimicrobial performance relative to soluble drug) would follow a 
trajectory toward the upper right corner of the scores plot. Similarly, formulations with worse 
antimicrobial performance relative to soluble would fall to the bottom left of the plot. 
Nanomedicine cocktails tended to fall closer to the top right corner than individual 
nanomedicine formulations, indicating that cocktails provide improved antimicrobial activity 
over individual formulations.  
To assess the relative contributions of individual descriptors to the antimicrobial 
performance, a VIP analysis was performed. The correlation of each descriptor (Table 6.4) to 
the objective function was calculated from the loading matrix (Figure 6.4). In this plot, 
positive values indicate positive correlation (worse antimicrobial performance) and negative 
values indicate inverse correlation (better antimicrobial performance) with Log2 ratio. Of the 
57 descriptors included in the analysis, 21 descriptors were highly correlated to the objective 
function. Polymer Mn and Tg (#2 & 3, respectively) were positively correlated with Log2 
ratio. Within polymer chemical structural descriptors, only N_group (#17) was identified. It 
was inversely correlated with Log2 ratio. Of drug physicochemical properties, LogP1, LogP4, 
pKa (strongest acid), pKa (strongest base), physiological charge, and polarizability (#30, 33, 
35–37, 43) were positively correlated, while water solubility 2 and LogP3 (#31–32) were 
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inversely correlated with Log2 ratio. Within the nanoparticle material characteristics group, 
all nanoparticle size descriptors except count geometrical mean diameter (#45–48) were 
strongly positively correlated and zeta potential (#49) was inversely correlated with Log2 
ratio. For release kinetics, fraction of drug released, fractional release slope, and mass 
released at 24 hours (#53, 55, 57) were positively correlated, while fraction released and 
fraction release slope at two hours (#52, 54) were inversely correlated with Log2 ratio. These 
results indicate that faster, more burst-heavy release kinetics provide better nanomedicine 
antimicrobial performance than slower, sustained release kinetics.   
Hierarchical modeling requires the definition of a minimal descriptor space to 
maximize robustness. VIP analysis enables the identification of descriptors that contribute 
significant information, while also identifying descriptors that are correlated. This latter 
function allows the exclusion of variables that fail to contribute sufficient orthogonal 
information to other variables. Accordingly, polymer Tg, polymer backbone Ngroup, drug 
LogP3, nanoparticle diameter and zeta potential, the fraction drug released at two hours, and 
the mass of drug released at 24 hours (#3, 17, 32, 46, 49, 54, 57) were identified as key 
descriptors associated with particle antimicrobial performance.  
6.4.4 Modeling Nanomedicine Antimicrobial Performance 
The relationships between the particle input descriptors (Tables 6.1 & 6.4) and 
antimicrobial activity (Tables 6.2-6.3) are extensively non-linear. This nonlinearity limits the 
utility of linear techniques, like principal component regression, for modeling these data. 
Neural networks have been used to capture such nonlinearity; however, these models need to 
be trained on hundreds to thousands of points for robust predictions. We used a graph theory-
based modeling approach, which has the advantages of capturing nonlinear data structures 
while avoiding the overfitting problems of neural networks within smaller data sets. 
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A graph analysis was performed on the polymer, drug, and particle descriptors for all 
formulations and cocktails in the library, including those without IC50 or Log2 data, 
compressing these 57 descriptors into five composite dimensions. A projection of the first 
two dimensions are shown in Figure 6.5, wherein each point is a particle formulation or 
cocktail. The graph analysis preserves curvilinear distances between formulations by 
projecting the geodesic distances along the higher-dimensional non-Euclidean manifold onto 
Euclidean distances in the lower-dimensional (Euclidean) representation [22]. In this map, 
similar formulations or cocktails are connected by a line, whose Euclidean distance 
represents the geodesic distance along the higher-dimensional manifold. This connectivity 
was used to interrogate design pathways between formulations, for example examining the 
impact of changing the antibiotic payload or polymer chemistry on antimicrobial 
performance. 
Beyond analyzing formulation connectivity, the nonlinearity-preserving 
dimensionality reduction offered by graph theory can be used to develop a multilinear 
regression modeling antimicrobial performance for individual particle formulations and 
cocktails (Figure 6.6). Inclusion of all 57 input descriptors into this model reduces the risk of 
over-fitting the small data set. Formulations and cocktails without nanomedicine IC50 values 
were included in the graph analysis to create a parameter space that can be used to predict the 
performance of such untested systems. The Log2 value model was fairly accurate within the 
training data, with an R2 value of 70.8%. Cross-validation indicated reasonable robustness. 
The model is limited by a relatively outlying cocktail ({20:80 CPH:SA 10% CAZ} : {20:80 
CPH:SA 10% RIF} 1:1) which has a Log2 value of 4.498. Elimination of this outlier 
improves the model accuracy to 77.8%. However, the model still predicted this cocktail to be 
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have the highest Log2 value, which matches experimental observations. Additionally, 
variability between replicates of some samples contributed to the error of the model. For 
example, the {20:80 CPH:SA 5% CAZ} : {20:80 CPH:SA 5% DOX}1:1 cocktail had 
observed Log2 values of 1.80 and 0.17 and a predicted Log2 value of 0.354. Given these 
constraints, the seemed to perform well for the training data. By predicting Log2 ratios of 
individual nanomedicine formulations and cocktails, the graph theory-based model enables 
virtual exploration of untested treatments against B. cepacia. 
6.4.5 Model Validation 
To validate the use of this model to predict the performance of untested formulations 
and cocktails, out-of-library testing was performed. Four new nanomedicine formulations 
encapsulating a new drug chloramphenicol (CAM) within 20:80 CPH:SA and 10:90 
CPTEG:SA nanoparticles were synthesized and evaluated for their release kinetics 
(Supplementary Figure 6.3). Importantly, chloramphenicol contains two chlorine atoms and a 
nitro group (Supplementary Figure 6.4), which were not present in the training data set. The 
model was used to predict Log2 values for these previously untested formulations (Table 
6.5). The model predicted that 20:80 CPH:SA 10% chloramphenicol would have a Log2 
value of 0.874 (near half the potency of soluble drug), while the measured Log2 value was 
0.357. This formulation showed the largest deviation from predictions of the four, however 
the model predicted it as a non-hit. The model predicted the remaining three formulations to 
have slightly negative Log2 values (i.e. weak hits, with slightly lower IC50 than soluble drug) 
(Table 6.5). Experimental results matched these predictions more closely than the previous 
formulation, with measured Log2 values between -0.10 and +0.10. 10:90 CPTEG:SA 10% 
chloramphenicol was the only formulation to have a different measured Log2 sign than the 
predictions; however, this formulation had the predicted Log2 value closest to zero. While the 
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model had some error in its Log2 predictions, it successfully predicted the relative 
performance of these four out-of-library formulations. This justifies the use of this model to 
rank-order particle candidates for antimicrobial testing. Overall, based on the model 
predictions we would have expected these out-of-library candidates to provide either 
marginal improvements or worse performance than soluble drug, and would have assigned 
them a low priority for testing. Indeed, such a conclusion was validated by experimental 
results.  
We also sought to use the model to predict hits and non-hits from within a pool of 
potential nanoparticle cocktails. Previously untested 10:90 CPTEG:SA microparticles 
encapsulating ceftazidime, meropenem, or doxycycline were paired with either previously 
tested nanoparticle formulations or the new chloramphenicol formulations at 1:1 drug ratios, 
for a total of 33 potential cocktails. Predicted Log2 ratios for these potential cocktails were 
generated using the model and three cocktails, including two predicted well-performing (#12 
and #25) and one poor-performing (#32) were tested against B. cepacia (Table 6.5 and 
Supporting Table 6.2) in experimental studies. The predicted Log2 values for #12 and #25 (-
1.683 and -1.066, respectively) were in good agreement with their measured values of -1.829 
and -0.886, respectively. The model showed more error for the poor-performing #33, with a 
predicted Log2 value of 1.968 and an experimental value of 3.016. Overall, the model 
successfully predicted the hit and non-hit status of untested particle cocktails. As seen with 
the new formulations, the model successfully predicted the relative performance of the 
experimentally validated cocktails, supporting this model’s capability to rank candidate 
nanomedicine cocktails for antimicrobial testing.  
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6.5 Discussion 
Antimicrobial resistant (AR) infections constitute an existential threat to the modern 
healthcare system. The 2019 CDC report on antimicrobial resistance highlighted the fact that 
we are living in a post-antibiotic era [32]. The report underscored the need for new 
approaches to kill AR bacteria and methods to protect the potency of the existing antibiotic 
supply [32]. Nanomedicines based on polyanhydride nanoparticles have demonstrated the 
capacity to overcome certain deficiencies of conventional antibiotic therapies. By guiding 
antibiotics past challenging biological barriers, they have been shown to improve the activity 
of encapsulated antimicrobials [5,10,11,33]. This function could be exploited to bring the 
potency of underused antibiotics into therapeutic significance, potentially contributing new, 
orthogonal therapies. Alternately, this capacity could be leveraged to repurpose antibiotics 
that are currently limited due to resistance.  
Conventional antibiotics also pose challenges from a patient compliance perspective. 
High doses of antibiotics are currently used to overcome the host cell barrier for intracellular 
bacteria, increasing the risk of toxicity [34,35]. The high local dose generated by 
nanomedicines could reduce the systemic dose needed [33], reducing the risk of side effects. 
Antibiotic regimens tend to be frequent, lengthy, and many are invasive. Polyanhydride 
nanoparticles’ ability to package multiple drugs [11] coupled with their controlled release 
[12,36] and needle-free capabilities [37] could ease compliance for patients. Improving 
adherence to antibiotic regimens could slow the development of resistance [38]. By 
contributing new therapies for AR bacteria and improving compliance, nanomedicines have 
the potential contribute to the next generation of antimicrobial therapies. 
Unfortunately, conventional high-throughput screening approaches used to identify 
promising antimicrobial compounds are not a realistic solution for finding lead nanomedicine 
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candidates. The massive dataspace occupied by these nanomedicine formulations makes 
screening antimicrobial against biosafety level 1–2 pathogens like B. cepacia impractical, 
even more so for high biosafety level organisms like the potential bioweapons Burkholderia 
pseudomallei and mallei. Data analytics approaches, like the hybrid informatics hierarchical 
modeling approach used herein, could improve the efficiency of screening efforts by 
suggesting candidates with high-likelihood of success based on trends from existing screens, 
which could be validated experimentally. This approach has the benefit of improving 
predictive accuracy over time, as new data can be incorporated to iteratively refine the 
model. 
In this work, a library of polyanhydride nanoparticles with varying polymer chemistry 
and payload type were synthesized (Figure 6.1 and Supporting Figure 6.1), characterized for 
release kinetics (Supplementary Figure 6.2), and evaluated for antimicrobial activity against 
B. cepacia (Tables 6.2–6.3). QSPRs were developed by analyzing the correlations of 
polymer, drug, and nanoparticle descriptors to antimicrobial activity using VIP analysis 
(Figure 6.4). Twenty-one descriptors, comprising polymer material characteristics and 
chemical structure, drug physicochemical properties, and nanoparticle material and release 
kinetics factors, were strongly correlated with nanomedicine antimicrobial performance. 
While it is unsurprising that antimicrobial performance is a function of such a complex mix 
of properties, this result motivates the use of nonlinear manifold learning models, like graph 
theory, to deconvolute such complexity to capture subtle trends that impact performance. Of 
note, VIP analysis identified that nanomedicines with faster, more burst-heavy release 
kinetics provide better antimicrobial activity than slower, sustained release formulations. 
This provides evidence for our hypothesis that faster release kinetics would be more 
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efficacious against AR bacteria by providing a rapid, suppressive pressure against growth, 
given adequate nanoparticle localization.  
Graph theory was used to define a set of composite input parameters, based on 
dimensional reduction of polymer, drug, and particle descriptors, which were used to model 
the relative antimicrobial activity of single particle formulations and particle cocktails 
compared to soluble drug. This model showed good accuracy within the training data set, and 
successfully predicted whether candidate formulations or cocktails would significantly 
improve antimicrobial activity, provide no improvement in activity, or provide worse activity 
than soluble drug. The model also successfully predicted the relative performance of these 
untested formulations and cocktails in relation to each other. To our knowledge, this is the 
first time an informatics approach has successfully predicted the antimicrobial activity of 
antibiotic nano- and micro-carriers. Because the input descriptor space is defined from 
generalized physicochemical characteristics describing the nanocarrier and drug payload 
(Table 6.4), this modeling approach could easily incorporate new systems that are not 
represented in the training data set. For example, meropenem has several closely related 
chemical cousins within the carbapenem antibiotic family. The model could be used to 
identify the carbapenem derivative with the highest likelihood for nanoparticle improvement 
in activity. Alternatively, other carrier chemistries, such as altered compositions of CPH, 
CPTEG, and SA copolymers or poly(lactic-co-glycolic acid) (PLGA), could be virtually 
explored for promising antimicrobial activity using this modeling approach.  
We can only make confident quantitative predictions for systems that are represented 
within the training data space. There are likely systems with unique behavior outside this 
space which this approach will fail to quantitatively describe. This was observed, to some 
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extent, with the higher error in the out-of-library testing compared to the training data set. 
However, the objective of this approach for systems containing elements and chemical 
groups not in our training data is to identify polymer and drug combinations that have 
promising characteristics. This qualitative feature allows this approach to prioritize chemical 
spaces where more experimentation is needed, whose results can be iteratively fed back into 
the analysis to refine the model.  
Given these results, we propose a framework for rational design and selection of 
nanomedicine formulations and cocktails with improved antibiotic potency (Scheme 1). In 
the first step, nanomedicine libraries are synthesized from varying polymer chemistries and 
drug types via high-throughput methods, and the particles are evaluated for size distribution, 
zeta potential, and release kinetics. These nanomedicine candidates, along with cocktailed 
combinations thereof at multiple drug ratios, are then fed into the multilinear graph theory to 
generate predicted Log2 values. Formulations with Log2 values less than –0.5 (nanomedicine 
IC50 < 70% soluble IC50) can be discarded, and such cocktails can be disregarded. The 
formulations and cocktails with the most negative Log2 values can be prioritized for in vitro 
minimum inhibitory concentration testing, ideally providing new lead candidates for testing 
in more complex models. A feedback loop provides iterative improvement to the model and 
gradual optimization of candidates when formulations or cocktails fail to meet the efficacy 
threshold.  
This framework is designed to be modular, and could be interfaced with predictive 
frameworks for other performance criteria like drug release kinetics [12], cellular 
internalization for intracellular bacteria, and intracellular viability. This methodology uses 
publicly available drug chemistry information and standard polymer and nanoparticle 
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characterization techniques; therefore it could readily incorporate other nanocarrier platforms 
and antibiotic classes. This latter function could leverage the massive public and corporate 
investment [39], regardless of clinical approval outcome, into antibiotic development to 
provide new therapies against resistant bacteria like B. cepacia. Furthermore, identification 
of nanomedicine formulations and cocktails with improved drug activity could allow 
repurposing of antibiotics limited by resistance. In these ways, this hybrid analytics 
framework contributes an important step toward the rational design of antimicrobial 
nanomedicines to counter resistant infections. 
6.6 Conclusions 
A hybrid informatics approach was used to identify polymer, drug, and nanoparticle 
properties that determine the antimicrobial activity of nanomedicines against the 
opportunistic, intrinsically resistant pathogen Burkholderia cepacia, and to develop a model 
for predicting nanomedicine performance. Polymer Tg, polymer backbone Ngroup, drug 
LogP3, nanoparticle mass mean diameter and zeta potential, the fraction drug released at two 
hours, and the mass of drug released at 24 hours were identified as key descriptors associated 
with particle antimicrobial performance. Graph analysis provided dimensionality reduction of 
the descriptor space while preserving nonlinear descriptor-property relationships, enabling 
accurate modeling of nanomedicine performance. Out-of-library validation confirmed the 
model’s accuracy, supporting its use in prioritizing candidate formulations and cocktails for 
in vitro testing based on predicted performance. This hybrid analytics approach provides an 
important step toward the development of a framework to rationally design nanomedicines to 
counter antimicrobial resistant infections by selecting appropriate carriers and payloads for 
improved antibiotic potency.  
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6.8 Tables 
Table 6.1 Particle library material characterization and release kinetics parameterization.  
 
FR fraction released. Data are presented as mean ± SD. 
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Table 6.4 Material and Molecular Descriptors Correlated to Antimicrobial Activity. 
 
Key descriptors identified by variable importance projection analysis (Figure 6.4) are 
italicized and bolded. aDescriptors were previously used by Li et al. [30] and equation 
numbers refer to corresponding equations in Bicerano [31]. bDescriptors were gathered from 
the DrugBank database [26]. 






Figure 6.1 Chemical structures of polymers and antibiotics used in particle library. Structures 
of CPH:SA (a), CPTEG:CPH (b), and CPTEG:SA (c) copolymers, where m and n are the 
number of repeats for each unit. (d-h) Structure of rifampicin (RIF, d), doxycycline (DOX, 
e), gentamicin (GEN, f), meropenem (MEM, g), and ceftazidime (CAZ, h).  
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Figure 6.2 PCA loadings plot mapping individual descriptor contributions to each principal 
component. PC1 is composed of contributions from each input descriptor group. PC2 is 
primarily composed of drug physicochemical properties and nanoparticle release kinetics. 
Nanoparticle antimicrobial performance (purple star) does not adhere to either PC, indicating 
that each descriptor group contributes to nanoparticle antimicrobial activity. 
 
Figure 6.3 PCA scores plot mapping the antimicrobial activity of individual nanoparticle 
formulations and cocktails. Improved nanoparticle performance compared to soluble drug 
follows a trajectory toward the top right corner. Generally, nanoparticle cocktails provide 




Figure 6.4 Correlation of descriptors with nanoparticle antimicrobial performance. Positive 
values correspond to positive correlation and negative values to inverse correlation. Twenty 
descriptors (of 57) were highly correlated with Log2 ratio. VIP analysis enabled elimination 
of cross-correlated descriptors, resulting in a minimal descriptor set of seven descriptors 
(marked by *). Table 6.4 includes the full descriptor list. 
 
Figure 6.5 Graph analysis for parameterizing the descriptor space. Graph analysis was used 
for dimensional reduction of the 57 input descriptors (Table 6.4) into five composite 
parameters while preserving nonlinearity via geodesic distances. A projection along the first 
two (most important) dimensions is depicted. Each point represents a particle formulation or 
cocktail, and similar points are connected by a line. These paths of connectivity can be used 
to interrogate design relationships between formulations. Untested formulations and cocktails 
of interest (Tables 6.5-6.6) were included to create a parameter space suitable for predicting 
their behavior. The dimensionally reduced parameters from this graph analysis were used as 
inputs for the predictive model in Figure 6.6. 
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Figure 6.6 Graph theory-based model predicts nanoparticle formulation and cocktail 
antimicrobial performance. The model had an R2 value of 70.8%, and therefore was 
reasonably accurate within the training data set. Cross-validation analysis showed reasonable 
robustness. These calculations are based on a hybrid informatics approach where nonlinear 
manifold projections serve as the input, which maintains complexity in descriptor-property 
relationships while minimizing the risk of over-fitting and reducing computational power. 
6.10 Supplementary Materials 
Supplementary Table 6.1 High-pressure liquid chromatography separation and detection 








Supplementary Figure 6.1 Scanning electron micrographs of the particle library. Particle size 
and morphology was primarily dependent on particle chemistry, not on payload. Note: scale 
bar changes for 10:90 CPTEG:SA formulations. 
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Supplementary Figure 6.2 Antibiotic release kinetics from particles in library encapsulating 
rifampicin (RIF, a), doxycycline (DOX, b), gentamicin (GEN, c), meropenem (MEM, d), and 
ceftazidime (CAZ, e). Data are presented as mean ± SD. Error bars are not depicted in cases 
where the error bar height is smaller than the symbol. Release profiles were parameterized 
into a 2 h burst, a 24 h burst, and slopes of release at 2 h and 24 h. The release kinetics from 
20:80 CPTEG:CPH and 20:80 CPH:SA meropenem- and ceftazidime-encapsulating 
formulations were used as validation data in [12]. 
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Supplementary Figure 6.3 Antibiotic release kinetics from nanoparticles used in out-of-
library validation. Chloramphenicol (CAM) nanoparticles show a burst-heavy release profile. 
Data are presented as mean ± SD. 
 
Supplementary Figure 6.4 Chemical structure of chloramphenicol. Chloramphenicol (CAM) 





CHAPTER 7.    CONCLUSIONS AND ONGOING/FUTURE WORK 
7.1 Conclusions 
Antimicrobial-resistant infections are a defining healthcare challenge of our age. 
Antibiotics, tools that built the modern healthcare system, are losing their efficacy, and the 
drug discovery and development pipeline is woefully underpopulated to meet society’s 
needs. This threat requires innovative solutions to provide new therapies against resistant 
pathogens and preserve our existing antibiotic supply. Polyanhydride-based nanomedicines 
have shown the striking capability to improve antibiotic efficacy, and deserve to be explored 
as one such solution. These nanomedicines provide control over the release rate of the drug, 
alter the biodistribution of the drug by enhancing its bioavailability, lower drug dose, reduce 
or eliminate off-target effects, and can be targeted for delivery to specific tissues or cross 
complex biological barriers, such as the insect cuticle, the bacterial cell wall, or the blood-
brain-barrier. By improving antimicrobial activity, nanomedicines could allow repurposing 
of existing antibiotics and contribute new therapies against resistant bacteria. To maximize 
nanomedicine success, modernized screening approaches are needed to compensate for the 
massive dataspace conferred by carrier chemistry, drug chemistry, and nanoparticle material 
properties. Informatics-assisted screening provides such an advance by efficiently developing 
structure-function relationships to guide selection of lead candidates. This approach would 
help deconvolute complex, interconnected relationships between drug type, carrier chemistry, 
particle properties, and biological activity that are notoriously difficult to model a priori, and 
provide a framework for rational design of antimicrobial nanomedicines to kill resistant 
pathogens. 
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In Chapter 4, a multivariate data analytics approach was developed to identify 
polymer and drug properties that significantly impacted drug encapsulation efficiency and 
release kinetics. A multilinear map of nanoparticle formulations captured non-linear behavior 
governing relationships between drug type, polymer chemistry, and nanoparticle release 
properties, enabling interrogation of nanomedicine design pathways. Predictive models for 
drug release kinetics of untested drugs were developed from this map. Release kinetics 
predictions of two drugs containing atoms not included in the model showed good agreement 
with experimental results, validating the model and indicating its potential to virtually 
explore new polymer and drug pairs. This multilinear modeling approach provides the first 
steps towards development of a framework that can be used to rationally design 
nanomedicine formulations by selecting the appropriate carrier for a drug payload to program 
desirable release kinetics profiles. 
In Chapter 5, a high-throughput method was adapted to rapidly screen the novel 
CPTEG:SA copolymer chemical space for interesting drug delivery properties. CPTEG:SA 
copolymers were shown to erode more rapidly than traditional polyanhydride copolymers, 
giving rise to rapid, chemistry-dependent drug release within three days. This rapid release 
could be beneficial for fast-growing pathogens by providing a quick, suppressive dose of 
antibiotic that is maintained over several days. The high-throughput method was adapted to 
synthesize polymer-drug films to screen for thermodynamic mixing interactions by melting 
point depression studies, which showed mixed agreement with predictions from group 
contribution methods. The interaction parameters estimated from these methods were able to 
explain trends in model drug release kinetics from nanoparticle libraries. Overall, these 
methods could improve nanomedicine screening by allowing parallel, semi-automated 
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synthesis of up to 24 different formulations and enabling high-throughput characterization of 
polymer-drug mixing thermodynamics. 
Finally, in Chapter 6, a particle library with varying polymer and nanoparticle 
chemistry was synthesized using the high-throughput methodology from Chapter 5. Single 
nanoparticle formulations and binary combinations of formulations were tested for 
antimicrobial efficacy against Burkholderia cepacia, an opportunistic, resistant pathogen. 
The multivariate data analytics approach was applied to identify drug, polymer, and carrier 
properties that determine antimicrobial performance of single nanoparticles and cocktails of 
nanoparticles encapsulating different drugs. A graph theory-based model, used in Chapter 4 
to model release kinetics, was developed to predict nanoparticle and cocktail efficacy. The 
model successfully discriminated high performing candidates from those with no 
improvement or worse efficacy than soluble drug. This hybrid informatics approach 
constitutes another step toward rational design of antimicrobial nanomedicines by identifying 
polymer and drug combinations that improve antibiotic potency. 
Overall, this dissertation has contributed improved nanomedicine screening methods 
and enabled the development of a framework to rationally select antibiotic-loaded 
nanoparticle candidates. The high-throughput method can accelerate the synthesis of 
antibiotic-loaded nanoparticle libraries and rapidly screen for polymer-drug compatibility. 
This enabled the characterization of the nano-delivery device capabilities based on a novel, 
rapidly degrading CPTEG:SA copolymer system. This work developed structure-function 
relationships between input polymer, drug, and nanoparticle properties and their controlled 
release and antimicrobial performance. An informatics approach to identify nanoparticle 
candidates with controlled release and improved antimicrobial efficacy was successfully 
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developed. In all these ways, this dissertation has provided the first steps toward a framework 
for the rational design of antimicrobial nanomedicines capable of killing resistant organisms 
and controlling drug release. Lead candidates identified by this framework could provide 
new therapies against resistant pathogens and enable repurposing of existing antibiotics 
limited by resistance. 
7.2 Ongoing and Future Work 
Ongoing work is focused on refining the structure-function relationships between the 
drug, polymer, and nanoparticle properties and biological activity by expanding the chemical 
and biological dataspace. Through multiple fruitful collaborations with the Bellaire group, 
we have generated in vitro biological activity data for nanomedicine formulations in bacterial 
and parasitic biological systems. The same nanoparticle library used in Chapter 6 is currently 
being evaluated for performance against potential bioweapons Burkholderia pseudomallei 
and mallei. These data could be mined to identify pathogen-specific and -nonspecific factors 
that influence nanomedicine efficacy, which could provide information about the 
generalizability of the trends identified in Chapter 6.   
We have ongoing collaborations with the Coats group to explore the biodistribution 
of polyanhydride particles in insect vectors. This work will provide preliminary evidence for 
the use of drug delivery devices for vector control. While experiments thus far have focused 
on mosquitoes, future experiments will investigate American cockroaches. Our goal is to 
investigate how differences in copolymer chemistry and particle size impact biodistribution.  
7.2.1 Generalizing the Antimicrobial Efficacy Model to Other Pathogens 
Drug-resistant tuberculosis infections pose a current challenge for global healthcare 
systems. The bacterium’s intracellular niche provides a barrier to achieving a high local 
antibiotic concentration, and its slow growth rate limits the effectiveness of antimicrobials 
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that act on actively replicating cells.1 Multidrug-resistant TB infections are often incurable by 
frontline drugs, and in 2006 “extensively drug-resistant” TB infections were defined to 
describe a subset of MDR-TB infections that are resistant second line therapies.2 The slowing 
rate of antibiotic discovery has also limited the development of therapies for parasitic 
infections. Acanthamoeba spp. infections in immunosuppressed individuals can cause 
granulomatous amebic encephalitis, which is often fatal due to a prodromal period, limited 
diagnostic tools, and a lack of effective antimicrobial treatments.3 Acanthamoeba can also 
cause a corneal infection called Acanthamoeba keratitis, which can impair vision and require 
enucleation if left untreated.4 Effective antimicrobial therapies capable of killing both the 
metabolically-active trophozoite and cyst forms of Acanthamoeba remain elusive. 
Polyanhydride nanoparticles have a demonstrated potential for increasing the potency of 
antimicrobial drugs and providing dose sparing effects,5,6 but conventional screening 
methods are too inefficient to adequately cover the large nanoparticle dataspace. Ideally, the 
trends between input descriptors and antimicrobial performance identified in Chapter 6 could 
be applied to these systems to guide candidate selection. However, the generalizability of that 
model to other biological systems is unknown. Here, we use data gathered in collaboration 
with the Bellaire lab to propose some new directions to characterize this generalizability. 
An in vitro assay has been developed by Dr. Andrea Binnebose from the Bellaire lab 
to characterize the effectiveness of drugs released from nanoparticles in Mycobacterium 
marinum. In this work, 20:80 CPTEG:CPH nanoparticles dual-encapsulating the anti-
tubercular drugs pyrazinamide/rifampicin (PZA/RIF) and isoniazid/ethambutol 
(IZD/ETHAM) were synthesized, and incubated in PBS to release their drug payloads. At 
regular time points, the particles were centrifuged, supernatants were collected, and fresh 
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PBS was added. These 24 h, 48 h, and 72 h supernatants containing all four drugs were used 
to treat M. marinum broth cultures, and CFUs were counted at regular intervals (Figure 7.1). 
At 24 h, there was no significant difference between the groups. At 120 h, the 24 h and 48 h 
supernatants generated more growth suppression than the soluble control, while the 72 h 
supernatants wasn’t as effective as the soluble control. At 168 h, both the 24 h and 48 h 
supernatants showed more activity than the soluble control, and the 72 h supernatant was 
indistinguishable from the soluble control. At both later timepoints, all soluble and 
nanoparticle groups were significantly different from untreated control. These results give a 
sense of combined release kinetics and efficacy of drugs released from nanoparticles. The 
released drug from nanoparticles loses potency at later time points, likely because less drug is 
released at these time points due to the burst release from the particles. Additionally, this 
assay provides an estimate of the overall potency of nanoparticle formulations encapsulating 
multiple payloads, for which drug release kinetics can be challenging to determine.  
Acanthamoeba were treated with rifampicin-encapsulating nanoparticles in vitro in 
collaboration with Nathan Peroutka-Bigus from Dr. Bellaire’s lab. The cells in groups treated 
by either soluble rifampicin or 5% rifampicin-loaded 10:90, 20:80, or 30:70 CPTEG:CPH 
nanoparticles were counted by Trypan blue exclusion hemocytometer counts and normalized 
to untreated controls to generate a percentage growth inhibition (Figure 7.2). At 12.5 µg/mL 
of rifampicin, only the 30:70 CPTEG:CPH nanoparticles had significantly different cell 
counts than the untreated control. There were no significant differences in percent growth 
inhibition between different chemistries or the soluble control at this low concentration. At 
25 µg/mL of rifampicin, both 20:80 and 30:70 CPTEG:CPH nanoparticles had significantly 
different cell counts than the untreated control. At this higher concentration, 20:80 and 30:70 
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CPTEG:CPH nanoparticles showed significantly higher growth inhibition than soluble drug, 
which was indistinguishable from the untreatable control and the 10:90 CPTEG:CPH nano-
formulation. These results show that polyanhydride nanoparticles encapsulating rifampicin 
can significantly reduce the growth of pathogenic Acanthamoeba. Furthermore, these studies 
illustrate that both dose and nanoparticle chemistry impact nanotherapeutic efficacy. These 
data from Mycobacterium and Acanthamoeba could be leveraged to provide additional 
insights into nanoparticle inputs that govern efficacy. It is hypothesized that some proportion 
of the factors that influenced nanoparticle efficacy against B. cepacia in Chapter 6 would 
maintain their influence in other biological systems, while others would likely be genus- or 
species-specific. 
As a case in point, we tested the antimicrobial performance of a subset of the 
nanoparticle library used in Chapter 6 against the potential bioweapon B. pseudomallei 
(Table 7.1). This project involves collaboration with the Bellaire group at ISU for 
microbiological performance of the nanoparticles, as well as with Dr. Scott Broderick and the 
Rajan group at the University of Buffalo for the informatics analysis. Like B. cepacia, B. 
pseudomallei are intracellular pathogens with intrinsic antibiotic resistance.7 B. pseudomallei 
is a biodefense threat because it is easily aerosolized and causes the disease melioidosis, 
which can be highly lethal and requires invasive, frequent, and lengthy antibiotic treatment.8,9 
B. pseudomallei had much more negative log2 values for hits than were observed previously 
in B. cepacia (Table 7.1), indicating that nanoparticles provided greater improvements in 
potency compared to soluble drug. A PCA analysis was performed to compare the 
nanoparticle performance in B. cepacia and pseudomallei. In the scores plot in Figure 7.3, B. 
pseudomallei were generally located closer to the top right corner than B. cepacia, indicating 
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a higher susceptibility toward nanoparticles. However, some B. pseudomallei data points lie 
on a trajectory orthogonal to the B. cepacia log2 vector. This indicates that, to some extent, 
different physics govern antimicrobial performance in the two species. More comprehensive 
testing of the nanoparticle library is needed to characterize the magnitude of the difference in 
performance, as well as to evaluate the organism-dependency of input descriptors’ effects on 
antimicrobial performance. Understanding the generalizability of the conclusions from 
Chapter 6 would improve translation of nanoparticle design between different pathogens by 
(1) identifying antimicrobial performance structure-property relationships that are broadly 
valid, if any, and (2) identifying descriptors that show the most variability in effect between 
pathogens.  
7.2.2 Enabling Design of Nanomedicines for Vector Control: Biodistribution of 
Nanoparticles in Insects 
Nanoparticles could improve vector control strategies by altering the biodistribution 
of hydrophobic agents in mosquitoes. These delivery technologies could enable lower 
effective doses of insecticides, target insecticides to tissues of action within pests, and enable 
treatment with novel insecticide candidates whose biodistribution and activity is encumbered 
by hydrophobicity. Through collaborations with Dr. Edmund Norris, previously of the Coats 
group at ISU, and Dr. Yash Phanse of the Bartholomay group at the University of Wisconsin, 
we sought to identify polyanhydride chemistries and nanoparticle sizes that are internalized 
by yellow fever mosquitoes and American cockroaches.  
We have developed a method of end group-functionalizing 20:80 CPH:SA and 20:80 
CPTEG:CPH with the fluorophore rhodamine B. When microparticles and nanoparticles are 
synthesized from these functionalized polymers, there is a persistent fluorescent signal from 
the conjugated label. In in vitro experiments using Aag2 and C636 insect cells, we 
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determined that majority of cells are labeled within two hours, and that nanoparticles achieve 
higher uptake than microparticles of the same chemistry (data not shown).  
We exposed mosquitoes to rhodamine B-labeled particles in surface contact 
experiments where mosquitoes are entrapped in a plastic cone containing a filter paper with a 
layer of nanoparticles. The mosquitoes were dissected and particle association was quantified 
by epifluorescence. We observed higher association of the nanoparticles with the legs and 
whole bodies than microparticles, confirming the results of in vitro experiments. CPH:SA 
nanoparticles showed a higher association with legs, whereas CPTEG:CPH nanoparticles 
showed a higher association with the bodies. We also investigated the biodistribution of 
nanoparticles in mosquito internal tissues after surface contact exposure. CPTEG:CPH 
nanoparticles showed much higher labeling in ovary, midgut, and Malpighian tubules (which 
function similarly to human kidneys) tissues than CPH:SA nanoparticles (Figure 7.4). In 
contrast, CPH:SA nanoparticles showed only a modest increase in fluorescence compared to 
non-treated controls in the midgut and Malpighian tubules.  
We also tested a topical application route of exposure. This route generated much 
more extensive labeling of internal tissues than surface contact (Figure 7.5). Both CPH:SA 
and CPTEG:CPH nanoparticles showed a statistically significant labeling of ovary, midgut, 
and Malpighian tubules tissues compared to untreated control. For each tissue, CPTEG:CPH 
nanoparticles labeled more extensively than CPH:SA nanoparticles. 
The above work in mosquitoes has resulted in a manuscript, which is being submitted 
to PLOS Negl Trop Dis. Future work will test nanoparticle biodistribution after different 
exposure routes in cockroaches. The larger size of this insect model in comparison to 
mosquitoes will likely enable us to characterize nanoparticle localization in the spinal cord. 
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Successful completion of this project will enable us to design vector-control nanomedicines 
for maximum potency by delivering neuroactive compounds to their tissues and sites of 
action. 
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7.4 Tables 





Figure 7.1 Growth inhibition of Mycobacterium marinum treated with nanoparticle release 
supernatants. The soluble group was treated with 10 µg of soluble PZA, RIF, INH, and 
ETHAM. Experimental groups were treated with release supernatants from nanoparticles 
dual-encapsulating PZA/RIF and IBH/ETHAM, gathered at the times specified in the legend. 
Treated groups were cultured in 7H9 broth, and plated at times listed on the x-axis on 




Figure 7.2 Effect of copolymer chemistry on rifampicin-medited growth inhibition of 
Acanthamoeba strain V062 at 72 hours post-treatment. Nanoparticles were loaded with 5% 
rifampicin (w/w). Treated groups are compared to untreated controls to generate a percentage 
growth inhibition. 
 
Figure 7.3 PCA scores plot comparing antimicrobial activity against Burkholderia cepacia 
and pseudomallei. Blue triangles represent B. cepacia single formulations, white squares B. 
cepacia cocktails, orange circles B. pseudomallei single formulations. Improved nanoparticle 
performance in B. cepacia compared to soluble drug follows a trajectory toward the top right 
corner. B. pseudomallei generally seem to be more sensitive to nanoparticles than B. cepacia. 
However, some B. pseudomallei lie on a trajectory orthogonal to the Log2 vector, indicating 
that, to some extent, different physics govern antimicrobial performance in B. pseudomallei 
compared to B. cepacia. B. cepacia data are the same as in Figure 6.3 
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Figure 7.5 Rhodamine-functionalized nanoparticle internalization in mosquitoes after topical 
exposure. 
 
 
